Humanized and affinity matured anti-CEACAM1 antibodies and methods of use
The interaction of CEACAM1 is blocked by binding monoclonal antibodies and antigen-binding fragments, and the problems of tumor cell metastasis and immunosuppression are solved, and the effect of inhibiting tumor growth and enhancing anti-tumor response is achieved. It is suitable for resistant patients.
Patent Information
- Application Number
- CN202380031369.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-03
- Filing Date
- 2023-03-02
- Publication Date
- 2024-11-26
Smart Images

Figure BDA0005064353920000371 
Figure BDA0005064353920000381 
Figure BDA0005064353920000691
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 316,140, filed on March 3, 2022, which is incorporated by reference in its entirety. Technical Field
[0003] The present invention relates generally to the fields of molecular biology and medicine. More specifically, the present invention provides monoclonal antibodies and antigen-binding fragments that bind to CEACAM1 and therapeutic compositions thereof, as well as methods of using such antibodies, including inhibiting homophilic and heterophilic interactions with CEACAM1, and methods for treating cancer and infectious diseases.
[0004] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0005] This invention was made with government support under DK51362 awarded by the National Institutes of Health. The government has certain rights in this invention. Background Art
[0006] Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a member of the carcinoembryonic antigen (CEA) family of immunoglobulin (Ig)-like transmembrane glycoproteins. CEACAM family members are involved in cell-cell recognition and regulate cellular processes ranging from the shaping of tissue architecture and neovascularization to the regulation of insulin homeostasis and T-cell proliferation.
[0007] A variety of cellular activities have been attributed to the CEACAM1 protein, including roles in differentiation and arrangement of tissue three-dimensional architecture, angiogenesis, apoptosis, tumor suppression, metastasis, and regulation of innate and adaptive immune responses. In addition, several cell types may express CEACAM1, including tumor cells, T cells, B cells, natural killer (NK) cells, and certain macrophages.
[0008] High CEACAM1 expression occurs in a variety of cancers, such as melanoma, colorectal cancer, gastric cancer, pancreatic cancer, bladder cancer and thyroid cancer, and is associated with poor tumor progression, metastasis and poor clinical prognosis. For example, non-small cell lung cancer (NSCLC) with high CEACAM1 expression exhibits high microvessel density, distal metastasis and shorter median overall survival and progression-free survival. CEACAM1 expression is also closely related to distal metastasis of pancreatic cancer. CEACAM1 expression on tumors promotes CEACAM1-mediated inhibition of T and NK cells. Therefore, inhibiting CEACAM1 activity can inhibit tumor cell metastasis and the formation of cancer stem cell niches.
[0009] CEACAM1 is also expressed in certain immune system cells and plays a role in immunosuppression and immune cell exhaustion. For example, high CEACAM1 expression on tumor infiltrating lymphocytes (TILs) and other tumor infiltrating immune cells from gastric cancer, lung cancer, melanoma, colorectal cancer and glioma is associated with poor prognosis. On T cells, CEACAM1 expression is mostly excluded from resting (primary) T cells, while the protein is expressed at high levels on activated T cells. CEACAM1-L is the main isoform expressed in most T cells, and acts as an inhibitory receptor that downregulates T cell activation and inhibits T cell function. Therefore, CEACAM1 inhibition of T cells can restore T cell activity and increase anti-tumor response.
[0010] CEACAM1 is further expressed on NK cells, which are lymphocytes involved in innate immunity, which are involved in early control of viral infections and immune surveillance of tumors. When NK cells encounter cells expressing class I major histocompatibility complex (MHC), inhibitory signals through receptor-ligand interactions prevent immune responses against these cells. However, when encountering cells in which class I MHC is downregulated, such as in virally infected cells or cancer cells, NK cells are activated due to the lack of inhibitory signals, which makes "sick" cells susceptible to NK cell-mediated killing. When CEACAM1 is present on the surface of NK and melanoma cells, CEACAM1:CEACAM1 interactions lead to inhibition of NK-mediated killing, regardless of class I MHC expression. Therefore, the destruction of this homophilic CEACAM1 interaction can be beneficial to restore NK-mediated immune responses.
[0011] CEACAM1 expression on macrophage subsets was further associated with fibrosis in the tumor microenvironment in mouse models. CEACAM1 also regulates other stromal cells in the tumor microenvironment such as the vascular endothelium. Therefore, inhibiting the interaction of CEACAM1 with its binding partners could further inhibit fibrosis and angiogenesis.
[0012] CEACAM1 also mediates cell-cell adhesion through the extracellular portion of CEACAM1 containing the IgV-like N domain, which is involved in homophilic (CEACAM1:CEACAM1) and heterophilic interactions (e.g., with CEA, CEACAM5, CEACAM8, T-cell immunoglobulin and mucin domain-containing 3 (TIM-3) protein and programmed cell death protein 1 (PD-1), Helicobacter pylori adhesin HopQ, Neisseria gonorrhoeae / meningitidis opacifying protein (OPA), Moraxella sp. Opa-like protein OlpA, Haemophilus influenzae outer membrane protein (OMP) P1, Haemophilus aegyptius OMP P1, Fusobacterium sp., Salmonella sp.), Streptococcus agalactiae and Candida albicans. TIM-3 is identified as a Th1-specific cell surface protein, which is expressed on activated T cells, dendritic cells and macrophage subsets and NK cells. TIM-3 is an activation-induced inhibitory molecule that is associated with tolerance and has been shown to induce T cell exhaustion in chronic viral infections and cancer. CEACAM1 is also expressed on activated T cells, has been shown to interact with TIM-3, and this interaction is important for TIM-3-mediated T cell inhibition. PD-1 represents the main checkpoint inhibitor pathway in humans.
[0013] As described above, CEACAM1 also acts as a cell receptor on the apical membrane of mucosal cells for a variety of Gram-negative bacterial pathogens associated with human mucosa as well as with fungal pathogens such as Candida albicans. For example, Neisseria gonorrhoeae, Neisseria meningitidis, Moraxella catarrhalis, Haemophilus influenzae, Haemophilus aegypti, and pathogenic Escherichia coli strains have well-characterized CEACAM1 binding adhesins. Engagement of CEACAM1 with bacterial adhesins triggers bacterial endocytosis into epithelial cells and microbial endocytic transport through intact epithelial layers, thus allowing microorganisms to utilize CEACAM1 during mucosal colonization. In addition, CEACAM1 is associated with infection with influenza virus H5N1 and sub-nematodes such as Wucheria bancrofti. Summary of the invention
[0014] Provided herein are antibodies and antigen-binding fragments thereof that bind to CEACAM1 and block the interaction of CEACAM1 with one or more binding partners. Also provided are therapeutic compositions of such antibodies and antigen-binding fragments thereof, and methods of using these antibodies. By blocking the interaction of CEACAM1 with one or more binding partners, the antibodies and antigen-binding fragments thereof can be used to reduce, inhibit and / or reverse T cell tolerance and / or to enhance T cell expansion. CEACAM1 antibodies and antigen-binding fragments thereof can also be used to treat cancer, reduce tumor growth, reduce tumor metastasis and / or reduce cancer stemness in subjects in need. CEACAM1 antibodies and antigen-binding fragments thereof can also be used to treat patients resistant to checkpoint therapy. Further provided are methods of using CEACAM1 antibodies and antigen-binding fragments thereof to reduce colonization of mammalian epithelium by bacteria or Candida albicans expressing bacterial adhesins.
[0015] In one aspect, an antibody or antigen-binding fragment thereof that binds to CEACAM1 is provided, the antibody or antigen-binding fragment comprising a heavy chain variable region and a light chain variable region;
[0016] wherein each of the heavy chain variable region and the light chain variable region comprises CDR1, CDR2 and CDR3; and wherein:
[0017] a) the sequence of CDR1H comprises the sequence DYYLY (SEQ ID NO: 1);
[0018] b) the sequence of CDR2H comprises the sequence TISVGGGQTSYADSVKG (SEQ ID NO: 2);
[0019] c) the sequence of CDR3H comprises the sequence GLYYGPSWVAY (SEQ ID NO: 3), ARTYGPAWFAY (SEQ ID NO: 4) or ALTYGPAWLAY (SEQ ID NO: 5);
[0020] d) the sequence of CDR1L comprises the sequence KSSQSLLNSANQKNYLA (SEQ ID NO: 6);
[0021] e) the sequence of CDR2L comprises the sequence FASTRES (SEQ ID NO: 7); and
[0022] f) The sequence of CDR3L comprises the sequence QSHYPFYYT (SEQ ID NO: 8) or QSHFPYPLT (SEQ ID NO: 9).
[0023] In one embodiment, the sequence of CDR3H comprises the sequence GLYYGPSWVAY (SEQ ID NO: 3); and the sequence of CDR3L comprises the sequence QSHYPFYYT (SEQ ID NO: 8).
[0024] In one aspect, an antibody or antigen-binding fragment thereof that binds to CEACAM1 is provided, the antibody or antigen-binding fragment comprising a heavy chain variable region and a light chain variable region, wherein the sequence of the heavy chain variable region comprises a sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 15-17 and wherein the sequence of the light chain variable region comprises a sequence at least 90% identical to SEQ ID NO: 21 or SEQ ID NO: 22.
[0025] In one embodiment, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a sequence that is at least 90% identical to the heavy chain variable region amino acid sequence of SEQ ID NO: 15, and the light chain variable region comprises a sequence that is at least 90% identical to the light chain variable region amino acid sequence of any one of SEQ ID NO: 21.
[0026] In an embodiment, the heavy chain variable region comprises a sequence at least 95% identical to a sequence selected from the group consisting of SEQ ID NOs: 15-17, and the light chain variable region comprises a sequence at least 95% identical to SEQ ID NO: 21 or SEQ ID NO: 22. In one embodiment, the sequence of the heavy chain variable region comprises a sequence at least 95% identical to the heavy chain variable region amino acid sequence of SEQ ID NO: 15, and the sequence of the light chain variable region comprises a sequence at least 95% identical to the light chain variable region amino acid sequence of any one of SEQ ID NOs: 21.
[0027] In an embodiment, the sequence of the heavy chain variable region comprises a sequence selected from the group consisting of SEQ ID NOs: 15-17, and the sequence of the light chain variable region comprises SEQ ID NO: 21 or SEQ ID NO: 22. In one embodiment, the sequence of the heavy chain variable region comprises SEQ ID NO: 15 and the sequence of the light chain variable region comprises SEQ ID NO: 21.
[0028] In some embodiments, the antibody or antigen-binding fragment thereof is a chimeric antibody, a CDR-grafted antibody, or a humanized antibody or antigen-binding fragment thereof.
[0029] In some embodiments, the antibody or antigen binding fragment is a multispecific or bispecific antibody or its antigen binding fragment. In some embodiments, the antibody or antigen binding fragment is a bispecific antibody, which comprises a complementary region that binds PD-1, PD-L1, CTLA-4, TIM-3, epidermal growth factor receptor (EGFR), CD25, CD19 or Fcγ receptor.
[0030] In some embodiments, the antibody or antigen-binding fragment is a scFv, Fv, Fab', Fab, F(ab')2, or a diabody.
[0031] In some embodiments, the antibody or antigen-binding fragment is of the IgG4 isotype.
[0032] In some embodiments, the antibody or antigen-binding fragment thereof contains an S241P substitution in the heavy chain constant region.
[0033] In some embodiments, the antibody or antigen-binding fragment is aglycosylated.
[0034] In some embodiments, the antibody or antigen-binding fragment lacks a C-terminal lysine in the heavy chain.
[0035] In some embodiments, the antibody or antigen-binding fragment is conjugated to one or more of a cytotoxin, a fluorescent label, and an imaging agent.
[0036] Provided herein are antibodies or antigen binding fragments thereof that bind to the same epitope on CEACAM1 as the antibodies or antigen binding fragments thereof disclosed herein. Provided herein are antibodies or antigen binding fragments thereof that bind to the IgV-like N domain of CEACAM1. In embodiments, the antibody or antigen binding fragment thereof does not bind to one or more of CEACAM3, CEACAM5, CEACAM6, and CEACAM8. In some embodiments, the antibody or antigen binding fragment thereof at least partially binds to the TIM-3 binding site on CEACAM1 and / or at least partially binds to the PD-1 binding site on CEACAM1. In some embodiments, the antibody or antigen binding fragment at least partially binds to the CEACAM1 binding site on CEACAM1 during homodimerization.
[0037] Provided herein are nucleic acids encoding the antibodies or antigen-binding fragments thereof disclosed herein. In one embodiment, the nucleic acid is an isolated nucleic acid. Provided herein are vectors comprising the nucleic acids disclosed herein.
[0038] Provided herein are cells comprising a vector disclosed herein. In one embodiment, the cell is an isolated cell. Provided herein are cells expressing an antibody disclosed herein or an antigen-binding fragment thereof. Provided herein are T cells having a chimeric antigen receptor comprising the CDRs of an antibody disclosed herein or an antigen-binding fragment thereof.
[0039] Provided herein are pharmaceutical compositions comprising an antibody or antigen-binding fragment thereof disclosed herein and a pharmaceutically acceptable excipient.
[0040] Provided herein is a method for inhibiting the binding of CEACAM1 to a CEACAM family member, the method comprising contacting CEACAM1 with an antibody or antigen-binding fragment thereof disclosed herein or a pharmaceutical composition disclosed herein. In some embodiments, the CEACAM family member is CEACAM5 or CEACAM8. In one embodiment, the CEACAM family member is CEACAM1.
[0041] Provided is a method for inhibiting the binding of CEACAM1 to a TIM family member, the method comprising contacting CEACAM1 with an antibody or antigen-binding fragment thereof disclosed herein or a pharmaceutical composition disclosed herein. In one embodiment, the TIM family member is TIM-3.
[0042] Provided is a method of inhibiting the binding of CEACAM1 to PD-1, the method comprising contacting CEACAM1 with an antibody or antigen-binding fragment thereof disclosed herein or a pharmaceutical composition disclosed herein.
[0043] A method for inhibiting the binding of CEACAM1 to bacterial adhesins, the method comprising contacting CEACAM1 with an antibody or antigen-binding fragment thereof disclosed herein or a pharmaceutical composition disclosed herein. In an embodiment, the bacterial adhesin is Helicobacter pylori adhesin HopQ, Neisseria gonorrhoeae opacity protein (Opa), Neisseria meningitidis Opa, Haemophilus influenzae outer membrane protein (OMP) P1, Haemophilus aegypti OMP P1, Moraxella Opa-like protein (OlpA), Fusobacterium trimeric autotransporter adhesin CbpF, Salmonella adhesin, or Streptococcus agalactiae IgI3-like β-protein adhesin.
[0044] Provided is a method of inhibiting the binding of CEACAM1 to Candida albicans, the method comprising contacting CEACAM1 with an antibody or antigen-binding fragment thereof disclosed herein or a pharmaceutical composition disclosed herein.
[0045] Provided is a method for reducing colonization of mammalian epithelium by bacteria expressing bacterial adhesins, the method comprising contacting CEACAM1 with an antibody or antigen-binding fragment thereof disclosed herein or a pharmaceutical composition disclosed herein. In an embodiment, the bacterial adhesin is Helicobacter pylori adhesin HopQ, Neisseria gonorrhoeae opacity protein (Opa), Neisseria meningitidis Opa, Haemophilus influenzae OMP P1, Haemophilus aegypti OMP P1 or Moraxella OlpA, Fusobacterium trimeric autotransporter adhesin CbpF, Salmonella adhesin or Streptococcus agalactiae IgI3-like beta protein adhesin.
[0046] Provided herein are methods of reducing colonization of mammalian epithelium by Candida albicans, the methods comprising contacting CEACAM1 with an antibody or antigen-binding fragment thereof disclosed herein or a pharmaceutical composition disclosed herein.
[0047] Provided herein are methods of reducing T cell tolerance, the methods comprising contacting a cell population comprising T cells with an antibody or antigen-binding fragment thereof disclosed herein or a pharmaceutical composition disclosed herein.
[0048] Provided herein are methods of enhancing T cell expansion, the methods comprising contacting a cell population comprising T cells with an antibody or antigen-binding fragment thereof disclosed herein or a pharmaceutical composition disclosed herein.
[0049] Provided herein are methods of reducing T cell tolerance in a subject in need thereof, the methods comprising administering to the subject an antibody or antigen-binding fragment thereof disclosed herein or a pharmaceutical composition disclosed herein.
[0050] Provided herein are methods of enhancing T cell expansion in a subject in need thereof, the methods comprising administering to the subject an antibody or antigen-binding fragment thereof disclosed herein or a pharmaceutical composition disclosed herein.
[0051] Provided herein are methods for treating cancer in a subject in need thereof, the methods comprising administering to the subject an antibody disclosed herein or an antigen-binding fragment thereof or a pharmaceutical composition disclosed herein. In embodiments, the cancer is melanoma, pancreatic cancer, thyroid cancer, lung cancer, colorectal cancer, squamous cell carcinoma, prostate cancer, breast cancer, bladder cancer, or gastric cancer.
[0052] Provided herein are methods of reducing tumor growth in a subject in need thereof, the methods comprising administering to the subject an antibody or antigen-binding fragment thereof disclosed herein or a pharmaceutical composition disclosed herein.
[0053] Provided herein are methods of reducing tumor metastasis in a subject in need thereof, the methods comprising administering to the subject an antibody or antigen-binding fragment thereof disclosed herein or a pharmaceutical composition disclosed herein.
[0054] Provided herein are methods of reducing tumor-associated fibrosis in a subject in need thereof, the methods comprising administering to the subject an antibody or antigen-binding fragment thereof disclosed herein or a pharmaceutical composition disclosed herein.
[0055] Provided herein are methods of reducing cancer stemness in a subject in need thereof, the methods comprising administering to the subject an antibody or antigen-binding fragment thereof disclosed herein or a pharmaceutical composition disclosed herein.
[0056] Provided herein is a method for reducing the colonization of the epithelium of a subject by bacteria expressing a bacterial adhesin in a subject in need thereof, the method comprising administering to the subject an antibody or antigen-binding fragment thereof disclosed herein. In embodiments, the bacterial adhesin is Helicobacter pylori adhesin HopQ, Neisseria gonorrhoeae opacity protein (Opa), Neisseria meningitidis Opa, Haemophilus influenzae OMP P1, Haemophilus aegypti OMP P1, Moraxella OlpA, Fusobacterium trimeric autotransporter adhesin CbpF, Salmonella adhesin, or Streptococcus agalactiae IgI3-like β-protein adhesin.
[0057] Provided herein are methods of reducing epithelial colonization of a subject by Candida albicans in a subject in need thereof, the methods comprising administering to the subject an antibody or antigen-binding fragment thereof disclosed herein or a pharmaceutical composition disclosed herein.
[0058] Provided herein are methods of reducing filarial invasion of the subject's lymphatic system in a subject in need thereof, the method comprising administering to the subject an antibody or antigen-binding fragment thereof disclosed herein. In one embodiment, the filarial worm is Wuchereria bancrofti.
[0059] Provided herein is a method for reducing cancer cell invasion of a subject's lymphatic system in a subject in need thereof, the method comprising administering to the subject an antibody disclosed herein or its antigen-binding fragment or a pharmaceutical composition disclosed herein. In embodiments, the method further comprises administering a checkpoint inhibitor. In embodiments, the checkpoint inhibitor is a CTLA-4, PD-1, PD-L1, and PD-L2 inhibitor.
[0060] In embodiments, the methods disclosed herein further include administering one or more inhibitors of LAG3, TIGIT, LAP, Podoplanin, protein C receptor, ICOS, GITR, CD226 and / or CD160. In embodiments, the methods disclosed herein further include administering a TIM-3 inhibitor. In embodiments, additional inhibitors are administered simultaneously or continuously with antibodies or antigen-binding fragments or pharmaceutical compositions. In embodiments, additional inhibitors are administered alone or as a mixture with antibodies or antigen-binding fragments thereof disclosed herein.
[0061] Provided are methods of treating a subject in need thereof, the methods comprising administering to the subject an antibody or antigen-binding fragment thereof disclosed herein or a pharmaceutical composition disclosed herein, wherein the subject has acquired resistance to therapy with a checkpoint inhibitor therapy. In embodiments, the subject has acquired resistance to therapy with one or more of a PD-1 inhibitor, a PD-L1 inhibitor, or a CTLA-4 inhibitor. BRIEF DESCRIPTION OF THE DRAWINGS
[0062] Figure 1 Affinity maturation library design is illustrated. CDRs (as defined by Kabat) are underlined. X = position targeted for mutagenesis. A single position may contain all 20 amino acids or a subset thereof. VH CDR3 block used for mutagenesis CTRGLYYGPAWFAYW (SEQ ID NO: 25). VL CDR3 block used for mutagenesis CQQHYSTPWTF (SEQ ID NO: 26).
[0063] Figure 2 Exemplary data from a periprep binding primary screen are illustrated. Wells with parental humanized scFv, irrelevant scFv, and media only are indicated. Clones with at least 50% inhibition are indicated by arrows.
[0064] Figure 3A , 3B , 3C, 3D and 3E show the parental antibody, twelve lead variants ( Figure 3A , 3B , 3C and 3D) and the pan-CEACAM antibody D14HD11 ( Figure 3E ) Results of cross-reactive ELISA binding to CEACAM-1 / -3 / -5 and -6 (from left to right).
[0065] Figure 4A and 4B exemplifies the specificity of antibody He14 / L1 as determined by single cycle surface plasmon resonance. Increasing concentrations (70 to 280 nM) of antibody He14 / L1 ( Figure 4A ) or control antibody CH14D11 ( Figure 4B ) Binding sensorgrams for hCEACAM1, hCEACAM3, hCEACAM5, and hCEACAM6. RU, resonance unit.
[0066] Figure 5A , 5B, 5C, 5D, and 5E show the structure of the CEACAM1:He14 / L1 Fab complex. Figure 5A The structure of the complex with the Fab heavy and light chains (L, H and C chains) is drawn as the Ca trace and the antigen is drawn as a ribbon. Figure 5B CEACAM1 molecules in the complex are superimposed on CEACAM1 molecules in the dimer. Strands are labeled A to G in bold. Figure 5C .View of composite CEACAM1 showing epitopes. The mapped molecular surface is drawn in semi-transparent light grey, the protein backbone is drawn as ribbons, and the relevant side chains are drawn as sticks and labeled. The surface area that interacts with the Fab is indicated. Figure 5D .Integral binding of He14 / L1 to the GFCC' surface of CEACAM1. Figure 5E He14L1 docks specifically on both faces of CEACAM1 and may disrupt higher-order CEACAM1 structure. In addition to the C'C"DE face, which may be associated with higher-order structure, the GFCC' face is the major interacting face.
[0067] Figure 6 The indicated CEACAM1 antibodies VH2 / Vκ4 (parent / parent), VH2 / L1 (parent / L1), He3 / L20, He17 / L1 and He14 / L1 are exemplified for blocking human CEACAM:human TIM-3 interaction. IgG4 = control antibody.
[0068] Figure 7 Results of an in vitro assay of T cell function (proliferation assay) are shown. Ki67 expression indicates T cell proliferation in response to CEACAM1 antibodies He3 / L20, He14 / L1, H17 / L1 and VH2 / L1 (parental / L1) in subjects resistant to pembrolizumab treatment.
[0069] Fig. 8A and 8B Shown, compared with control antibody ( Figure 8B ) compared with the He14 / L1 antibody treatment ( Fig. 8A ) resulted in the expansion of B cells (from 164 cells to 347 cells) and T cells (from 394 cells to 913 cells) within 42 hours, indicating that He14 / L1 caused a widespread induction of B cells and T cells, and these responses are important for antitumor activity.
[0070] Fig.9A , 9B and 9C exemplify that CEACAM1 expression of epitopes recognized by antibodies derived from parental antibodies (including He14 / L1) is associated with resistance to therapy. Fig.9A.CEACAM1 expression of meta-clusters representing proplasmablastic B cells identified by Citrus analysis (meta-clusters identified by Citrus C36175, C36194) shows that treatment resistance is associated with increased CEACAM1 expression for resistance (R) compared to naive (N) tumor samples. Median levels of CEACAM1 expression were determined by ANOVA. *, p<0.05. Fig. 9B .CEACAM1 expression of meta-clusters representing tumor-associated monocytes shows that treatment resistance is associated with increased CEACAM1 expression for resistance (R) compared to naive (N) tumor samples in meta-clusters identified by Citrus (C58750, C58749, C58832, C58843, C58885, C58888). Median levels of CEACAM1 expression were determined by ANOVA. *, p<0.05 and **, p<0.01 significance. Fig. 9C . Represents dysfunctional CD8 + CEACAM1 expression of meta-clusters of central memory T cells shows that treatment resistance is associated with increased CEACAM1 expression for resistance (R) compared to naive (N) tumor samples in meta-clusters identified by Citrus (C58736, C58786, C58789). Median levels of CEACAM1 expression were determined by ANOVA. *, p<0.05 significance. DETAILED DESCRIPTION
[0071] Antibody
[0072] The term "antibody" is used in the broadest sense and includes monoclonal antibodies (including full-length or intact monoclonal antibodies), polyclonal antibodies, multivalent antibodies, multispecific antibodies (e.g., bispecific antibodies), antibody fragments and antigen-binding portions thereof (e.g., paratopes, CDRs), so long as they exhibit the desired biological activity and specificity.
[0073] As used herein, "antibody variable domain" refers to the portion of the light and heavy chains of an antibody molecule that includes the amino acid sequences of the complementarity determining regions (CDRs; i.e., CDR1, CDR2, and CDR3) and framework regions (FRs). H Refers to the variable domain of the heavy chain. L Refers to the variable domain of the light chain. The amino acid positions assigned to CDRs and FRs can be defined according to Kabat or according to Chothia. The term "framework region" (FR) refers to those variable domain residues other than the CDR residues.
[0074] As used herein, the term "complementarity determining region" (CDR) refers to the portion of the antibody variable domain that is (usually) involved in antigen binding. Each variable domain typically has three CDR regions identified as CDR1, CDR2, and CDR3. Each CDR may comprise amino acid residues from CDRs as defined by, for example, Kabat (i.e., about residues 24-34 (L1), 50-56 (L2), and 89-97 (L3) in the light chain variable domain and about residues 31-35 (H1), 50-65 (H2), and 95-102 (H3) in the heavy chain variable domain (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Edition Public Health Service, National Institutes of Health, Bethesda, Md. (1987, 1991)). Each CDR may also include amino acid residues from a "hypervariable loop" (i.e., approximately residues 26-32 (L1), 50-52 (L2), and 91-96 (L3) in the light chain variable domain and approximately residues 26-32 (H1), 53-55 (H2), and 96-101 (H3) in the heavy chain variable domain (Chothia and Lesk 196 J. Mol. Biol. 901 (1987)). In some cases, a CDR may include amino acids from both a CDR region and a hypervariable loop according to the Kabat definition. The Kabat residue names do not always correspond directly to the linear numbering of the amino acid residues. Number (primary amino acid sequence). The actual linear amino acid sequence may contain fewer or additional amino acids than in the strict Kabat numbering, corresponding to shortening or insertion of structural components (whether framework or CDR) of the basic variable domain structure. For a given antibody or antigen-binding fragment thereof, the Kabat numbering of the correct residue can be determined by aligning the homologous residues in the antibody or antigen-binding fragment sequence with the "standard" Kabat numbering sequence. Alternatively, CDRs can be defined according to the ImMunoGeneTics (IMGT) system (Lefranc, M.-P. et al., Dev. Comp. Immunol., 27, 55-77 (2003)).
[0075] In one embodiment, the CEACAM1 antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain comprising three CDRs, wherein:
[0076] (i) the sequence of CDR1H comprises the sequence DYYLY (SEQ ID NO: 1);
[0077] (ii) the sequence of CDR2H comprises the sequence TISVGGGQTSYADSVKG (SEQ ID NO: 2);
[0078] (iii) the sequence of CDR3H comprises the sequence GLYYGPSWVAY (SEQ ID NO: 3), ARTYGPAWFAY (SEQ ID NO: 4) or ALTYGPAWLAY (SEQ ID NO: 5).
[0079] In one embodiment, the CEACAM1 antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain comprising three CDRs, wherein:
[0080] (i) the sequence of CDR1H comprises the sequence DYYLY (SEQ ID NO: 1);
[0081] (ii) the sequence of CDR2H comprises the sequence TISVGGGQTSYADSVKG (SEQ ID NO: 2); and
[0082] (iii) The sequence of CDR3H comprises the sequence GLYYGPSWVAY (SEQ ID NO: 3).
[0083] In one embodiment, the CEACAM1 antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain comprising three CDRs, wherein:
[0084] (i) the sequence of CDR1H comprises the sequence DYYLY (SEQ ID NO: 1);
[0085] (ii) the sequence of CDR2H comprises the sequence TISVGGGQTSYADSVKG (SEQ ID NO: 2); and
[0086] (iii) The sequence of CDR3H comprises the sequence ARTYGPAWFAY (SEQ ID NO: 4).
[0087] In one embodiment, the CEACAM1 antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain comprising three CDRs, wherein:
[0088] (i) the sequence of CDR1H comprises the sequence DYYLY (SEQ ID NO: 1);
[0089] (ii) the sequence of CDR2H comprises the sequence TISVGGGQTSYADSVKG (SEQ ID NO: 2); and
[0090] (iii) The sequence of CDR3H comprises the sequence ALTYGPAWLAY (SEQ ID NO: 5).
[0091] In one embodiment, the CEACAM1 antibody or antigen-binding fragment thereof provided herein comprises a variable light chain comprising three CDRs, wherein:
[0092] (i) the sequence of CDR1L comprises the sequence KSSQSLLNSANQKNYLA (SEQ ID NO: 6);
[0093] (ii) the sequence of CDR2L comprises the sequence FASTRES (SEQ ID NO: 7); and
[0094] (iii) The sequence of CDR3L comprises the sequence QSHYPFYYT (SEQ ID NO: 8) or QSHFPYPLT (SEQ ID NO: 9).
[0095] In one embodiment, the CEACAM1 antibody or antigen-binding fragment thereof provided herein comprises a variable light chain comprising three CDRs, wherein:
[0096] (i) the sequence of CDR1L comprises the sequence KSSQSLLNSANQKNYLA (SEQ ID NO: 6);
[0097] (ii) the sequence of CDR2L comprises the sequence FASTRES (SEQ ID NO: 7); and
[0098] (iii) The sequence of CDR3L comprises the sequence QSHYPFYYT (SEQ ID NO: 8).
[0099] In one embodiment, the CEACAM1 antibody or antigen-binding fragment thereof provided herein comprises a variable light chain comprising three CDRs, wherein:
[0100] (i) the sequence of CDR1L comprises the sequence KSSQSLLNSANQKNYLA (SEQ ID NO: 6);
[0101] (ii) the sequence of CDR2L comprises the sequence FASTRES (SEQ ID NO: 7); and
[0102] (iii) The sequence of CDR3L comprises the sequence QSHFPYPLT (SEQ ID NO: 9).
[0103] In one embodiment, the CEACAM1 antibody or antigen-binding fragment thereof provided herein comprises six CDRs, wherein:
[0104] (i) the sequence of CDR1H comprises the sequence DYYLY (SEQ ID NO: 1);
[0105] (ii) the sequence of CDR2H comprises the sequence TISVGGGQTSYADSVKG (SEQ ID NO: 2);
[0106] (iii) the sequence of CDR3H comprises the sequence GLYYGPSWVAY (SEQ ID NO: 3), ARTYGPAWFAY (SEQ ID NO: 4) or ALTYGPAWLAY (SEQ ID NO: 5);
[0107] (iv) the sequence of CDR1L comprises the sequence KSSQSLLNSANQKNYLA (SEQ ID NO: 6);
[0108] (v) the sequence of CDR2L comprises the sequence FASTRES (SEQ ID NO:7); and
[0109] (vi) The sequence of CDR3L comprises the sequence QSHYPFYYT (SEQ ID NO: 8) or QSHFPYPLT (SEQ ID NO: 9).
[0110] In one embodiment, the CEACAM1 antibody or antigen-binding fragment thereof provided herein comprises six CDRs, wherein:
[0111] (i) the sequence of CDR1H comprises the sequence DYYLY (SEQ ID NO: 1);
[0112] (ii) the sequence of CDR2H comprises the sequence TISVGGGQTSYADSVKG (SEQ ID NO: 2);
[0113] (iii) the sequence of CDR3H comprises the sequence GLYYGPSWVAY (SEQ ID NO: 3);
[0114] (iv) the sequence of CDR1L comprises the sequence KSSQSLLNSANQKNYLA (SEQ ID NO: 6);
[0115] (v) the sequence of CDR2L comprises the sequence FASTRES (SEQ ID NO:7); and
[0116] (vi) The sequence of CDR3L comprises the sequence QSHYPFYYT (SEQ ID NO: 8).
[0117] According to certain embodiments, the antibody and Fab thereof under consideration are also characterized by a humanized framework for reducing immunogenicity. In certain embodiments, the CDR of the antibody or Fab thereof under consideration is located in a framework obtained from a human antibody or Fab thereof. In other embodiments, the surface-exposed framework residues of the antibody or Fab thereof under consideration are replaced by framework residues of a human antibody or Fab thereof. The CDR may also be located in a mouse or humanized framework connected to a human constant region (i.e., a chimeric antibody). In a preferred embodiment, the CDR of the antibody or Fab thereof under consideration is located in a framework as a complex of two or more human antibodies. In such embodiments, the contemplated antibody or antigen-binding fragment thereof comprises two or more sequence segments ("complexes") derived from the V regions of unrelated human antibodies, the V regions being selected to maintain the monoclonal antibody sequences important for antigen binding of the starting precursor anti-human CEACAM1 monoclonal antibody, and having all been filtered for the presence of potential T cell epitopes using "in silico tools" (Holgate and Baker, IDrugs. 2009 April; 12(4): 233-7). Tight fit of the human sequence segments to all portions of the starting antibody V regions and elimination of CD4 prior to synthesis of the antibody or antigen-binding fragment thereof is achieved. + T cell epitopes allow this technology to circumvent immunogenicity while maintaining optimal affinity and specificity through previously analyzed sequences essential for antigen specificity (Holgate and Baker, 2009).
[0118] Also provided herein are variable heavy chain sequences and variable light chain sequences and pairs thereof comprising sequences similar but not identical to the variable heavy chain and variable light chain and pairs thereof disclosed in SEQ ID NOs: 10-22.
[0119] In one embodiment, the CEACAM1 antibody or antigen-binding fragment thereof comprises a heavy chain variable domain comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to a sequence selected from the group consisting of SEQ ID NOs: 10-17. In one embodiment, the CEACAM1 antibody or antigen-binding fragment thereof comprises a heavy chain variable domain comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to a sequence selected from the group consisting of SEQ ID NOs: 15-17.
[0120] In some embodiments, the CEACAM1 antibody or antigen-binding fragment thereof comprises a variable heavy chain amino acid sequence selected from the group consisting of SEQ ID NOs: 10- 17. In some embodiments, the CEACAM1 antibody or antigen-binding fragment thereof comprises a variable heavy chain amino acid sequence selected from the group consisting of SEQ ID NOs: 15-17.
[0121] In one embodiment, the CEACAM1 antibody or antigen-binding fragment thereof comprises a light chain variable domain comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to a sequence selected from the group consisting of SEQ ID NOs: 18-22.
[0122] In one embodiment, the CEACAM1 antibody or antigen-binding fragment thereof comprises a light chain variable domain comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO:21 or SEQ ID NO:22.
[0123] In some embodiments, the antibody or antigen-binding fragment thereof comprises a variable light chain amino acid sequence selected from the group consisting of SEQ ID NOs: 18 to 22. In some embodiments, the antibody or antigen-binding fragment thereof comprises a variable light chain amino acid sequence comprising SEQ ID NO: 21 or SEQ ID NO: 22.
[0124] In one embodiment, the CEACAM1 antibody or antigen-binding fragment thereof comprises
[0125] (i) a heavy chain variable domain comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to a sequence selected from the group consisting of SEQ ID NOs: 10-17; and
[0126] (ii) a light chain variable domain comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to a sequence selected from the group consisting of SEQ ID NOs: 18-22.
[0127] In one embodiment, the CEACAM1 antibody or antigen-binding fragment thereof comprises
[0128] (i) a heavy chain variable domain comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from the group consisting of SEQ ID NOs: 15-17; and
[0129] (ii) a light chain variable domain comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO:21 or SEQ ID NO:22.
[0130] In one embodiment, the CEACAM1 antibody or antigen-binding fragment thereof comprises
[0131] (i) a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 10-17; and / or
[0132] (ii) a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 18-22.
[0133] In one embodiment, the CEACAM1 antibody or antigen-binding fragment thereof comprises
[0134] (i) a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 15-17; and / or
[0135] (ii) a light chain variable domain comprising SEQ ID NO:21 or SEQ ID NO:22.
[0136] In one embodiment, the CEACAM1 antibody or antigen-binding fragment thereof comprises
[0137] (i) a heavy chain variable domain comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 15; and
[0138] (ii) a light chain variable domain comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO:21.
[0139] In one embodiment, the CEACAM1 antibody or antigen-binding fragment thereof comprises
[0140] (i) a heavy chain variable domain comprising SEQ ID NO: 15; and
[0141] (ii) a light chain variable domain comprising SEQ ID NO: 21.
[0142] In one embodiment, the CEACAM1 antibody or antigen-binding fragment thereof comprises
[0143] (i) a heavy chain variable domain comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 16; and
[0144] (ii) a light chain variable domain comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO:21.
[0145] In one embodiment, the CEACAM1 antibody or antigen-binding fragment thereof comprises
[0146] (i) a heavy chain variable domain comprising SEQ ID NO: 16; and
[0147] (ii) a light chain variable domain comprising SEQ ID NO: 21.
[0148] In one embodiment, the CEACAM1 antibody or antigen-binding fragment thereof comprises
[0149] (i) a heavy chain variable domain comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 17; and
[0150] (ii) a light chain variable domain comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO:22.
[0151] In one embodiment, the CEACAM1 antibody or antigen-binding fragment thereof comprises
[0152] (i) a heavy chain variable domain comprising SEQ ID NO: 17; and
[0153] (ii) a light chain variable domain comprising SEQ ID NO:22.
[0154] As used herein, the term "identity" refers to the sequence identity between two nucleic acid molecules or polypeptides. Identity can be determined by comparing the positions in each sequence that is aligned for comparison purposes. For example, when a position in the nucleotide sequence being compared is occupied by the same base, then the molecules are identical at that position. The degree of identity between nucleic acid or amino acid sequences is a function of the number of identical or matching nucleotides or amino acids at the shared position. For example, polypeptides having at least 85%, 90%, 95%, 98% or 99% identity to a particular polypeptide described herein and preferably exhibiting substantially the same function, and polynucleotides encoding such polypeptides are contemplated. Methods and computer programs for determining sequence identity and similarity are publicly available and include, but are not limited to, the GCG program package (Devereux et al., Nucleic Acids Research 12:387, 1984), BLASTP, BLASTN, FASTA (Altschul et al., J. Mol. Biol. 215:403 (1990), and the ALIGN program (version 2.0). The well-known Smith Waterman algorithm can also be used to determine similarity. The BLAST program is publicly available from NCBI and other sources (BLAST Manual, Altschul, et al., NCBI NLM NIH, Bethesda, Md. 20894; BLAST 2.0 website http: / / www.ncbi.nlm.nih.gov / blast / ). These methods take into account various substitutions, deletions and other modifications when comparing sequences.
[0155] In one embodiment, a CEACAM1 antibody or antigen-binding fragment thereof is provided comprising
[0156] (i) a heavy chain variable domain comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to the heavy chain variable domain sequence of SEQ ID NO: 15;
[0157] (ii) a light chain variable domain comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to the heavy chain variable domain sequence of SEQ ID NO: 21; and
[0158] (iii) six CDRs, of which:
[0159] a. The CDR1 sequence of the heavy chain variable region comprises SEQ ID NO: 1;
[0160] b. the CDR2 sequence of the heavy chain variable region comprises SEQ ID NO: 2;
[0161] c. the CDR3 sequence of the heavy chain variable region comprises SEQ ID NO: 3;
[0162] d. the CDR1 sequence of the light chain variable region comprises SEQ ID NO: 6;
[0163] e. the CDR2 sequence of the light chain variable region comprises SEQ ID NO: 7; and
[0164] f. The CDR3 sequence of the light chain variable region comprises SEQ ID NO:8.
[0165] In one embodiment, a CEACAM1 antibody or antigen-binding fragment thereof is provided comprising
[0166] (i) a heavy chain variable domain comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to the heavy chain variable domain sequence of SEQ ID NO: 16;
[0167] (ii) a light chain variable domain comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to the heavy chain variable domain sequence of SEQ ID NO: 21; and
[0168] (iii) six CDRs, of which:
[0169] a. The CDR1 sequence of the heavy chain variable region comprises SEQ ID NO: 1;
[0170] b. the CDR2 sequence of the heavy chain variable region comprises SEQ ID NO: 2;
[0171] c. the CDR3 sequence of the heavy chain variable region comprises SEQ ID NO: 4;
[0172] d. the CDR1 sequence of the light chain variable region comprises SEQ ID NO: 6;
[0173] e. the CDR2 sequence of the light chain variable region comprises SEQ ID NO: 7; and
[0174] f. The CDR3 sequence of the light chain variable region comprises SEQ ID NO:8.
[0175] In one embodiment, a CEACAM1 antibody or antigen-binding fragment thereof is provided comprising
[0176] (i) a heavy chain variable domain comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to the heavy chain variable domain sequence of SEQ ID NO: 17;
[0177] (ii) a light chain variable domain comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to the heavy chain variable domain sequence of SEQ ID NO: 22; and
[0178] (iii) six CDRs, of which:
[0179] a. The CDR1 sequence of the heavy chain variable region comprises SEQ ID NO: 1;
[0180] b. the CDR2 sequence of the heavy chain variable region comprises SEQ ID NO: 2;
[0181] c. the CDR3 sequence of the heavy chain variable region comprises SEQ ID NO: 5;
[0182] d. the CDR1 sequence of the light chain variable region comprises SEQ ID NO: 6;
[0183] e. the CDR2 sequence of the light chain variable region comprises SEQ ID NO: 7; and
[0184] f. The CDR3 sequence of the light chain variable region comprises SEQ ID NO:9.
[0185] Obviously, any framework described herein can be used in combination with any CDR and CDR motif described herein. In some embodiments, the CEACAM1 antibody or antigen-binding fragment thereof uses the framework described in Table 4.
[0186] In some embodiments of the aspects described herein, amino acid sequence modifications of antibodies or antigen-binding fragments thereof that bind to CEACAM1 described herein are contemplated. Amino acid sequence variants of antibodies or antigen-binding fragments thereof are prepared by introducing appropriate nucleotide changes into nucleic acids encoding the antibodies or antigen-binding fragments thereof or by peptide synthesis. Such modifications include, for example, deletions and / or insertions and / or substitutions of residues in the amino acid sequence of the antibodies or antigen-binding fragments thereof. Any combination of deletions, insertions and substitutions is performed to obtain the final construct, provided that the final construct has the desired characteristics, such as binding specificity, inhibition of biological activity.
[0187] One type of variant is a conservative amino acid substitution variant. These variants have at least one amino acid residue in the antibody or antigen-binding fragment thereof replaced by a different residue with similar side chain properties. Amino acids can be grouped according to the similarity of their side chain properties (see Lehninger, BIOCHEMISTRY (2nd ed., Worth Publishers, New York, 1975): (1) non-polar: Ala (A), Val (V), Leu (L), Ile (I), Pro (P), Phe (F), Trp (W), Met (M); (2) uncharged polar: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gln (Q); (3) acidic: Asp (D), Glu (E); (4) basic: Lys (K), Arg (R), His (H).
[0188] Thus, a non-limiting example of a conservative amino acid substitution is replacement of a non-polar amino acid with another non-polar amino acid.
[0189] Alternatively, naturally occurring residues can be grouped based on common side-chain properties:
[0190] (1) Hydrophobicity: Ala (A), Val (V), Leu (L), Ile (I), Met (M);
[0191] (2) Neutral hydrophilicity: Ser (S), Thr (T), Cys (C), Asn (N), Gln (Q);
[0192] (3) Acidic: Asp (D), Glu (E);
[0193] (4) Basic: Lys (K), Arg (R), His (H);
[0194] (5) Residues that affect chain orientation: Gly (G), Pro (P);
[0195] (6) Aromatic: Phe (F), Trp (W), Tyr (Y).
[0196] Thus, a non-limiting example of a conservative amino acid substitution is replacement of a hydrophobic amino acid with another hydrophobic amino acid.
[0197] Amino acid sequence insertions are also contemplated, which may include amino and / or carboxyl terminal fusions of polypeptides ranging in length from one residue to one hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include antibodies or antigen-binding fragments thereof having an N-terminal methionyl residue or antibodies or antigen-binding fragments thereof fused to a cytotoxic polypeptide. Other insertion variants of antibodies or antigen-binding fragments thereof include fusing the N or C terminus of the antibody or antigen-binding fragment thereof to an enzyme or polypeptide (e.g., biotin) that increases the serum half-life of the antibody or antigen-binding fragment thereof.
[0198] Any cysteine residue that is not involved in maintaining the correct conformation of the antibody or antigen-binding fragment thereof that binds CEACAM1 may also be substituted, for example with serine or alanine, to improve the oxidative stability of the molecule and prevent aberrant cross-linking.
[0199] Conversely, cysteine bond(s) may be added to the antibody or antigen-binding fragment thereof to improve its stability (particularly where the antibody or antigen-binding fragment thereof is an antibody fragment such as an Fv fragment).
[0200] In some embodiments, the antibody or its antigen-binding fragment has an amino acid change that changes the original glycosylation pattern of the antibody or its antigen-binding fragment. "Altering the original glycosylation pattern" means deleting one or more carbohydrate moieties present in the antibody or its antigen-binding fragment, and / or adding one or more glycosylation sites that are not present in the antibody or its antigen-binding fragment. The glycosylation of the antibody is usually N-connected or O-connected. N-connected refers to the connection of the carbohydrate moiety to the side chain of the asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine (where X is any amino acid except proline) are recognition sequences for enzymatic connection of the carbohydrate moiety to the asparagine side chain. Therefore, the presence of any of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-connected glycosylation refers to the connection of one of the sugars N-acetylgalactosamine, galactose or xylose to a hydroxyamino acid, the most common of which is serine or threonine, although 5-hydroxyproline or 5-hydroxylysine can also be used. Glycosylation sites are added to the antibody or antigen-binding fragment thereof that binds to CEACAM1 by altering the amino acid sequence so that it contains one or more of the above-mentioned tripeptide sequences (for N-linked glycosylation sites). The alteration can also be made by adding or substituting one or more serine or threonine residues in the sequence of the original antibody or antigen-binding fragment thereof (for O-linked glycosylation sites).
[0201] In some embodiments, the CEACAM1 antibody or antigen-binding fragment thereof provided herein is deglycosylated or non-glycosylated. In some embodiments, the CEACAM1 antibody or antigen-binding fragment thereof contemplated lacks a C-terminal lysine in the heavy chain and / or contains an S241P substitution in the constant region of the heavy chain. In some embodiments, the CEACAM1 antibody or antigen-binding fragment thereof lacks a glycosylation site in the CDR1 of the variable light chain. In some embodiments, the CEACAM1 antibody or antigen-binding fragment thereof lacks a NXS / T consensus sequence in the CDR1 of the variable light chain. In some embodiments, the CEACAM1 antibody or antigen-binding fragment thereof has a mutation in CDR residues 26 and / or 29 (Kabat numbering) of the CDR1 of the variable light chain. When the antibody or antigen-binding fragment thereof comprises an Fc region, the carbohydrate attached thereto may be changed. For example, an antibody having a mature carbohydrate structure is described that lacks fucose attached to the Fc region of the antibody or antigen-binding fragment thereof. See, for example, U.S. Patent Publication Nos. 2003 / 0157108; 2004 / 0093621. Antibodies having bisecting N-acetylglucosamine (GlcNAc) in the carbohydrate attached to the Fc region of the antibody or antigen binding fragment thereof are cited in WO 03 / 011878; U.S. Pat. No. 6,602,684. Antibodies having at least one galactose residue in the oligosaccharide attached to the Fc region of the antibody or antigen binding fragment thereof are reported in WO 97 / 30087. See also WO 98 / 58964; WO 99 / 22764, which relate to antibodies having altered carbohydrates attached to their Fc region.
[0202] In some embodiments, it may be desirable to modify the antibodies or antigen-binding fragments thereof described herein that bind to CEACAM1 in terms of effector function, for example to enhance the antigen-dependent cell-mediated cytotoxicity (ADCC) and / or complement-dependent cytotoxicity (CDC) of the antibody or antigen-binding fragment thereof. This can be achieved by introducing one or more amino acid substitutions in the Fc region of the antibody or antigen-binding fragment thereof. Alternatively or additionally, one or more cysteine residues may be introduced in the Fc region, thereby allowing the formation of interchain disulfide bonds in this region. The homodimeric antibody or antigen-binding fragment thereof thus produced may have improved internalization capacity and / or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., 176 J. Exp. Med. 1191 (1992); Shopes, 148 J. Immunol. 2918 (1992). As described by Wolff et al., 53 Cancer Res. 2560 (1993), heterobifunctional cross-linkers can also be used to prepare homodimeric antibodies with enhanced anti-tumor activity. Alternatively, antibodies or antigen-binding fragments thereof having dual Fc regions can be engineered and thus can have enhanced complement lysis and ADCC capabilities. See Stevenson et al., 3 Anti-Cancer Drug Design 219 (1989).
[0203] In some embodiments, the antibodies or antigen-binding fragments thereof disclosed herein are modified to exhibit reduced or eliminated effector functions. This can be achieved, for example, by: (i) reducing or eliminating wild-type mammalian glycosylation of the antibody (e.g., by producing the antibody in an environment where such glycosylation cannot occur, by mutating one or more carbohydrate attachment points so that the antibody cannot be glycosylated, or by chemically or enzymatically removing one or more carbohydrates from the antibody after the antibody is glycosylated); (ii) by reducing or eliminating the Fc receptor binding ability of the antibody (e.g., by mutating the Fc region, by deleting or eliminating the Fc region within the Fc region); or (iii) by utilizing an antibody isotype known to have minimal or no effector function (i.e., including but not limited to IgG4). In some embodiments, the heavy chain constant region has one or more of the following mutations: S228P; N297Q; and T299A (according to Kabat numbering). In some embodiments, the heavy chain constant region has one or more of the following mutations: L234A, L235A, and P329G (Kabat EU index numbering).
[0204] For example, WO 00 / 42072 describes an antibody with improved ADCC function in the presence of human effector cells, wherein the antibody comprises an amino acid substitution in its Fc region. Preferably, the antibody or its Fab with improved ADCC comprises a substitution (Eu numbering of residues) at positions 298, 333 and / or 334 in the Fc region. Typically, the Fc region of the change is a human IgG1 Fc region comprised of a substitution at one, two or three of these positions or consisting thereof. Such substitutions are optionally combined with substitutions that increase C1q binding and / or CDC. Substitutions include the Asn297Ala mutation in IgG1 Fc.
[0205] Antibodies with altered Clq binding and / or complement dependent cytotoxicity (CDC) are described in WO 99 / 51642, U.S. Pat. Nos. 6,194,551, 6,242,195, 6,528,624 and 6,538,124. The antibodies comprise amino acid substitutions at one or more of amino acid positions 270, 322, 326, 327, 329, 313, 333 and / or 334 of the Fc region thereof (Eu numbering of residues).
[0206] Antibodies with improved binding to the neonatal Fc receptor (FcRn) and increased half-life are described in WO 00 / 42072 and U.S. Patent Publication No. 2005 / 0014934. These antibodies comprise an Fc region having one or more substitutions therein that improve binding of the Fc region to CEACAM1. For example, the Fc region may have a substitution at one or more of positions 238, 250, 256, 265, 272, 286, 303, 305, 307, 311, 312, 314, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424, 428, or 434 (Eu numbering of residues). Antibody variants comprising preferred Fc regions with improved CEACAM1 binding comprise amino acid substitutions at one, two or three of positions 307, 380 and 434 of its Fc region (Eu numbering of residues). In one embodiment, the antibody or antigen-binding fragment thereof has 307 / 434 mutations. Engineered antibodies that bind to CEACAM1 with three or more (e.g., four) functional antigen-binding sites are also contemplated. See, e.g., U.S. Patent Publication No. US2002 / 0004587.
[0207] Antibody fragments and types
[0208] In some embodiments of the aspects described herein, the CEACAM1 antibody fragment is a Fab fragment comprising the variable (V L ) and constant (C L) domain and the variable domain of the heavy chain (V H ) and the first constant domain (C H 1) or consisting essentially of.
[0209] In some embodiments of the aspects described herein, the CEACAM1 antibody fragment is a Fab' fragment, which refers to a fragment of H Fab fragments having one or more cysteine residues at the C-terminus of the 1 domain.
[0210] In some embodiments of the aspects described herein, the CEACAM1 antibody fragment is a fragment comprising V H and C H 1 domain or an Fd fragment consisting essentially of the same.
[0211] In some embodiments of the aspects described herein, the CEACAM1 antibody portion comprises V H and C H 1 domain and in C H The Fd' fragment contains one or more cysteine residues at the C-terminus of the 1 domain.
[0212] Single-chain Fv or scFv antibody fragments contain the V H and V L domains, such that these domains are present in a single polypeptide chain. H With V L The domains also contain a polypeptide linker that allows the scFv to form the desired structure for antigen binding. See, for example, Pluckthun, 113 Pharmacology Monoclonal Antibodies 269 (Rosenburg and Moore, eds., Springer-Verlag, New York, 1994). Thus, in some embodiments of the aspects described herein, the CEACAM1 antibody fragment is a V comprising a single arm of the antibody. L and V H Fv fragments consisting essentially of or comprising a structural domain.
[0213] In some embodiments of the aspects described herein, the CEACAM1 antibody portion is a diabody comprising two antigen binding sites, which comprises, in the same polypeptide chain, a light chain variable domain (V L )'s heavy chain variable domain (V H ).
[0214] In some embodiments of the aspects described herein, the CEACAM1 antibody portion comprises V H A dAb fragment consisting essentially of or comprising a domain.
[0215] In some embodiments of the aspects described herein, the CEACAM1 antibody portion is a F(ab')2 fragment comprising a bivalent fragment comprising two Fab' fragments linked by a disulfide bond at the hinge region.
[0216] Linear antibodies are antibodies as described in Zapata et al., Protein Engin., 8(10):1057-1062 (1995). Briefly, these antibodies comprise a pair of tandem Fd segments (V H -C H 1-V H -C H 1), which together with the complementary light chain polypeptide form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific. In some embodiments of the aspects described herein, the CEACAM1 antibody fragment is a fragment comprising a pair of tandem Fd fragments (V H -C H 1-V H -C H 1), the tandem Fd fragments and the complementary light chain polypeptides together form a pair of antigen binding regions.
[0217] A variety of techniques have been developed and can be used to produce antibody fragments. Traditionally, these fragments are obtained by proteolytic digestion of intact antibodies. See, for example, Morimoto et al., 24 J. Biochem. Biophys. Meths. 107 (1992); Brennan et al., 229 Science 81 (1985). However, these fragments can now be produced directly by recombinant host cells. For example, antibody fragments can be isolated from the antibody phage library discussed herein. Alternatively, Fab'-SH fragments can be directly recovered from Escherichia coli and chemically coupled to form F(ab')2 fragments (Carter et al., 1992). According to another method, F(ab')2 fragments can be directly isolated from recombinant host cell cultures. Other techniques for preparing antibody fragments are obvious to those skilled in the art. In other embodiments, the antibody fragment selected is a single-chain Fv fragment (scFv). See, for example, WO 93 / 16185.
[0218] In one embodiment, the antibody is a bispecific antibody comprising a complementary region that binds to CEACAM1 and a complementary region that binds to PD-1. In one embodiment, the antibody is a bispecific antibody comprising a complementary region that binds to CEACAM1 and a complementary region that binds to PD-L1. In one embodiment, the antibody is a bispecific antibody comprising a complementary region that binds to CEACAM1 and a complementary region that binds to TIM-3. In one embodiment, the antibody is a bispecific antibody comprising a complementary region that binds to CEACAM1 and a complementary region that binds to epidermal growth factor receptor (EGFR). In one embodiment, the antibody is a bispecific antibody comprising a complementary region that binds to CEACAM1 and a complementary region that binds to Fcγ receptors.
[0219] The contemplated antibodies or antigen-binding fragments may have constant regions of all types, including IgM, IgG, IgD, and IgE, and any isotype, including IgG1, IgG2, IgG3, and IgG4. In one embodiment, human isotype IgG1 is used. In another embodiment, human isotype IgG4 is used. The light chain constant region may be λ or κ. An antibody or antigen-binding fragment thereof may contain sequences from more than one class or isotype.
[0220] Also disclosed herein are chimeric antigen receptor T cells (CAR T cells) that bind CEACAM1. In one embodiment, one or more CDRs of the anti-CEACAM antibodies disclosed herein are transplanted onto a chimeric antigen receptor (CAR) on a T cell. Such genetically modified T cells utilize CAR (also referred to as chimeric T cell receptors) to target antigens expressed on tumor cells in a human leukocyte antigen-independent manner.
[0221] Antibody Binding
[0222] The human CEACAM1 gene produces 11 isoforms by alternative splicing. Each isoform has a variable (V)-like Ig domain at the amino (N) terminus of the protein. In addition to CEACAM1-1L and CEACAM1-1S isoforms, different isoforms also have 2 or 3 constant C2-like Ig domains. Eight CEACAM1 isoforms are anchored to the cell membrane through a transmembrane domain, and three CEACAM1 isoforms (CEACAM1-4C1-3 and -3C2) lack a transmembrane domain and are secreted. Two isoforms (CEACAM1-3AL and -3AS) have an Alu family repeat (A) between the constant C2-like Ig domain and the transmembrane domain. Transmembrane CEACAM1 isoforms also have long (L) or short (S) cytoplasmic domains, which are determined by including or excluding CEACAM1 exon 7 in the messenger. The CEACAM1 L cytoplasmic domain has two ITIM motifs, which are unique to CEACAM1 among the CEACAM family members. In one aspect, a CEACAM1 antibody or antigen-binding fragment thereof is provided, including an antibody described herein by its structural features, which binds to an extracellular variable (V)-like Ig domain at the amino (N) terminus (N domain) of the protein of CEACAM1, i.e., a domain common to all isoforms of CEACAM1, including CEACAM1 isoforms 1L, 1S, 3L, 3S, 4L, 4S, 3A1, 3AS, 3, 4C1, and 4C2. In some embodiments, the antibodies and antigen-binding fragments thereof provided bind to human CEACAM1. In some embodiments, the antibodies and antigen-binding fragments thereof provided bind to mammalian CEACAM1. The sequence of the full-length form of CEACAM1 (NCBI reference sequence NP_001703.2; UNIPROT ID P13688) is provided as SEQ ID NO: 23 (signal sequence: residues 1-34 of SEQ ID NO: 23; Ig-V N domain: residues 35-142 of SEQ ID NO: 23. The mature form of CEACAM1 (without signal sequence) is provided as SEQ ID NO: 24.
[0223] As used herein, "binding" of an antibody or antigen-binding fragment thereof to CEACAM1, an epitope on CEACAM1, or in certain embodiments described below, a specific residue on CEACAM1 includes selective interaction of the antibody or antigen-binding fragment thereof with CEACAM1. Thus, binding includes, for example, primary and secondary interactions, including hydrogen bonds, ionic interactions, salt bridges, and hydrophilic and hydrophobic interactions.
[0224] In certain embodiments, the CEACAM1 antibodies or antigen-binding fragments thereof described herein are present in an amount of 10 -5 Up to 10 -12mol / l, 10 -6 Up to 10 -12 mol / l, 10 -6 Up to 10 -9 mol / l, 10 -7 Up to 10 -12 mol / l, 10 -8 Up to 10 -12 mol / l, 10 -9 Up to 10 -12 mol / l, 10 -10 Up to 10 -12 mol / l or 10 -11 Up to 10 -12 mol / l K D In other embodiments, the CEACAM1 antibodies or antigen-binding fragments thereof described herein are present in an amount of 10 -5 Up to 10 -11 mol / l, 10 -6 Up to 10 -11 mol / l, 10 -7 Up to 10 -11 mol / l, 10 -8 Up to 10 -11 mol / l, 10 -9 Up to 10 -11 mol / l or 10 -10 Up to 10 -11 mol / l K D In other embodiments, the CEACAM1 antibodies or antigen-binding fragments thereof described herein are present in an amount of 10 -5 Up to 10 -10 mol / l, 10 -6 Up to 10 -10 mol / l, 10 -7 Up to 10 -10 mol / l, 10 -8 Up to 10 -10 mol / l or 10 -9 Up to 10 -10 mol / l K D In other embodiments, the CEACAM1 antibodies or antigen-binding fragments thereof described herein are present in an amount of 10 -5 Up to 10 -8 mol / l, 10 -6 Up to 10 -8 mol / l or 10 -7 Up to 10 - 8 mol / l K D Binds to CEACAM1.
[0225] The term "specificity" herein refers to the ability of an antibody or antigen-binding fragment thereof (such as an anti-CEACAM1 antibody or antigen-binding fragment thereof) to recognize an epitope within CEACAM1, with little or no detectable reactivity with other parts of CEACAM1. Specificity can be relatively determined by competition assays or by epitope identification / characterization techniques described herein or their equivalents known in the art.
[0226] As used herein, an "epitope" can be formed by continuous amino acids or non-continuous amino acids juxtaposed by tertiary folding of proteins. Epitopes formed by continuous amino acids are usually retained when exposed to denaturing solvents, while epitopes formed by tertiary folding are usually lost when treated with denaturing solvents. An epitope usually includes at least 3, more usually at least 5, about 9, or about 8-10 amino acids in a specific spatial conformation. An "epitope" includes a conventional sequence of an immunoglobulin V or V region. H / V L The epitope defines the minimum binding site of an antibody or antigen-binding fragment thereof and therefore represents the specific target of the antibody or antigen-binding fragment thereof. In the case of single-domain antibodies, the epitope represents the structural unit bound by the isolated variable domains.
[0227] In a particular embodiment, the contemplated antibody or antigen-binding fragment specifically binds to the same epitope as antibody He14 / L1.
[0228] In one aspect, the present invention provides antibodies and antigen-binding fragments thereof, including antibodies described herein by their structural features, wherein the antibodies and antigen-binding fragments thereof specifically bind to at least a portion of the homophilic binding domain on CEACAM1 (i.e., the portion of the CEACAM1 protein involved in the formation of CEACAM1:CEACAM1 homodimers), thereby blocking CEACAM1 homophilic interactions. The CEACAM1 residues involved in homodimerization are shown in Table 1.
[0229] Table 1. Interactions observed in the crystal structure of the human CEACAM1 wild-type dimer (PDB ID 4QXW). The side chains of residues S32, Y34, Q44, Q89, N97 and E99 form a hydrogen bond network at the GFCC' interface, which includes additional side chain to main chain backbone interactions between S32 and L95, Q44 and N97 and E99 and G41, as well as hydrophobic interactions of residues F29, V39 and I91.
[0230] Interaction number hCEACAM1(A) residues hCEACAM1(B) residues 1 A:L95 B:S32 2 A:E99 B:G41 3 A:L95 B:Q44 4 A:Y34 B:Q89 5 A:Q89 B:Q89 6 A:Q44 B:N97 7 A:S32 B:N97 8 A:Y34 B:N97 9 A:Q89 B:N97 10 A:S32 B:L95 11 A:G41 B:E99 12 A:Q44 B:L95 13 A:Q89 B:Q89 14 A:Q89 B:Y34 15 A:N97 B:Q44 16 A:N97 B:S32 17 A:N97 B:Y34
[0231] In some embodiments, the CEACAM antibody or antigen-binding fragment thereof binds to residues in the GFCC' face of CEACAM1, such as F29, Y31, Q44, Y48, T56, Q89, D94, L95 and / or N97 of SEQ ID NO:24.
[0232] In some embodiments, the CEACAM antibody or antigen-binding fragment thereof binds to a residue in the ABED face of CEACAM1, such as M7, E16, Q27, Y48, Q53, Y68, or N70 of SEQ ID NO:24.
[0233] As used herein, a "blocking" antibody or antibody "antagonist" is an antibody that inhibits or reduces the biological activity of the antigen to which it binds. For example, in some embodiments, a CEACAM1 antagonist antibody or antigen-binding fragment thereof binds to CEACAM1 and inhibits the activity of CEACAM1 and / or the binding of CEACAM1 to a heterologous binding partner (such as other CEACAM proteins or TIM-3). Inhibition of activity and inhibition of binding include partial inhibition. Methods for identifying CEACAM1 antibodies that block CEACAM1 homophilic and heterophilic interactions are described herein and are known to those skilled in the art. For example, competing antibodies, cross-blocking antibodies, and cross-blocked antibodies can be identified using any suitable method known in the art, including competitive ELISA or Assays in which binding of a competing or cross-blocking antibody to human CEACAM1 prevents binding of an antibody disclosed herein, and vice versa.
[0234] In certain embodiments, not all CDRs are directly involved in binding to the antigen. In one embodiment, four of the six CDRs of the CEACAM1 antibody or its antigen-binding fragment are in contact with the antigen. In one embodiment, five of the six CDRs of the CEACAM1 antibody or its antigen-binding fragment are in contact with the antigen. In one embodiment, six of the six CDRs of the CEACAM1 antibody or its antigen-binding fragment are in contact with the antigen.
[0235] CEACAM family members are widely expressed on a variety of cell types (especially leukocytes), thereby affecting the strength of cell function. For example, CEACAM1 is expressed on epithelial cells, endothelial cells, lymphocytes, and myeloid cells, CEACAM3 is expressed on granulocytes and neutrophils, CEACAM5 is expressed on epithelial cells, and CEACAM6 is expressed on epithelial cells and granulocytes. However, the N domain of CEACAM1 has about 90% similarity to the N domain of CEACAM family members 3, 5, and 6, making it difficult to selectively target CEACAM1.
[0236] Although the N domain is highly similar among CEACAM family members, in some embodiments, the antibodies or antigen-binding fragments thereof provided herein, including the antibodies described herein by their structural features, are selective for CEACAM1. By selectively targeting CEACAM1, embodiments of the present invention can avoid unwanted interference, such as the broad activation function of CEACAM3.
[0237] The terms "selective" and "selectivity" herein refer to the preferential binding of an antibody or antigen-binding fragment thereof (i.e., a CEACAM1 antibody or antigen-binding fragment thereof) to a specific region, target or peptide; the region, target or peptide is typically a region or epitope in CEACAM1 rather than one or more other biological molecules, including other CEACAM family members.
[0238] In some embodiments, the contemplated CEACAM1 antibody or antigen-binding fragment thereof does not exhibit significant binding to CEACAM3, CEACAM5, CEACAM6 and / or CEACAM8. In some embodiments, the contemplated CEACAM1 antibody or antigen-binding fragment thereof does not exhibit detectable binding to CEACAM3, CEACAM5, CEACAM6 and / or CEACAM8. In some embodiments, the contemplated CEACAM1 antibody or antigen-binding fragment thereof binds to CEACAM1 with an affinity that is at least 10 times greater, such as at least 100 times greater, and at least 1000 times greater, and up to 10,000 times greater or stronger than the binding affinity of the contemplated CEACAM1 antibody or antigen-binding fragment thereof to another target or polypeptide.
[0239] As used herein, the equilibrium constant (K) for the dissociation of an antigen from an antigen binding protein is D "Affinity" as expressed in terms of affinity is a measure of the strength of binding between an antigenic determinant and an antigen binding site on an antigen binding protein (such as an antibody or antibody fragment thereof). D The smaller the value, the stronger the binding strength between the antigenic determinant and the antigen-binding molecule. Alternatively, affinity can also be expressed as an affinity constant (K A ), which is 1 / K D ). As is clear to the skilled person, affinity can be determined in a manner known per se, depending on the specific antigen of interest.
[0240] In one aspect, the present invention provides antibodies and antigen-binding fragments thereof, including antibodies described herein by their structural features, wherein the antibodies and antigen-binding fragments thereof specifically bind to at least a portion of one or more other members of the CEACAM family binding site on CEACAM1, thereby blocking the interaction of CEACAM1 with one or more other members of the CEACAM family. These CEACAM family members include, but are not limited to, CEACAM5 and CEACAM8 (Ramani et al., Anal. Biochem. Jan. 15, 2012; 420(2); 127-38; Scheffrahn et al., J. Immunol. May. 15, 2002; 168(10); 5139-46).
[0241] In one aspect, the present invention provides antibodies and antigen-binding fragments thereof, including antibodies described herein by their structural features, wherein the antibodies and antigen-binding fragments thereof specifically bind to at least a portion of the TIM family member binding site on CEACAM1, thereby blocking the interaction between CEACAM1 and the TIM family member. In some embodiments, this TIM family member is TIM-1, TIM-3 or TIM-4. In some embodiments, the CEACAM1 antibody or antigen-binding fragment thereof specifically binds to one or more of the CEACAM1 residues Y34, G41, N42, Q44, Q89, S93, D94, V96 and / or N97 of SEQ ID NO: 17, which residues have been shown to be involved in CEACAM1 binding to TIM-3 (Huang et al., Nature. 2015 Jan 15; 517(7534): 386-90).
[0242] In one aspect, the present invention provides antibodies and antigen-binding fragments thereof, including antibodies described herein by their structural features, wherein the antibodies and antigen-binding fragments thereof specifically bind to at least a portion of the pathogen binding site on CEACAM1, thereby blocking the interaction between CEACAM1 and the pathogen.
[0243] In one aspect, the invention provides antibodies and antigen-binding fragments thereof, including antibodies described herein by their structural features, wherein the antibodies and antigen-binding fragments thereof specifically bind to at least a portion of a bacterial adhesion surface protein (adhesin) binding site on CEACAM1, thereby blocking the interaction between CEACAM1 and the adhesin. In certain embodiments, the adhesin is expressed on the surface of a pathogenic bacterium that binds to CEACAM1, including but not limited to Escherichia coli, particularly diffusely adherent Escherichia coli (DAEC), Neisseria gonorrhoeae, Neisseria meningitidis, commensal Neisseria, Moraxella catarrhalis, Haemophilus influenzae, Haemophilus aegypti, Helicobacter pylori, Fusobacterium, Salmonella, and / or Streptococcus agalactiae. In one embodiment, the adhesin is a beta protein from Streptococcus agalactiae.
[0244] In one embodiment, the CEACAM1 antibody or antigen binding fragment thereof disrupts the interaction between CEACAM1 and Streptococcus agalactiae (Group B Streptococcus). In one embodiment, the CEACAM1 antibody or antigen binding fragment thereof disrupts the interaction between CEACAM1 and the beta protein from Streptococcus agalactiae. The interactions observed in the crystal structure of the BIgI domain of the beta protein from Streptococcus agalactiae and human CEACAM1 are shown in Table 2. In one embodiment, the CEACAM1 antibody or antigen binding fragment thereof disrupts one or more interactions shown in Table 2.
[0245] Table 2. Interactions observed in the crystal structure of the BIgI domain of the beta protein from Streptococcus agalactiae and human CEACAM1 (PDB ID 6V3P).
[0246] interaction Adhesin (C) residues hCEACAM1(B) residues 1 C:PHE 41 B:SER 93 2 C:ASP 54 B:TYR 34 3 C:THR 58 B:LEU 95 4 C:TYR 60 B:ASP 94 5 C:VAL 52 B:GLN 44 6 C:ASP 54 B:GLY 41
[0247] In one embodiment, the CEACAM1 antibody or antigen binding fragment thereof disrupts the interaction between CEACAM1 and HopQ expressed on the surface of Helicobacter pylori. In one embodiment, the CEACAM1 antibody or antigen binding fragment specifically binds to one or more of CEACAM1 residues F29, Y34, N42, Q89 and N97, which have been predicted to be involved in CEACAM1 binding to HopQ. The interactions observed in the crystal structure of HopQ and hCEACAM1 are shown in Table 3. In one embodiment, the CEACAM1 antibody or antigen binding fragment thereof disrupts one or more interactions shown in Table 3.
[0248] Table 3. Interactions observed in the crystal structure of HopQ and hCEACAM1 (PDB ID 6AW2).
[0249]
[0250]
[0251] In another embodiment, the CEACAM1 antibody or antigen-binding fragment thereof disrupts the interaction between CEACAM1 and an opacity-associated (Opa) adhesin protein expressed on the surface of Neisseria, including but not limited to Opa. 52 、Opa 65 、Opa 68 、Opa 70 、Opa 72 、Opa 73 、Opa 74 and Opa 75 In one embodiment, the CEACAM1 antibody or antigen-binding fragment specifically binds to one or more of CEACAM1 residues Q44 and A49, which residues have been predicted to be involved in the binding of CEACAM1 to the Neisserial Opa protein.
[0252] In another embodiment, the CEACAM1 antibody or antigen-binding fragment thereof disrupts the interaction between CEACAM1 and the Opa-like protein OlpA expressed on the surface of Moraxella.
[0253] In one embodiment, the CEACAM1 antibody or antigen-binding fragment thereof disrupts the interaction between CEACAM1 and Haemophilus influenzae OMP P 1. In one embodiment, the CEACAM1 antibody or antigen-binding fragment specifically binds to one or more of CEACAM1 residues Q44 and A49, which have been predicted to be involved in CEACAM1 binding to Haemophilus influenzae OMP P 1.
[0254] In another embodiment, the CEACAM1 antibody or antigen binding fragment thereof disrupts the interaction between CEACAM1 and Haemophilus aegypti OMP P1. In one embodiment, the CEACAM1 antibody or antigen binding fragment specifically binds to CEACAM1 residue F29, which has been predicted to be involved in CEACAM1 binding to Haemophilus aegypti OMP P1.
[0255] In another embodiment, the CEACAM1 antibody or antigen-binding fragment thereof disrupts the interaction between CEACAM1 and Candida albicans.
[0256] In another embodiment, the present invention provides a method for inhibiting the binding of CEACAM1 to a sub-nematode using the CEACAM1 antibody or antigen-binding fragment thereof described herein, the method comprising contacting CEACAM1 with the CEACAM1 antibody or antigen-binding fragment thereof described herein. In one embodiment, the sub-nematode is Wuchereria bancrofti.
[0257] Antibody conjugates
[0258] In some embodiments of the aspects described herein, the antibody or antigen-binding fragment thereof that binds CEACAM1 is conjugated to a functional moiety.Examples of useful functional moieties include, but are not limited to, blocking moieties, detectable moieties, diagnostic moieties, targeting moieties, and therapeutic moieties.
[0259] Exemplary blocking moieties include moieties that have sufficient steric hindrance and / or charge to reduce the occurrence of glycosylation, for example by blocking the ability of glycosidases to glycosylate the antibody or antigen-binding fragment thereof. Additionally or alternatively, blocking moieties can reduce effector function, for example by inhibiting the ability of the Fc region to bind receptors or complement proteins. Preferred blocking moieties include cysteine adducts and PEG moieties.
[0260] In a preferred embodiment, the blocking moiety is a cysteine, preferably a cysteine that associates with a free cysteine, such as in cell culture, such as during or after translation of an Fc-containing polypeptide. Other blocking cysteine adducts include cystine, mixed disulfide adducts, or disulfide bonds.
[0261] In another preferred embodiment, the blocking moiety is a polyalkylene glycol moiety, such as a PEG moiety, and preferably a PEG-maleimide moiety. Preferred pegylated moieties (or related polymers) can be, for example, polyethylene glycol ("PEG"), polypropylene glycol ("PPG"), polyoxyethylated glycerol ("POG") and other polyoxyethylated polyols, polyvinyl alcohol ("PVA") and other polyoxyalkylene oxides, polyoxyethylated sorbitol or polyoxyethylated glucose. The polymer can be a homopolymer, a random or block copolymer, a terpolymer based on the monomers listed above, which is linear or branched, substituted or unsubstituted, as long as it has at least one active sulfone moiety. The polymer moiety can have any length or molecular weight, but these features can affect biological properties. The average molecular weight of polymers that are particularly useful for reducing clearance in pharmaceutical applications is in the range of 2,000 to 35,000 Daltons. In addition, if two groups are attached to the polymer, one at each end, the length of the polymer can affect the effective distance and other spatial relationships between the two groups. Therefore, those skilled in the art can change the length of the polymer to optimize or impart the desired biological activity. For several reasons, PEG can be used for biological applications. PEG is usually transparent, colorless, tasteless, soluble in water, heat-stable, inert to many chemical reagents, non-hydrolyzed and non-toxic. Pegylation can improve the pharmacokinetic properties of the molecule by increasing the apparent molecular weight of the molecule. The increased apparent molecular weight reduces the clearance rate from the body after subcutaneous or systemic administration. In many cases, Pegylation can reduce antigenicity and immunogenicity. In addition, Pegylation can increase the solubility of bioactive molecules.
[0262] Examples of detectable moieties useful in the methods and antibodies and antigen-binding fragments thereof contemplated by the present invention include fluorescent moieties or labels, imaging agents, radioisotope moieties, radiopaque moieties, and the like, such as detectable labels, such as biotin, fluorophores, chromophores, spin resonance probes, or radioactive labels. Exemplary fluorophores include fluorescent dyes (e.g., fluorescein, rhodamine, etc.) and other luminescent molecules (e.g., luminal). Fluorophores may be sensitive to the environment such that if they are located near one or more residues in the modified protein, their fluorescence changes (undergoing structural changes upon binding to a substrate (e.g., a dansyl probe)). Exemplary radioactive labels include those containing a molecule having one or more low-sensitivity nuclei ( 13 C. 15 N. 2 H. 125 I. 123 I. 99 Tc, 43 K. 52 Fe, 67 Ga, 68 Ga,111 In, etc.) Other useful moieties are known in the art.
[0263] Examples of diagnostic moieties useful for the methods and antibodies and antigen-binding fragments thereof contemplated by the present invention include detectable moieties useful for revealing the presence of a disease or condition. Typically, diagnostic moieties allow determination of the presence, absence or level of a molecule (e.g., a target peptide, one or more proteins) associated with a disease or condition. Such diagnostics are also useful for predicting and / or diagnosing a disease or condition and its progression.
[0264] Examples of therapeutic moieties useful in the methods and antibodies and antigen-binding fragments thereof contemplated by the invention include, for example, anti-inflammatory agents, anti-cancer agents, anti-neurodegenerative agents, or anti-infective agents. Functional moieties may also have one or more of the above functions.
[0265] Exemplary therapeutic moieties include radionuclides with high energy ionizing radiation that are capable of causing multiple strand breaks in nuclear DNA and are therefore useful for inducing cell death (e.g., of cancer). Exemplary high energy radionuclides include: 90 Y. 125 I. 131 I. 123 I. 111 In, 105 Rh, 153 Sm, 67 Cu, 67 Ga, 166 Ho, 177 Lu, 186 Re and 188 Re. These isotopes generally produce high energy alpha or beta particles with short path lengths. Such radionuclides kill cells in their immediate vicinity, such as neoplastic cells to which the conjugate has attached or has entered. They have little or no effect on nonlocalized cells and are essentially nonimmunogenic.
[0266] Exemplary therapeutic moieties also include cytotoxic agents, such as cytostatic agents (e.g., alkylating agents, DNA synthesis inhibitors, DNA intercalators or cross-linking agents, or DNA-RNA transcription regulators), enzyme inhibitors, gene regulators, cytotoxic nucleosides, tubulin binding agents, hormones and hormone antagonists, anti-angiogenic agents, and the like.
[0267] Exemplary therapeutic moieties also include alkylating agents, such as the anthracycline family (e.g., adriamycin, carminomycin, cyclosporin-A, chloroquine, methotrexate, mithramycin, porfiromycin, streptonigrin, anthracenedione, and aziridine). In another embodiment, the chemotherapeutic moiety is a cytostatic agent, such as a DNA synthesis inhibitor. Examples of DNA synthesis inhibitors include, but are not limited to, methotrexate and dichloromethotrexate, 3-amino-1,2,4-benzotriazine 1,4-dioxide, aminopterin, cytosine β-D-arabinofuranoside, 5-fluoro-5′-deoxyuridine, 5-fluorouracil, ganciclovir, hydroxyurea, actinomycin-D, and mitomycin C. Exemplary DNA intercalators or cross-linkers include, but are not limited to, bleomycin, carboplatin, carmustine, chlorambucil, cyclophosphamide, cisplatin (II) (cisplatin), melphalan, mitoxantrone, and oxaliplatin.
[0268] Exemplary therapeutic moieties also include transcriptional regulators such as actinomycin D, daunorubicin, doxorubicin, homoharringtonine and idarubicin. Other exemplary cell growth inhibitors compatible with the present invention include ansamycin benzoquinone, quinone derivatives (e.g., quinolones, genistein, bactacyclin), busulfan, ifosfamide, nitrogen mustard, triimidazole quinone, diaziquone, carboquinone, indolequinone EO9, diaziridinyl benzoquinone methyl DZQ, triethylene phosphoramide and nitrosourea compounds (e.g., carmustine, lomustine, semustine).
[0269] Exemplary therapeutic moieties also include cytotoxic nucleosides, such as, for example, adenosine, cytarabine, cytosine arabinoside, 5-fluorouracil, fludarabine, floxuridine, ftorafur, and 6-mercaptopurine; tubulin binding agents, such as taxanes (e.g., paclitaxel, docetaxel, taxanes), nocodazole, rhizoctonia, dolastatin (e.g., dolastatin 10, 11, or 15), colchicine and colchicinoids (e.g., ZD6126), combretastatin (e.g., tadalafil), phenytoin, tadalafil, ... etastatin) (e.g., combretastatin A-4, AVE-6032) and vinca alkaloids (e.g., vinblastine, vincristine, vindesine and vinorelbine (navelbine)); anti-angiogenic compounds such as angiostatin K1-3, DL-α-difluoromethyl-ornithine, endostatin, fumagillin, genistein, minocycline, staurosporine and (±)-thalidomide.
[0270] Exemplary therapeutic moieties also include hormones and hormone antagonists, such as corticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone or medroxyprogesterone), estrogens (e.g., diethylstilbestrol), antiestrogens (e.g., tamoxifen), androgens (e.g., testosterone), aromatase inhibitors (e.g., aminogluthetimide), 17-(allylamino)-17-demethoxygeldanamycin, 4-amino-1,8-naphthalimide, apigenin, brefeldin A, cimetidine, dichloromethylene-bisphosphonic acid, leuprolide (leuprorelin), luteinizing hormone-releasing hormone, pifithrin-α, rapamycin, sex hormone binding globulin, and thapsigargin.
[0271] Exemplary therapeutic moieties also include enzyme inhibitors such as S(+)-camptothecin, curcumin, (-)-deguelin, 5,6-dichlorobenzene-imidazole 1-β-D-ribofuranoside, etoposide, formestane, forsitracin, hispidin, 2-imino-1-imidazolidineacetic acid (cyclocreatine), mevinolin, trichostatin A, tyrosine phosphorylation inhibitor AG34, and tyrosine phosphorylation inhibitor AG 879.
[0272] Exemplary therapeutic moieties also include gene modulators such as 5-aza-2'-deoxycytidine, 5-azacytidine, cholecalciferol (vitamin D3), 4-hydroxytamoxifen, melatonin, mifepristone, raloxifene, trans-retinal (vitamin A aldehyde), retinoic acid, retinoic acid, 9-cis-retinoic acid, 13-cis-retinoic acid, retinol (vitamin A), tamoxifen, and troglitazone.
[0273] Exemplary therapeutic moieties also include cytotoxic agents, such as, for example, pteridine family drugs, enediynes, and podophyllotoxins. Particularly useful members of these classes include, for example, methotrexate, podophyllotoxin or podophyllotoxin derivatives such as etoposide or etoposide phosphate, isovinabine, vindesine, vinblastine, etc.
[0274] Still other cytotoxins compatible with the teachings herein include auristatins (e.g., auristatin E and monomethyl auristatin E), calicheamicin, gramicidin D, maytansanoids (e.g., maytansine), neocarcinostatin, topotecan, taxanes, cytochalasin B, ethidium bromide, emetine, tenoposide, colchicine, dihydroxyanthracenedione, mitoxantrone, procaine, tetracaine, lidocaine, propranolol, puromycin, and analogs or homologs thereof.
[0275] Techniques for conjugating such therapeutic moieties to antibodies are well known, see, e.g., Amon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in Controlled Drug Delivery (2nd ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", Immunol. Rev., 62: 119-58 (1982).
[0276] In order to increase the half-life of an antibody or polypeptide containing an amino acid sequence described herein, a salvage receptor binding epitope may be linked to an antibody or antigen-binding fragment thereof (particularly an antibody fragment), as described, for example, in U.S. Pat. No. 5,739,277. The term "salvage receptor binding epitope" may refer to an epitope of the Fc region of an IgG molecule (e.g., IgG1, IgG2, IgG3, or IgG4) that is responsible for increasing the in vivo serum half-life of the IgG molecule (e.g., Ghetie et al., 18 Ann. Rev. Immunol. 739 (2000). Antibodies having substitutions in their Fc region and increased serum half-life are also described in WO 00 / 42072, WO 02 / 060919; Shields et al., 276 J. Biol. Chem. 6591 (2001); Hinton, 279 J. Biol. Chem. 6213-6216 (2004). For example, a nucleic acid molecule encoding a salvage receptor binding epitope can be linked in frame to a nucleic acid encoding a polypeptide sequence described herein, such that a fusion protein expressed by the engineered nucleic acid molecule comprises a salvage receptor binding epitope and a polypeptide sequence described herein. In another embodiment, serum half-life can also be increased, for example, by linking to other polypeptide sequences. For example, an antibody or antigen-binding fragment thereof useful in the methods of the present invention can be linked to serum albumin or a portion of serum albumin that binds to a CEACAM1 receptor or a serum albumin binding peptide, such that serum albumin binds to the antibody or antigen-binding fragment thereof, such as WO 01 / 45746. In one embodiment, the half-life of the Fab is increased by these methods. See also Dennis et al., 277 J. Biol. Chem. 35035 (2002) for additional serum albumin binding peptide sequences.
[0277] Other types of functional moieties are known in the art and can be readily employed in the methods and compositions of the present invention based on the teachings contained herein.
[0278] Nucleic Acids
[0279] Also provided herein are nucleic acids encoding CEACAM1 antibodies and antigen-binding fragments thereof, as well as vectors, host cells and expression systems. As used herein, the term "nucleic acid" refers to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. Thus, this term includes, but is not limited to, single-stranded, double-stranded or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or polymers containing purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural or derived nucleotide bases.
[0280] The nucleic acid encoding the CEACAM1 antibody and antigen-binding fragment thereof can be, for example, a DNA, cDNA, RNA, synthetically produced DNA or RNA, or a recombinantly produced chimeric nucleic acid molecule comprising any of those polynucleotides alone or in combination. For example, an expression vector comprising a polynucleotide sequence encoding the CEACAM1 antibody or antigen-binding fragment thereof described herein is provided, the polynucleotide sequence being operably linked to an expression control sequence suitable for expression in a eukaryotic and / or prokaryotic host cell.
[0281] The term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid connected thereto."Vector" includes but is not limited to viral vectors, plasmids, RNA vectors or linear or circular DNA or RNA molecules, which may be composed of chromosomes, non-chromosomes, semi-synthetic or synthetic nucleic acids. In some embodiments, the vector used is a vector capable of autonomous replication (episomal vector) and / or expression of a nucleic acid connected thereto (expression vector). A large number of suitable vectors are known to those skilled in the art and are commercially available. Viral vectors include retroviruses, adenoviruses, parvoviruses (e.g., adeno-associated virus, AAV), coronaviruses, negative-strand RNA viruses such as orthomyxoviruses (e.g., influenza virus), rhabdoviruses (e.g., rabies and vesicular stomatitis virus), paramyxoviruses (e.g., measles and Sendai virus), positive-strand RNA viruses such as picornaviruses and alphaviruses, and double-stranded DNA viruses include adenoviruses, herpes viruses (e.g., herpes simplex virus type 1 and type 2, Epstein-Barr virus, cytomegalovirus) and poxviruses (e.g., vaccinia, fowlpox and canarypox). Other viruses include, for example, Norwalk virus, togavirus, flavivirus, reovirus, papovavirus, hepadnavirus and hepatitis virus. Examples of retroviruses include avian leukosis-sarcoma, mammalian C-type, B-type, D-type viruses, HTLV-BLV group, lentivirus and foamy virus.
[0282] A variety of expression vectors have been developed for efficient synthesis of antibodies and antigen-binding fragments thereof in prokaryotic cells (such as bacteria) and in eukaryotic systems (including but not limited to yeast and mammalian cell culture systems). Vectors may contain segments of chromosomal, non-chromosomal, and synthetic DNA sequences. Cells comprising expression vectors for expressing a desired CEACAM1 antibody or antigen-binding fragment thereof are also provided.
[0283] Antibody production and expression system
[0284] The antibody of the present invention or its antigen-binding fragment is usually produced by recombinant expression. The nucleic acid encoding the light chain and heavy chain variable region (optionally connected to the constant region) is inserted into the expression vector. The light chain and the heavy chain can be cloned in the same or different expression vectors. The DNA segment encoding the immunoglobulin chain is operably connected to the control sequence in the expression vector to ensure the expression of the immunoglobulin polypeptide. The expression control sequence includes but is not limited to a promoter (such as a naturally associated or heterologous promoter), a signal sequence, an enhancer element and a transcription termination sequence. Preferably, the expression control sequence is a eukaryotic promoter system in a vector capable of transforming or transfecting a eukaryotic host cell. Once the vector is integrated into a suitable host, the host is maintained under conditions suitable for high-level expression of nucleotide sequences and collection and purification of cross-reactive antibodies.
[0285] These expression vectors are usually replicable in the host organism as episomes or as an integral part of the host chromosomal DNA. Typically, the expression vector comprises a selection marker (e.g., ampicillin resistance, hygromycin resistance, tetracycline resistance or neomycin resistance) to allow detection of those cells transformed with the desired DNA sequence (see, e.g., Itakura et al., U.S. Patent No. 4,704,362).
[0286] The expression of antibodies and antigen-binding fragments contemplated by the present invention can occur in prokaryotic or eukaryotic cells. Suitable hosts include bacterial or eukaryotic hosts, including yeast, insect, fungi, bird and mammalian cells in vivo or in situ, or host cells of mammalian, insect, bird or yeast origin. Mammalian cells or tissues can be human, primate, hamster, rabbit, rodent, cattle, pig, sheep, horse, goat, dog or cat origin, but any other mammalian cells can be used.
[0287] Escherichia coli is a prokaryotic host particularly useful for cloning polynucleotides (e.g., DNA sequences) of the present invention. Other suitable microbial hosts include bacilli, such as Bacillus subtilus, and other Enterobacteriaceae, such as Salmonella, Serratia, and various Pseudomonas species.
[0288] Other microorganisms such as yeast can also be used for expression. Saccharomyces and Pichia are exemplary yeast hosts, with suitable vectors having expression control sequences (e.g., promoters), replication origins, termination sequences, etc. as required. Typical promoters include 3-phosphoglycerate kinase and other glycolytic enzymes. Inducible yeast promoters include, in particular, promoters from alcohol dehydrogenase, isocytochrome C, and enzymes responsible for methanol, maltose, and galactose utilization.
[0289] In addition, by using, for example, the yeast ubiquitin hydrolase system, in vivo synthesis of ubiquitin-transmembrane polypeptide fusion proteins can be achieved. The fusion proteins so produced can be processed in vivo or purified and processed in vitro, thereby allowing the synthesis of CEACAM1 antibodies or antigen-binding fragments thereof of the present invention having specific amino-terminal sequences. In addition, problems associated with retaining methionine residues derived from start codons in direct yeast (or bacteria) expression can be avoided. Sabin et al., 7 Bio / Technol. 705 (1989); Miller et al., 7 Bio / Technol. 698 (1989).
[0290] When yeast is grown in a medium rich in glucose, any of a series of yeast gene expression systems incorporating promoter and terminator elements of a large number of active expression genes encoding glycolytic enzymes can be used to obtain the recombinant CEACAM1 antibody or peptide of the present invention. Known glycolytic genes can also provide very effective transcriptional control signals. For example, the promoter and terminator signals of the phosphoglycerate kinase gene can be used.
[0291] Production of CEACAM1 antibodies or antigen-binding fragments thereof in insects can be achieved, for example, by infecting an insect host with a baculovirus engineered to express a transmembrane polypeptide by methods known to those skilled in the art. See Ausubel et al., 1987, 1993.
[0292] In addition to microorganisms, mammalian tissue culture can also be used to express and produce the antibodies or antigen-binding fragments thereof of the present invention (e.g., polynucleotides encoding immunoglobulins or fragments thereof). See Winnacker, From Genes to Clones, VCH Publishers, NY, NY (1987). Eukaryotic cells are actually preferred because many suitable host cell lines capable of secreting heterologous proteins (e.g., complete immunoglobulins) have been developed in the art, and the cell lines include CHO cell lines, various COS cell lines, HeLa cells, 293 cells, myeloma cell lines, transformed B cells and hybridomas. The expression vectors of these cells can include expression control sequences, such as replication origins, promoters and enhancers (Queen et al., Immunol. Rev. 89: 49 (1986)), as well as necessary processing information sites, such as ribosome binding sites, RNA splicing sites, polyadenylation sites and transcription terminator sequences. Preferred expression control sequences are promoters derived from immunoglobulin genes, SV40, adenovirus, bovine papilloma virus, cytomegalovirus, etc. See Co et al., J. Immunol. 148:1149 (1992).
[0293] Alternatively, the nucleotide sequence encoding the antibody or antigen-binding fragment thereof can be incorporated into a transgene for introduction into the genome of a transgenic animal and subsequently expressed in the milk of the transgenic animal (see, e.g., Deboer et al., U.S. Pat. No. 5,741,957, Rosen, U.S. Pat. No. 5,304,489, and Meade et al., U.S. Pat. No. 5,849,992). Suitable transgenes include coding sequences for light and / or heavy chains operably linked to promoters and enhancers from mammary gland-specific genes such as casein or beta lactoglobulin.
[0294] In addition, plants have become a convenient, safe and economical alternative mainstream expression system for recombinant antibody production, which is based on large-scale culture of microorganisms or animal cells. Antibodies or their antigen-binding fragments can be expressed in plant cell cultures or conventionally grown plants. Expression in plants can be systemic, limited to subcellular plastids or limited to seeds (endosperm). See, for example, U.S. Patent Publication No. 2003 / 0167531; U.S. Patent Nos. 6,080,560 and 6,512,162; and WO0129242. Several plant-derived antibodies have reached a mature stage of development, including clinical trials (see, for example, Biolex, NC).
[0295] The vector containing the polynucleotide sequence of interest (for example, heavy chain and light chain coding sequence and expression control sequence) can be transferred to the host cell by well-known methods, depending on the type of cell host. For example, calcium chloride transfection is usually used for prokaryotic cells, while calcium phosphate treatment, electroporation, lipofection, biolistics or virus-based transfection can be used for other cell hosts. (generally referring to Sambrook et al., Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Press, 2nd edition, 1989). Other methods for transforming mammalian cells include the use of polybrene, protoplast fusion, liposomes, electroporation and microinjection (generally referring to Sambrook et al., the same). In order to produce transgenic animals, transgenic microinjection can be carried out into fertilized oocytes, or the genome of embryonic stem cells can be incorporated, and the nucleus of such cells is transferred into enucleated oocytes.
[0296] Antibodies of the present invention and Fabs thereof can be expressed using a single vector or two vectors. When antibody heavy chains and light chains are cloned onto a separate expression vector, the vector is cotransfected to obtain expression and assembly of a complete immunoglobulin. Once expressed, the complete antibodies of the present invention, their dimers, separate light chains and heavy chains or other immunoglobulin forms can be purified according to the standard procedures of this area, and the standard procedures include ammonium sulfate precipitation, affinity columns, column chromatography, HPLC purification, gel electrophoresis, etc. (generally referring to Scopes, Protein Purification (Springer-Verlag, NY, (1982)). For pharmaceutical use, substantially pure immunoglobulins of at least about 90% to 95% homogeneity are preferred, and 98% to 99% or higher homogeneity are most preferred.
[0297] Methods for modulating CEACAM1 activity
[0298] In one aspect, the present invention provides methods of using the antibodies and antigen-binding fragments thereof described herein to reduce the interaction between CEACAM1 and another member of the CEACAM family, including but not limited to CEACAM1, CEACAM5, and CEACAM8. In some embodiments, the antibodies or antigen-binding fragments thereof disrupt the homophilic interaction between CEACAM1 monomers.
[0299] On the other hand, the present invention provides a method of reducing the interaction between CEACAM1 and TIM family members (including but not limited to TIM-1, TIM-3 and TIM-4) using the antibodies and antigen-binding fragments thereof of the present invention. In some embodiments, the antibody or antigen-binding fragment thereof disrupts the heterophilic interaction between CEACAM1 and TIM-3. By using the antibodies and antigen-binding fragments thereof contemplated by the present invention to disrupt the interaction between CEACAM1 and TIM-3, the inhibitory function of CEACAM1 can be reversed while maintaining the activation function of TIM-3.
[0300] In another aspect, the present invention provides a method of reducing the interaction between CEACAM1 and PD-1 using the antibodies and antigen-binding fragments thereof of the present invention.
[0301] Embodiments of the present invention can be used to reduce immunosuppression, such as T cell tolerance. "Reduction" means the ability to cause an overall reduction of about 20% or more, 30% or more, 40% or more, 45% or more, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, or 75%, 80%, 85%, 90%, 95% or more compared to an untreated control. Immunosuppression can be mediated by immunosuppressive receptors expressed on the surface of immune cells and their interactions with their ligands. For example, cytotoxic CD8 T cells can enter a "functional exhaustion" or "no response" state, whereby they express inhibitory receptors that prevent antigen-specific responses (such as proliferation and cytokine production). Therefore, by inhibiting the activity and / or expression of such inhibitory receptors, it is possible to enhance or not inhibit the suppressed, suppressed or unresponsive immune response to cancer or tumors. Such enhancement or reversal of immune response suppression can lead to higher T cell activity, responsiveness and / or the ability or receptivity of activation.
[0302] Methods for measuring T cell activity are known in the art. As a non-limiting example, T cell tolerance can be induced by contacting T cells with recall antigens, anti-CD3 (in the absence of costimulation) and / or ionomycin. The level of IL-27, LDH-A, RAB10 and / or ZAP70 (intracellular or secreted) can be monitored, for example, to determine the degree of T cell tolerance (wherein the level of IL-2, interferon-γ and TNF is related to the increased T cell tolerance). The response of cells pretreated with, for example, ionomycin to antigens can also be measured to determine the degree of T cell tolerance in cells or cell colonies, for example, by monitoring secreted and / or intracellular IL-2 and / or TNF-α levels (see, for example, Macian et al. Cell 2002109:719-731). Other characteristics of T cells that have undergone adaptive tolerance include increased levels of Fyn and ZAP-70 / Syk, Cbl-b, GRAIL, Ikaros, CREM (cAMP response element regulator), B lymphocyte-induced maturation protein-1 (Blimp-1), PD-1, CD5, and SHP2; increased phosphorylation of ZAP-70 / Syk, LAT, PLCyl / 2, ERK, PKC-θ / IKBA; increased activation of intracellular calcium levels; decreased histone acetylation or hypoacetylation and / or increased CpG methylation at the IL-2 locus. Therefore, in some embodiments, one or more of any of these parameters can be determined to determine whether the antibodies or antigen-binding fragments thereof disclosed herein that inhibit CEACAM1 reduce immune tolerance. The reduction of T cell tolerance can also be assessed by examining tumor-infiltrating lymphocytes or T lymphocytes within lymph nodes draining from established tumors. For example, such T cells exhibit "exhaustion" characteristics through reduced expression of cell surface molecules (such as PD-1, TIM-3 or LAG-3) and secretion of cytokines (such as interferon-γ). Thus, evidence that T cell tolerance has been reduced in the presence of a CEACAM1 antibody or antigen-binding fragment thereof includes, for example, an increase in the number of T cells observed in the absence of the inhibitor, the T cells having (a) antigenic specificity for a tumor-associated antigen (e.g., as determined by major histocompatibility complex class I or class II tetramers containing tumor-associated peptides) and (b) the ability to secrete high levels of interferon-γ and cytolytic effector molecules (such as granzyme-B).
[0303] CEACAM1 antibodies and antigen-binding fragments thereof can be further used to enhance T cell expansion, activation and proliferation.
[0304] In one aspect, the present invention provides a method for reducing the interaction between CEACAM1 and bacterial adhesins using antibodies and antigen-binding fragments thereof of the present invention. In some embodiments, antibodies and antigen-binding fragments thereof of the present invention are effective in reducing and / or preventing colonization of mammalian epithelia. In some embodiments, adhesins are expressed by Escherichia coli, in particular diffusely adherent Escherichia coli (DAEC), Neisseria gonorrhoeae, Neisseria meningitidis, commensal Neisseria, Moraxella catarrhalis, Haemophilus influenzae, Haemophilus aegypti, Helicobacter pylori, Fusobacterium, Salmonella and / or Streptococcus agalactiae. In one embodiment, CEACAM1 antibodies or antigen-binding fragments thereof disrupt the interaction between CEACAM1 and HopQ expressed on the surface of Helicobacter pylori. In one embodiment, CEACAM1 antibodies or antigen-binding fragments thereof disrupt the interaction between CEACAM1 and turbidity-associated (Opa) adhesin proteins expressed on the surface of Neisseria. In one embodiment, CEACAM1 antibodies or antigen-binding fragments thereof disrupt the interaction between CEACAM1 and. In one embodiment, the CEACAM1 antibody or antigen binding fragment thereof disrupts the interaction between CEACAM1 and an OMP adhesin protein expressed on the surface of Haemophilus. In one embodiment, the CEACAM1 antibody or antigen binding fragment thereof disrupts the interaction between CEACAM1 and. In one embodiment, the CEACAM1 antibody or antigen binding fragment thereof disrupts the interaction between CEACAM1 and an adhesin expressed on the surface of Streptococcus agalactiae. In one embodiment, the CEACAM1 antibody or antigen binding fragment thereof disrupts the interaction between CEACAM1 and an IgI3-like beta protein adhesin of Streptococcus agalactiae.
[0305] In one embodiment, the CEACAM1 antibody or antigen binding fragment thereof disrupts the interaction between CEACAM1 and Candida albicans. In one embodiment, the invention provides a method of inhibiting the binding of CEACAM1 to a sub-nematode using the CEACAM1 antibody or antigen binding fragment thereof described herein. In one embodiment, the sub-nematode is Wuchereria bancrofti.
[0306] Treatment
[0307] In one aspect, the present invention provides CEACAM1 antibodies and antigen-binding fragments thereof, which can also be used to treat a subject in need thereof.
[0308] In the methods described herein, a therapeutically effective amount of an antibody or antigen-binding portion thereof described herein is administered to a mammal in need thereof. Although the antibodies or antigen-binding portions thereof described herein are particularly useful for administration to humans, they may also be administered to other mammals. As used herein, the term "mammal" is intended to include, but is not limited to, humans, laboratory animals, domestic pets, and farm animals. "Therapeutically effective amount" means an amount effective to produce the desired therapeutic effect when an antibody or antigen-binding portion thereof described herein is administered to a mammal.
[0309] In some aspects, the antibody or its antigen-binding fragment binds to CEACAM1 expressed by exhausted T cells or natural killer (NK) cells, thereby restoring T cell and NK cell activity and leading to increased anti-tumor response. In other aspects, the antibody or its antigen-binding fragment binds to CEACAM1 expressed by tumor cells, thereby inhibiting tumor cell metastasis and the formation of cancer stem cell niches. In another aspect, the antibody or its antigen-binding fragment binds to CEACAM1 expressed by macrophages associated with fibrosis in the tumor environment, thereby inhibiting fibrosis. On the other hand, the antibody or its antigen-binding fragment binds to CEACAM1 expressed by other stromal cells (such as vascular endothelial cells) in the tumor microenvironment, thereby inhibiting angiogenesis.
[0310] Therefore, the present invention also provides a method for treating a subject with cancer or a tumor and / or reducing tumor growth, which comprises administering an effective amount of a CEACAM1 antibody or an antigen-binding fragment thereof provided herein. "Reducing" includes inhibiting and / or reversing, and can refer to, for example, the symptoms of the condition being treated, the presence or size of metastases or micrometastases, the size of primary tumors, the presence or size of dormant tumors.
[0311] The term "cancer" refers to or describes a physiological condition characterized by unregulated cell growth in mammals. This definition includes benign and malignant cancers, as well as dormant tumors or micrometastases. Therefore, as used herein, the term "cancer" refers to the uncontrolled growth of cells, which interferes with the normal function of body organs and systems (including cancer stem cells and tumor vascular niches). A subject suffering from cancer is a subject in which objectively measurable cancer cells are present in the subject. This definition includes benign and malignant cancers, as well as dormant tumors or micrometastases. Cancers that transfer from their original location and inoculate important organs can eventually lead to the death of the subject by functional degradation of the affected organs. Hematopoietic cancers, such as leukemia, can overcome the normal hematopoietic compartment of the subject, resulting in hematopoietic failure (in the form of anemia, thrombocytopenia and neutropenia), ultimately leading to death.
[0312] "Subject" means a mammal, including but not limited to a human or a non-human mammal, such as a cow, horse, dog, sheep or cat, etc. Individuals and patients are also subjects herein.
[0313] As used herein, the term "treat, treated, treating or treatment" refers to therapeutic treatment, wherein the purpose is to slow down (mitigate) an unwanted physiological condition, disorder or disease, or to obtain a beneficial or desired clinical result. For the purposes of the present invention, a beneficial or desired clinical result includes, but is not limited to, relief of symptoms; a reduction in the extent of a condition, disorder or disease; a stable state of a condition, disorder or disease (i.e., not worsening); a delayed onset or slowed progression of a condition, disorder or disease; an improvement in a condition, disorder or disease state; and relief (whether partial or complete) (whether detectable or undetectable) or enhancement or improvement of a condition, disorder or disease. Treatment includes inducing a clinically significant response without excessive side effects. Treatment also includes an extension of survival compared to the expected survival without treatment. The terms "prevent", "prevention" and the like refer to acting before the onset of an apparent disease or disorder to prevent the development of a disease or disorder or to minimize the extent of a disease or disorder, or to slow down its development process.
[0314] Embodiments of the present invention can be used to treat metastasis, which involves cancer spreading from its primary site to other parts of the body. Cancer cells can break away from the primary tumor, infiltrate lymph and blood vessels, circulate through the bloodstream, and grow in distant lesions (metastasis) in normal tissues elsewhere in the body. Metastasis can be local or distant. Metastasis is a continuous process, depending on tumor cells falling off from the primary tumor, passing through the bloodstream and stopping at a distant site. In the new site, cells establish a blood supply and can grow to form a life-threatening mass. Both the stimulation and inhibition of molecular pathways in tumor cells regulate this behavior, and the interaction between tumor cells and host cells at distant sites is also important. In addition to monitoring specific symptoms, metastasis is most often detected by using magnetic resonance imaging (MRI) scans, computed tomography (CT) scans, blood and platelet counts, liver function studies, chest X-rays, and bone scans alone or in combination.
[0315] Also contemplated is a method of reducing cancer stemness, comprising administering a CEACAM1 antibody or antigen-binding fragment thereof disclosed herein. Cancer stemness may refer to the ability of a cell to self-renew and produce additional phenotypically different cell types. Cancer stem cells (CSCs) are cancer cells that exhibit stem cell-like properties. CSCs typically exhibit at least one cancer marker and are capable of producing at least one additional phenotypically different cell type. In addition, cancer stem cells are capable of asymmetric and symmetric replication. It should be understood that cancer stem cells may be produced by differentiated cancer cells that acquire stemness traits and / or stem cells that acquire a phenotype associated with cancer cells. Alternatively, cancer stem cells may reconstruct non-stromal cell types within a tumor.
[0316] CEACAM1 is expressed by many tumor types, and CEACAM1 can regulate the growth and metastatic behavior of tumors. In another embodiment, CEACAM1 inhibition will reduce tumor growth and metastasis.
[0317] CEACAM1 expression on a subset of macrophages is associated with fibrosis during carcinogenesis. In another embodiment, CEACAM1 inhibition will reduce tumor-associated fibrosis.
[0318] Cancers that can be treated by the compositions and methods contemplated by the present invention include tumors that are not vascularized or not substantially vascularized, as well as vascularized tumors. Cancers may include non-solid tumors (such as blood tumors, e.g., leukemias and lymphomas) or may include solid tumors. Types of cancer to be treated include, but are not limited to, benign and malignant tumors, and malignant tumors such as sarcomas, carcinomas, and melanomas. Also included are adult tumors / cancers and pediatric tumors / cancers. Examples of cancers include, but are not limited to, carcinomas, lymphomas, blastomas, sarcomas, and leukemias. More specific examples of such cancers include, but are not limited to, basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and CNS cancer; breast cancer; peritoneal cancer; cervical cancer; choriocarcinoma; colon and rectal cancer; connective tissue cancer; digestive system cancer; endometrial cancer; esophageal cancer; eye cancer; head and neck cancer; stomach cancer (including gastrointestinal cancer); glioblastoma; hepatic carcinoma; hepatoma; intraepithelial neoplasia; kidney or renal cancer; laryngeal cancer; leukemia; liver cancer; lung cancer (e.g., small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, and lung squamous cell carcinoma); lymphoma, including Hodgkin's and non-Hodgkin's lymphoma); melanoma; myeloma; neuroblastoma; oral cancer (e.g., lip, tongue, mouth, and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; colorectal cancer; respiratory cancer; salivary gland cancer; sarcoma; skin cancer; squamous cell carcinoma; stomach cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; urinary tract cancer; vulvar cancer; vulvar sarcoma; and other cancers and sarcomas; and B-cell lymphomas (including low-grade / follicular non-Hodgkin lymphoma (NHL); small lymphocytic (SL) NHL; intermediate-grade / follicular NHL; intermediate-grade diffuse NHL; high-grade immunoblastic NHL; high-grade lymphoblastic NHL; high-grade small non-lytic cell NHL; large mass disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's macroglobulinemia (Waldenstrom's Macroglobulinemia); chronic lymphocytic leukemia (CLL); acute lymphocytic leukemia (ALL); hairy cell leukemia; chronic myeloblastic leukemia; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal blood vessel proliferation associated with keloids, edema (such as that associated with brain tumors), and Meigs' syndrome. Patients may have more than one type of cancer.
[0319] The efficacy of cancer treatment methods including therapeutic formulations comprising compositions of antibodies and antigen-binding fragments thereof described herein can be measured by various endpoints commonly used to evaluate cancer treatments, including but not limited to tumor regression, tumor weight or size reduction, time to progression, survival duration, progression-free survival, overall response rate, response duration, and quality of life. In the case of cancer, a therapeutically effective amount of a recombinant CEACAM1 antibody or antigen-binding fragment thereof can reduce the number of cancer cells; reduce tumor size; inhibit (i.e., slow down to some extent and preferably prevent) cancer cell infiltration into surrounding organs; inhibit (i.e., slow down to some extent and preferably prevent) tumor metastasis; inhibit tumor growth to some extent; and / or alleviate one or more symptoms associated with the condition to some extent. In the case of a patient with more than one type of cancer, a therapeutically effective amount of a recombinant CEACAM1 antibody or antigen-binding fragment thereof is an amount that effectively treats at least one of the cancers. Insofar as a recombinant CEACAM1 antibody or antigen-binding fragment thereof is used to prevent growth and / or kill existing cancer cells, it can be cytostatic and / or cytotoxic. For cancer therapy, in vivo efficacy can be measured, for example, by assessing survival duration, progression-free survival duration (PFS), response rate (RR), response duration, and / or quality of life.
[0320] Checkpoint proteins interact with specific ligands, sending signals to T cells and shutting off or inhibiting T cell function. By expressing high levels of checkpoint proteins on their surface, cancer cells can control the function of T cells entering the tumor microenvironment, thereby inhibiting anticancer immune responses. The immune checkpoint protein programmed death-1 (PD-1) is a key immune checkpoint receptor expressed by activated T and B cells and mediates immunosuppression. PD-1 is a member of the CD28 receptor family, which includes CD28, CTLA-4, ICOS, PD-1, and BTLA. Two cell surface glycoprotein ligands of PD-1, programmed death ligand-1 (PD-L1) and programmed death ligand-2 (PD-L2), have been identified, which are expressed on antigen presenting cells and many human cancers and have been shown to downregulate T cell activation and cytokine secretion when binding to PD-1 (Freeman et al., 2000; Latchman et al., 2001). Inhibition of PD-1 / PD-L1 interaction can promote effective anti-tumor activity. Examples of PD-1 inhibitors include, but are not limited to, pembrolizumab (MK-3475), nivolumab (MDX-1106), cemiplizumab-rwlc (REGN2810), pidilizumab (CT-011), spartalizumab (PDR001), tisellizumab (BGB-A317), PF-06801591, AK105, BCD-100, BI 754091, JS001, LZM009, MEDI0680, MGA012, Sym021, TSR-042. Examples of PD-L1 inhibitors include, but are not limited to, atezolizumab (MPDL3280A), durvalumab (MEDI4736), avelumab (MSB0010718C), BGB-A333, CK-301, CS1001, FAZ053, KN035, MDX-1105, MSB2311, SHR-1316.
[0321] However, there is a large population of cancer patients receiving checkpoint inhibitor therapy who (1) do not respond to this type of therapy (innate or primary resistance) or (2) initially respond but eventually develop disease progression (secondary or acquired resistance). Resistant cancers may also be referred to as refractory cancers. As shown in the examples below, tumor-associated cells isolated from patients with acquired resistance to PD-1 / PD-L1 inhibitors upregulate CEACAM1 expression relative to tumor-associated cells isolated from primary patients who were not exposed to PD-1 inhibitors. When CEACAM1 is expressed in the context of acquired resistance, cells carrying CEACAM1 are more likely to be effector memory cells rather than central memory cells, which is consistent with the reduction in anticancer responses in resistant patients.
[0322] Therefore, the present invention also provides a method for treating patients with resistance to checkpoint inhibitors (such as inhibitors of PD-1, PD-L1 and / or CTLA-4) using CEACAM1 antibodies and antigen-binding fragments thereof (including but not limited to specific CEACAM1 antibodies and antigen-binding fragments thereof provided herein). In some embodiments, the CEACAM1 antibody used to treat patients with resistance to inhibitors of PD-1, PD-L1 and / or CTLA-4 is He14 / L1. In some embodiments, resistance is innate or primary resistance. In some embodiments, resistance is secondary or acquired resistance. In some embodiments, the administered CEACAM1 antibody (including but not limited to CEACAM1 antibodies and antigen-binding fragments thereof provided herein) reverses T cell exhaustion in patients with resistance to checkpoint inhibitor therapy. Any cancer that exhibits resistance to PD-1, PDL-1 and / or CTLA-4 is suitable for treatment with the methods of the present invention. In some embodiments, CEACAM1 antibodies or antigen-binding fragments are administered to patients who have not previously received checkpoint inhibitor therapy.
[0323] In another aspect, the present invention provides for the use of the CEACAM1 antibodies and antigen-binding fragments provided herein in treating patients resistant to therapy with other checkpoint inhibitors, including but not limited to PD-L2, B7-H3, B7-H4, BTLA, HVEM, GAL9, LAG3, TIM-3, VISTA, KIR, 2B4 (belongs to the CD2 family of molecules and is present in all NK, γδ and memory CD8 + (αβ) T cells), CD160 (also known as BY55), CGEN-15049, CHK1 and CHK2 kinases, A2aR, and various B-7 family ligands (including but not limited to B7-1, B7-2, B7-DC, B7-H1, B7-H2, B7-H3, B7-H4, B7-H5, B7-H6 and B7-H7).
[0324] In another aspect, the present invention provides a method of using the CEACAM1 antibodies and antigen-binding fragments thereof disclosed herein to treat a subject in need of reducing and / or preventing colonization of mammalian epithelium by Candida albicans and / or bacteria expressing bacterial adhesins (including but not limited to Escherichia coli, particularly diffusely adhering Escherichia coli (DAEC), Neisseria gonorrhoeae, Neisseria meningitidis, commensal Neisseria, Moraxella catarrhalis, Haemophilus influenzae, Haemophilus aegypti, Helicobacter pylori, Fusobacterium, Salmonella and / or Streptococcus agalactiae).
[0325] In another aspect, the present invention provides a method for treating a subject in need of reducing and / or preventing infection with a sub-nematode (such as Wuchereria bancrofti) using the CEACAM1 antibodies and antigen-binding fragments thereof disclosed herein. In another aspect, the present invention provides a method for treating a subject in need of reducing and / or preventing the development of lymphedema and / or hydrocele associated with infection with a sub-nematode (such as Wuchereria bancrofti) using the CEACAM1 antibodies and antigen-binding fragments thereof disclosed herein. In one embodiment, the present invention provides a method for reducing filarial invasion of the subject's lymphatic system in a subject in need using the CEACAM1 antibodies or antigen-binding fragments thereof described herein. In one embodiment, the sub-nematode is Wuchereria bancrofti. The subject may be infected with one or more bacteria expressing bacterial adhesins, Candida albicans, influenza virus and / or sub-nematodes.
[0326] In another embodiment, the present invention provides a method of using the CEACAM1 antibodies or antigen-binding fragments thereof described herein to reduce invasion of the subject's lymphatic system by cancer cells in a subject in need thereof.
[0327] Screening methods
[0328] Also provided herein are methods for identifying a patient population that is likely to respond to treatment with the CEACAM1 antibodies and antibody fragments provided herein, including but not limited to He14 / L1.
[0329] In some embodiments, the CEACAM1 expression on certain cell types of cancer patients is screened, and the cell types include T cells, NK cells, B cells, tumor cells, fibroblasts or other cells in the tumor microenvironment, such as macrophages. In some embodiments, cancer patients who show increased CEACAM1 expression on certain cell types compared to the control are selected for treatment with CEACAM1 antibodies and antibody fragments provided herein. The "control" level of CEACAM1 expression may refer to the level of CEACAM1 expression in one or more individuals who do not suffer from cancer. The level can be measured on an individual-by-individual basis, or on an aggregate basis such as an average value. In some embodiments, the control level of CEACAM1 expression obtained at different times from the same individual whose condition is monitored. In certain embodiments, the "control" level may refer to the level obtained from the same patient at an earlier time (e.g., weeks, months, or years ago). In some embodiments, the control level is obtained from the patient before the patient receives any cancer therapy. In some embodiments, the control level is obtained from the patient before the patient receives checkpoint inhibitor treatment.
[0330] In some embodiments, CEACAM1 expression is determined for patients who are resistant to checkpoint inhibitor therapy (including but not limited to therapy with PD-1 / PD-L1 / CTLA-4 inhibitors). In some embodiments, patients who are resistant to checkpoint inhibitor therapy and show increased CEACAM1 expression on certain cell types compared to controls are selected for treatment with CEACAM1 antibodies and antibody fragments provided herein (including but not limited to He14 / L1).
[0331] In some embodiments, the patient is determined for allelic variants of human CEACAM1. Based on the allelic variants of human CEACAM1 expressed by the patient, more or less anti-CEACAM1 antibodies can be administered to the patient compared to patients expressing wild-type variants of CEACAM1. In some embodiments, the presence of Y34C, Q44L and / or Q89H allelic variants of CEACAM1 in the patient is determined. In some embodiments, a patient found to express Y34C, Q44L, A49V and / or Q89H allelic variants of CEACAM1 is administered a higher and / or more frequent dose of anti-CEACAM1 antibody compared to patients expressing wild-type variants of CEACAM1.
[0332] Pharmaceutical composition
[0333] In another aspect, the present invention provides a pharmaceutically acceptable composition comprising a therapeutically effective amount of a CEACAM1 antibody or antigen-binding fragment thereof described herein formulated together with one or more pharmaceutically acceptable excipients.
[0334] The dosage of the active agent may vary according to the reason for use, individual subjects and mode of administration. The dosage may be adjusted based on the subject's weight, the subject's age and health, and the tolerance of the compound or composition. For example, depending on the disease, for an antibody or its antigen-binding fragment, this may require 0.1, 1.0, 3.0, 6.0 or 10.0 mg / Kg. For an IgG (two binding sites) with a molecular weight of 150,000 g / mole, these dosages correspond to binding sites of about 18 nM, 180 nM, 540 nM, 1.08 μM and 1.8 μM for a volume of 5 L of blood.
[0335] Active agents and excipients can be formulated into compositions and dosage forms according to methods known in the art. The pharmaceutical compositions of the present invention can be particularly formulated into solid or liquid forms, including those suitable for parenteral administration, such as by subcutaneous, intratumoral, intramuscular or intravenous injection, such as as sterile solutions or suspensions.
[0336] Therapeutic compositions comprising antibodies or antigen-binding fragments thereof that bind to CEACAM1 can be formulated with one or more pharmaceutically acceptable excipients, which can be pharmaceutically acceptable materials, compositions or vehicles, such as liquid or solid fillers, diluents, carriers, manufacturing aids (e.g., lubricants, talc, magnesium, calcium or zinc stearate, or stearic acid), solvents or encapsulating materials involved in carrying or transporting the therapeutic compound for administration to a subject, fillers, salts, surfactants and / or preservatives. Some examples of materials that can be used as pharmaceutically acceptable excipients include: sugars, such as lactose, glucose, and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethyl cellulose, and cellulose acetate; gelatin; talc; waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols, such as ethylene glycol and propylene glycol; polyols, such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffers; water; isotonic saline; pH buffered solutions; and other nontoxic compatible substances used in pharmaceutical formulations.
[0337] Bulking agents are compounds that add mass to the pharmaceutical formulation and contribute to the physical structure of the formulation in lyophilized form. Suitable bulking agents according to the present invention include mannitol, glycine, polyethylene glycol and sorbitol.
[0338] The use of surfactants can reduce the aggregation of reconstructed proteins and / or reduce the formation of particles in the reconstructed formulation. The amount of surfactant added should be able to reduce the aggregation of reconstructed proteins and minimize the formation of particles after reconstruction. Suitable surfactants according to the present invention include polysorbates (e.g., polysorbate 20 or 80); Poloxamers (e.g., Poloxamer 188); Triton; Sodium dodecyl sulfate (SDS); Sodium lauryl sulfate; Sodium octyl glucoside; Lauryl-, myristyl-, linoleyl- or stearyl-sulfobetaine; Lauryl-, myristyl-, linoleyl- or stearyl-sarcosine; Linoleyl-, myristyl- or cetyl-betaine; Lauramide propyl-, cocoamidopropyl-, linoleamidopropyl-, myristamidopropyl-, palmitamidopropyl- or isostearamidopropyl-betaine (e.g., lauroamidopropyl); myristamidopropyl-, palmitamidopropyl- or isostearamidopropyl-dimethylamine; sodium methyl cocoyl or disodium methyl oleyl taurate; and polyethylene glycol, polypropylene glycol, and copolymers of ethylene glycol and propylene glycol (e.g., Pluronics, PF68, etc.).
[0339] Preservatives can be used in the preparation of the present invention. Suitable preservatives for preparation of the present invention include octadecyl dimethyl benzyl ammonium chloride, hexamethyl ammonium chloride, benzalkonium chloride (a mixture of alkyl benzyl-dimethyl ammonium chloride, wherein the alkyl group is a long-chain compound) and benzethonium chloride. Other types of preservatives include aromatic alcohols such as phenol, butyl and benzyl alcohol, alkyl parabens such as methyl paraben or propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol and meta-cresol. Other suitable excipients can be found in standard pharmacy textbooks, such as "Remington's Pharmaceutical Sciences", The Science and Practice of Pharmacy, the 19th edition Mack Publishing Company, Easton, Pa., (1995).
[0340] Compositions comprising antibodies or antigen-binding fragments thereof and pharmaceutically acceptable carriers may include various concentrations of CEACAM1 antibodies or antigen-binding portions thereof as described herein. For example, the composition may include 10 mg / ml to 200 mg / ml, 25 mg / ml to 130 mg / ml, 50 mg / ml to 125 mg / ml, 75 mg / ml to 110 mg / ml or 80 mg / ml to 100 mg / ml of antibodies or antigen-binding fragments thereof. The composition may also include about 10 mg / ml, 20 mg / ml, 30 mg / ml, 40 mg / ml, 50 mg / ml, 60 mg / ml, 70 mg / ml, 80 mg / ml, 90 mg / ml, 100 mg / ml, 110 mg / ml, 120 mg / ml, 130 mg / ml, 140 mg / ml or 150 mg / ml of antibodies or antigen-binding fragments thereof.
[0341] In some embodiments, the composition comprising the antibody or antigen-binding fragment thereof and a pharmaceutically acceptable carrier is lyophilized and provided in the composition for reconstitution prior to administration.
[0342] Application method
[0343] The therapeutic composition comprising the contemplated antibody or antigen-binding fragment thereof can be administered in any convenient manner, including by injection, infusion, implantation or transplantation. The compositions described herein can be administered to a patient subcutaneously, intradermally, intratumorally, intranodally, intramedullary, intramuscularly, intracranially, by intravenous or intralymphatic injection, or intraperitoneally. In one embodiment, the cell composition of the present invention is preferably administered by intravenous injection.
[0344] In certain embodiments, the antibody or its antigen-binding fragment is administered to a mammal by intravenous infusion, i.e., the antibody or its antigen-binding fragment is introduced into the vein of the mammal over a period of time. In certain embodiments, the period of time is about 5 minutes, about 10 minutes, about 30 minutes, about 1 hour, about 2 hours, about 4 hours, or about 8 hours.
[0345] In certain embodiments, the dosage of the compound or composition is applied to the subject every day, every other day, every two days, every three days, once a week, twice a week, three times a week, once every two weeks, or once a month. In other embodiments, two, three or four doses of compounds or compositions are applied to the subject every day, every two days, every three days, once a week, once every two weeks, or once a month. In some embodiments, the dosage of the compound or composition is applied for 2 days, 3 days, 5 days, 7 days, 14 days, 21 days, or 28 days. In certain embodiments, the dosage of the compound or composition is applied for 1 month, 1.5 months, 2 months, 2.5 months, 3 months, 4 months, 5 months, 6 months, or longer.
[0346] Combination therapy
[0347] In one aspect, the present invention provides a CEACAM1 antibody or an antigen-binding fragment thereof administered with an additional therapeutic agent. Such additional agents include, but are not limited to, cytotoxic agents, chemotherapeutic agents, growth inhibitors, anti-inflammatory agents, anti-cancer agents, anti-neurodegenerative agents, and anti-infective agents. The agents used in such combination therapies may belong to one or more of the aforementioned categories. The administration of the antibody or its antigen-binding fragment and the additional therapeutic agent may be simultaneous or continuous. The administration of the antibody or its antigen-binding fragment and the additional therapeutic agent may be separate or as a mixture. In addition, the therapeutic methods contemplated by the present invention may involve treatment in combination with one or more cancer therapies selected from the group consisting of antibody therapy, chemotherapy, cytokine therapy, dendritic cell therapy, gene therapy, hormone therapy, laser therapy, and radiotherapy.
[0348] Exemplary additional therapeutic agents also include radionuclides with high energy ionizing radiation that are capable of causing multiple strand breaks in nuclear DNA and are therefore useful for inducing cell death (e.g., of cancer). Exemplary high energy radionuclides include: 90 Y. 125 I. 131 I. 123 I. 111 In, 105 Rh, 153 Sm, 67 Cu, 67 Ga, 166 Ho, 177 Lu, 186 Re and 188Re. These isotopes generally produce high energy alpha or beta particles with short path lengths. Such radionuclides kill cells in their immediate vicinity, such as neoplastic cells to which the conjugate has attached or has entered. They have little or no effect on nonlocalized cells and are essentially nonimmunogenic.
[0349] Exemplary additional therapeutic agents also include cytotoxic agents, such as cytostatic agents (e.g., alkylating agents, DNA synthesis inhibitors, DNA intercalators or cross-linking agents, or DNA-RNA transcription regulators), enzyme inhibitors, gene regulators, cytotoxic nucleosides, tubulin binding agents, hormones and hormone antagonists, anti-angiogenic agents, and the like.
[0350] Exemplary additional therapeutic agents also include alkylating agents, such as the anthracycline family (e.g., doxorubicin, carmine, cyclosporin-A, chloroquine, methotrexate, mithramycin, porfiromycin, streptomycin, anthracenedione and aziridine). In another embodiment, the chemotherapeutic moiety is a cytostatic agent, such as a DNA synthesis inhibitor. Examples of DNA synthesis inhibitors include, but are not limited to, methotrexate and dichloromethotrexate, 3-amino-1,2,4-benzotriazine 1,4-dioxide, aminopterin, cytosine β-D-arabinofuranoside, 5-fluoro-5′-deoxyuridine, 5-fluorouracil, ganciclovir, hydroxyurea, actinomycin-D and mitomycin C. Exemplary DNA intercalators or crosslinkers include, but are not limited to, bleomycin, carboplatin, carmustine, chlorambucil, cyclophosphamide, cis-dichlorodiaminoplatinum (II) (cisplatin), melphalan, mitoxantrone and oxaliplatin.
[0351] Exemplary additional therapeutic agents also include transcriptional regulators, such as actinomycin D, daunorubicin, doxorubicin, homoharringtonine and idarubicin. Other exemplary cell growth inhibitors compatible with the present invention include ansamycin benzoquinone, quinone derivatives (e.g., quinolones, genistein, bactacyclin), busulfan, ifosfamide, nitrogen mustard, triimidoquinone, serine, carboquinone, indolequinone EO9, diaziridinylbenzoquinone methyl DZQ, triethylenephosphoramide and nitrosourea compounds (e.g., carmustine, lomustine, semustine).
[0352] Exemplary additional therapeutic agents also include cytotoxic nucleosides, such as, for example, adenosine, cytarabine, cytosine arabinoside, 5-fluorouracil, fludarabine, floxuridine, tegafur, and 6-mercaptopurine; tubulin binding agents, such as taxanes (e.g., paclitaxel, docetaxel, taxanes), nocodazole, rhizoctonia, dolastatin (e.g., dolastatin 10, 11, or 15), colchicine and colchicine-like agents (e.g., ZD6126), combretastatin (e.g., combretastatin A-4, AVE-6032), and vinca alkaloids (e.g., vinblastine, vincristine, vindesine, and vinorelbine (Navelbine)); anti-angiogenic compounds, such as angiostatin K1-3, DL-α-difluoromethyl-ornithine, endostatin, fumagillin, genistein, minocycline, staurosporine, and (±)-thalidomide.
[0353] Exemplary additional therapeutic agents also include hormones and hormone antagonists, such as corticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone or medroxyprogesterone), estrogens (e.g., diethylstilbestrol), antiestrogens (e.g., tamoxifen), androgens (e.g., testosterone), aromatase inhibitors (e.g., aminoglutethimide), 17-(allylamino)-17-demethoxygeldanamycin, 4-amino-1,8-naphthalimide, apigenin, brefeldin A, cimetidine, dichloromethylene-bisphosphonic acid, leuprolide, luteinizing hormone-releasing hormone, pyrifos, rapamycin, sex hormone binding globulin, and thapsigargin.
[0354] Exemplary additional therapeutic agents also include enzyme inhibitors such as S(+)-camptothecin, curcumin, (-)-deguelin, 5,6-dichlorobenzimidazole 1-β-D-ribofuranoside, etoposide, formestane, forsitracin, milk echinopsin, 2-imino-1-imidazolidineacetic acid (cyclocreatine), mavinocine, trichostatin A, tyrosine phosphorylation inhibitor AG 34, and tyrosine phosphorylation inhibitor AG 879.
[0355] Exemplary additional therapeutic agents also include gene modulators such as 5-aza-2'-deoxycytidine, 5-azacytidine, cholecalciferol (vitamin D3), 4-hydroxytamoxifen, melatonin, mifepristone, raloxifene, trans-retinal (vitamin A aldehyde), retinoic acid, retinoic acid, 9-cis-retinoic acid, 13-cis-retinoic acid, retinol (vitamin A), tamoxifen, and troglitazone.
[0356] Exemplary additional therapeutic agents also include cytotoxic agents, such as, for example, pteridine family drugs, enediynes, and podophyllotoxins. Particularly useful members of these classes include, for example, methotrexate, podophyllotoxin or podophyllotoxin derivatives such as etoposide or etoposide phosphate, isovinabine, vindesine, vinblastine, etc.
[0357] Still other additional therapeutic agents compatible with the teachings herein include auristatins (e.g., auristatin E and monomethyl auristatin E), calicheamicin, gramicidin D, maytansinoids (e.g., maytansine), neocarzinostatin, topotecan, taxanes, cytochalasin B, ethidium bromide, emetine, teniposide, colchicine, dihydroxyanthracenedione, mitoxantrone, procaine, tetracaine, lidocaine, propranolol, puromycin, and analogs or homologs thereof.
[0358] In one embodiment, CEACAM antibodies or their antigen binding fragments are administered in combination with agents as checkpoint inhibitors. Such inhibitors may include small molecule inhibitors or may include antibodies or their antigen binding fragments that bind and block or inhibit immune checkpoint receptors or antibodies that bind and block or inhibit immune checkpoint receptor ligands. Illustrative checkpoint molecules that may be targeted for blocking or inhibiting include but are not limited to CTLA-4, PD-L1, PD-L2, PD-1, B7-H3, B7-H4, BTLA, HVEM, GAL9, LAG3, TIM-3, VISTA, KIR, 2B4 (belonging to CD2 family molecules and in all NK, γδ and memory CD8 + (αβ) T cells), CD160 (also known as BY55), CGEN-15049, CHK1 and CHK2 kinases, A2aR and various B-7 family ligands. B7 family ligands include, but are not limited to, B7-1, B7-2, B7-DC, B7-H1, B7-H2, B7-H3, B7-H4, B7-H5, B7-H6 and B7-H7. Checkpoint inhibitors include antibodies or antigen-binding fragments thereof, other binding proteins, biotherapeutics or small molecules that bind to and block or inhibit the activity of one or more of CTLA-4, PD-L1, PD-L2, PD-1, BTLA, HVEM, TIM-3, GAL9, LAG3, VISTA, KIR, 2B4, CD160 and CGEN-15049. Illustrative immune checkpoint inhibitors include Tremelimumab (CTLA-4 blocking antibody), anti-OX40 and Yervoy / ipilimumab (anti-CTLA-4 checkpoint inhibitors) and the above-mentioned PD-1 and PD-L1 inhibitors. Checkpoint protein ligands include, but are not limited to, PD-L1, PD-L2, B7-H3, B7-H4, CD28, CD86, and TIM-3.
[0359] In some embodiments, the CEACAM1 antibodies and antigen-binding fragments thereof described herein are administered with a TIGIT, LAP, Podoplanin, Protein C receptor, ICOS, GITR, CD226, or CD160 inhibitor.
[0360] In some embodiments, the CEACAM1 antibodies and antigen-binding fragments thereof described herein are administered together with a CTLA-4, PD-1, PD-L1 or PD-L2 inhibitor. In some embodiments, the CEACAM1 antibodies and antigen-binding fragments thereof described herein are administered together with a TIM-3 inhibitor.
[0361] It should be understood that the present invention is not limited to the specific molecules, compositions, methods or schemes described, because these can change. Any methods and materials similar or equivalent to those described herein can be used to implement or test embodiments of the present invention. It should also be understood that the disclosure of the present invention in this specification includes all possible combinations of such specific features. For example, in the case where specific features are disclosed in the context of a specific aspect or embodiment of the present invention or a specific claim, the features may also be used in combination with other specific aspects and embodiments of the present invention to the extent possible and / or in the context of other specific aspects and embodiments of the present invention, and are generally used in the present invention.
[0362] Where reference is made herein to a method comprising two or more defined steps, the defined steps may be performed in any order or simultaneously (unless the context excludes that possibility), and the method may include one or more additional steps performed before any defined step, between two defined steps, or after all defined steps (unless the context excludes those possibilities).
[0363] All other cited patents and applications are incorporated herein by reference in their entirety. In addition, to the extent that the definition or use of a term in a reference incorporated herein by reference is inconsistent or contradictory to the definition of that term provided herein, the definition of that term provided herein shall prevail and the definition of that term in the reference shall no longer apply.
[0364] In order to facilitate a better understanding of the present invention, the following examples of specific embodiments are given. The following examples should not be construed as limiting or defining the entire scope of the present invention.
[0365] Example
[0366] Example 1: Generation of fully humanized CEACAM1 antibody
[0367] 1. Construction of chimeric antibodies
[0368] Mouse anti-CEACAM1 antibody served as the starting point for humanization. Hybridomas expressing the parental antibody were sequenced to identify a single heavy chain sequence and two κ light chain sequences. In order to determine which light chain sequence encodes the CEACAM1 binding motif, VH and two Vκ sequences were synthesized with flanking restriction enzyme sites for cloning into the pANT expression vector system of IgG4 (S241P) heavy chain and κ light chain. The VH region was cloned using MluI and HindIII restriction sites, and the Vκ region was cloned using BssHII and BamHI restriction sites.
[0369] 2. Expression and Purification of Chimeric Antibodies
[0370] IgG4(S241P) VH was transiently transfected into HEK EBNA adherent cells using PEI with two possible combinations of Vκ chains encoding the chimeric parental antibody and incubated for 7 days post-transfection. The combination of VH and one of the Vκ chains failed to express, while VH combined with the second Vκ sequence produced significant levels of antibody. The expressed antibody was purified from the cell culture supernatant on a protein A agarose column, the buffer was exchanged to PBS pH 7.4, and the extinction coefficient (Ec) based on the predicted amino acid sequence was used. 0.1% =1.53) and quantified at OD 280nm.
[0371] 3. Competition ELISA analysis of chimeric antibody binding to human CEACAM1
[0372] Purified chimeric antibodies were evaluated for binding to human CEACAM1 in a competition ELISA assay. Nunc ImmunoMaxiSorp 96-well flat-bottom microtiter plates were pre-coated with 1 μg / ml human GST-CEACAM1 in 1xPBS overnight at 4°C. The next day, the plates were blocked with 2% BSA / PBS for 1 hour at room temperature and then washed twice with PBS / 0.05% Tween 20 pH 7.4.
[0373] A 4-fold dilution series of chimeric or irrelevant control IgG4 antibodies from 50 μg / ml to 0.068 μg / ml was premixed with a constant concentration of the mouse parent antibody (0.15 μg / ml final concentration), added to the plate and incubated for 1 hour at room temperature. After 3 PBST washes, the binding of the mouse antibody was detected with anti-mouse-HRP and TMB substrate. The reaction was stopped with 3M HCl and the absorbance was read at 450nm on a Dynex Technologies MRX TC II plate reader.
[0374] The expressed chimeric antibody was able to compete with the murine parent antibody for binding to GST-CEACAM1, confirming that the correct light chain had been identified. As expected, there was no competition from unrelated human IgG4. The variable heavy chain (VH0) and variable light chain (Vκ0) of the chimeric antibody are provided as SEQ ID NOs: 10 and 18, respectively.
[0375] 4. Design of the variable region sequence of the composite human antibody
[0376] The structural model of the mouse parent antibody V region was generated using Swiss PDB, and analyzed to identify the important "restricted" amino acids in the V region that may be crucial to the antibody binding properties. Most of the residues contained in the CDR (defined using Kabat and Chothia) and several framework residues are considered important. The VH and Vκ sequences of the mouse parent antibody contain typical framework residues, and CDR 1, 2 and 3 motifs are comparable to many mouse antibodies. Sequence analysis also revealed potential N-linked glycosylation motifs at position 27D (Kabat numbering) of the original mouse hybridoma light chain CDR1 and position 56 of the heavy chain CDR2.
[0377] The composite human sequence of the parent antibody is generated from several human antibodies that combined together produce CDRs that are similar or identical to those in the mouse sequence. For regions outside of and flanking the CDRs, a wide selection of human sequence segments are identified as possible components of new humanized V regions.
[0378] 5.CD4 + T cells Epitope avoidance
[0379] Based on structural analysis, a large preliminary set of sequence segments that could be used to generate humanized variants was selected and analyzed in silico using iTope for peptides binding to human MHC class II alleles. TM technique (Perry et al. 2008) and TCED using T cell epitopes associated with known antibody sequences TM (Bryson et al. 2010). TM Sequence segments that obtained significant hit scores were discarded.
[0380] This obtains a group of reduced segments, and the combination of these segments is analyzed again as described above to ensure that the connection between the segments does not contain potential T cell epitopes. The selected sequence segments are assembled into complete V region sequences, which lack important T cell epitopes. Five heavy chains (VH1 to VH5) and four preferred light chains (Vκ1 to Vκ4) sequences are then selected for gene synthesis, expressed in mammalian cells and tested for activity.
[0381] 6. Construction of humanized variants
[0382] Five humanized VH (VH1 to VH5) and four humanized Vκ sequences (Vκ1 to Vκ4) were synthesized as described above for the chimeric antibodies and cloned into the pANT expression vector system for IgG4 (S241P) heavy chain and kappa light chain. See Table 4.
[0383] Table 4. Selection of heavy and light chains for gene synthesis.
[0384]
[0385] 7. Expression and Purification of Humanized Variants
[0386] All combinations of composite IgG4 (S241P) VH and Vκ chains (i.e., 20 pairs in total) plus 2 control antibodies (chimeric VH (VH0) with variant Vκ1 and variant VH1 with chimeric Vκ (Vκ0)) were transiently transfected into HEK EBNA adherent cells using the PEI transfection method and incubated for 5-7 days after transfection. Antibodies were purified from cell culture supernatants on a protein A agarose column as described above. The extinction coefficient based on the predicted amino acid sequence was calculated by OD 280nm Antibodies were quantified. 1.5 μg of each antibody was analyzed by SDS-PAGE and bands corresponding to typical antibody curves were observed.
[0387] 8. Competition ELISA analysis of humanized variants binding to CEACAM1
[0388] Purified antibodies were assessed for binding to human CEACAM1 in a competition ELISA assay as described above. The ability of each variant to compete with the murine parent antibody for binding to GST-CEACAM1 was compared to the ability of the chimeric antibody (VH0 / Vκ0) to compete for binding to GST-CEACAM1 included on each plate.
[0389] Competition ELISA data are summarized in Table 5. Variants VH1 / Vκ1, VH1 / Vκ2, VH1 / Vκ3, VH2 / Vκ1, VH2 / Vκ2, and VH2 / Vκ3 bound CEACAM1 within 2-fold of the chimeric antibody, so these variants were carried forward for Biacore multi-cycle kinetic analysis.
[0390] Table 5. Summary of composite human antibody variants and control antibody titers and binding data. Antibody expression titers (μg / ml) from static HEK EBNA transient transfections. IC50 values obtained in competition assays were normalized to the chimeric parent antibody tested on the same plate.
[0391] Variants Average expression titer (μg / ml) Average relative IC50 value chimera 9.5 1 VH0 / Vκ1 27.1 2.5 VH1 / Vκ0 14.7 1.0 VH1 / Vκ1 24.4 1.5 VH1 / Vκ2 26.5 1.3 VH1 / Vκ3 29.4 1.2 VH1 / Vκ4 26.1 4.4 VH2 / Vκ1 30.6 1.7 VH2 / Vκ2 31.9 1.6 VH2 / Vκ3 33.4 1.7 VH2 / Vκ4 20.3 7.2 VH3 / Vκ1 25.6 Weak / no binding VH3 / Vκ2 31.9 Weak / no binding VH3 / Vκ3 35.3 Weak / no binding VH3 / Vκ4 24.3 Weak / no binding VH4 / Vκ1 29.8 Weak / no binding VH4 / Vκ2 34.8 Weak / no binding VH4 / Vκ3 34.3 Weak / no binding VH4 / Vκ4 35.2 Weak / no binding VH5 / Vκ1 26.0 Weak / no binding VH5 / Vκ2 29.2 Weak / no binding VH5 / Vκ3 24.8 Weak / no binding VH5 / Vκ4 27.0 Weak / no binding
[0392] 9. Kinetic Analysis of Humanized Variants Binding to CEACAM1
[0393] As an alternative method to evaluate the binding of antibody combinations and control antibodies to CEACAM1, kinetic analysis was performed on a Biacore T200 running Biacore T200 evaluation software V2.0.1. All experiments were performed at 25°C with HBS-P+ running buffer (pH 7.4).
[0394] All kinetic experiments were performed using CEACAM1-HIS (Sino Biologics Inc.) as the analyte. For all experiments, the antibody was immobilized on the surface of the S-series Protein A sensor chip. For kinetic experiments, the amount of immobilized / captured ligand needed to be limited to avoid mass transfer effects on the chip surface, and the surface should ideally have an analyte binding level (R) of 50-150 RU. max The capture settings for all samples antibody used a MW of 45 kDa for CEACAM1 analyte, an antibody ligand of 150 kDa (estimated value for IgG), an Rmax of 50 RU, and a stoichiometry (S) of 2 due to the ability of each antibody to bind 2 target molecules. m ), target response level of 100RU.
[0395] Single cycle analysis
[0396] To evaluate all Composite Human Antibodies TM The binding of variants was analyzed by single cycle kinetics on the supernatants of all transiently transfected HEKEBNA cells. Purified chimeric antibodies and purified chimeric antibodies spiked into HEK EBNA culture medium were used as positive controls. The supernatant was diluted to a concentration of 1 μg / mL in HBS-P+ (determined by IgG quantitative ELISA). At the beginning of each cycle, the antibody was loaded onto the Fc2, Fc3 and Fc4 of the protein A chip and captured at a flow rate of 8 μL / min to obtain about 100 RUs. The surface was then stabilized. Single cycle kinetic data were obtained at a flow rate of 38 μl / min to minimize any potential mass transfer effects. The chimeric antibodies were repeated multiple times to check the stability of the surface and the analyte in the kinetic cycle. The signal from the reference channel Fc1 (no antibody) was subtracted from the signal of Fc2, Fc3 and Fc4 to correct for differences in nonspecific binding to the reference surface. A 5-point 2-fold dilution range of 3.125 to 50 nM CEACAM1 was used without regeneration between each concentration. The association phase of 5 injections of increasing concentrations of CEACAM1 was monitored for 150 seconds and after the last injection of CEACAM1, a single dissociation phase was measured for 150 seconds. Regeneration of protein A was performed using 2 injections of 10 mM glycine-HCL pH 1.5, followed by a stabilization period of 500 seconds.
[0397] In the raw sensorgrams of the single cycle kinetics, the signal from the blank run (no CEACAM1) of each antibody was subtracted to correct for differences in surface stability. The single cycle kinetics (Table 6) showed that the chimeric antibodies and the humanized variants containing VH3, VH4 and VH5 had significant kinetic curve differences in both association and dissociation rates. This change in kinetics was closely related to the inability of these variants to effectively compete with the chimeric antibodies in the competition ELISA. Antibody variants containing Vκ4 were also unable to bind to CEACAM1, again confirming the results of the competition ELISA.
[0398] Table 6. Non-purified complex human antibodies as determined using Biacore T200 TM Single cycle kinetic data of variant and control antibody binding to CEACAM1-HIS. The KD fold difference compared to the chimeric parent antibody was calculated by dividing the KD of the test antibody variant by the KD of the spiked chimeric parent antibody. NB indicates variant with no binding.
[0399] Variants <![CDATA[K D (nM)]]> <![CDATA[Relative K for chimeric parental antibodies D > Purified VH0 / Vκ0 47.6 1.1 Spiked VH0 / Vκ0 43.2 1.0 VH0 / Vκ1 56.1 1.3 VH1 / Vκ0 76.6 1.8 VH1 / Vκ1 93.4 2.2 VH1 / Vκ2 148.0 3.4 VH1 / Vκ3 119.0 2.8 VH1 / Vκ4 143.0 3.3 VH2 / Vκ1 180.0 4.2 VH2 / Vκ2 138.0 3.2 VH2 / Vκ3 72.6 1.7 VH2 / Vκ4 77.8 1.8 VH3 / Vκ1 1500.0 34.7 VH3 / Vκ2 265.0 6.1 VH3 / Vκ3 13400.0 310.2 VH3 / Vκ4 NB NB VH4 / Vκ1 243.0 5.6 VH4 / Vκ2 3950.0 91.4 VH4 / Vκ3 7060.0 163.4 VH4 / Vκ4 NB NB VH5 / Vκ1 12100.0 280.1 VH5 / Vκ2 12200.0 282.4 VH5 / Vκ3 185.0 4.3 VH5 / Vκ4 NB NB
[0400] Multi-cycle analysis
[0401] Six lead variants (VH1 / Vκ1, VH1 / Vκ2, VH1 / Vκ3, VH2 / Vκ1, VH2 / Vκ2, and VH2 / Vκ3) were tested in competition ELISA by multi-cycle kinetic analysis.
[0402] For multi-cycle kinetic analysis, the purified antibody was fixed in HBS-P+ with a protein concentration of 1 μg / mL. At the beginning of each cycle, the antibody was captured on protein A to obtain about 100 RU and stabilize the surface. Kinetic data were obtained at a flow rate of 35 μl / min to minimize any potential mass transfer effects. Multiple repetitions of blank (no CEACAM1) and repetitions of single concentrations of analyte were programmed into the kinetic run to check the stability of the surface and analyte in the kinetic cycle. For kinetic analysis, a 2-fold dilution series from 100 to 1.5625 nM CEACAM1 was selected. The association phase of CEACAM1 was initially monitored for 180 seconds. In subsequent experiments, a longer association time (275 seconds) was used to better achieve a steady state. The dissociation phase was measured for 250 seconds. At the end of each cycle, 2 injections of 10 mM glycine-HCL pH 1.5 were used to regenerate the protein A surface.
[0403] The signal from the reference channel Fc1 was subtracted from the signals for Fc2, Fc3, and Fc4 to correct for differences in nonspecific binding to the reference surface, using a global Rmax parameter in a 1-to-1 binding model. TM Variant K D Divide by the KD of the chimeric parental antibody on the same chip to calculate the relative KD compared to the chimeric parental antibody. D The data are summarized in Table 7.
[0404] The composite human antibody variants VH1 / Vκ1, VH1 / Vκ2, VH1 / Vκ3, VH2 / Vκ1, VH2 / Vκ2 and VH2 / Vκ3 showed affinities within 2-fold of the chimeric parent antibody. See Table 8.
[0405] Table 7. Multi-cycle kinetic data of six composite human antibody variants binding to CEACAM1-HIS as determined using Biacore T200 (n=1). D Divide by the KD of the chimeric parent antibody tested on each chip to calculate the KD compared to the chimeric parent antibody. D Multiple difference.
[0406]
[0407]
[0408] Table 8. Summary of relative KD values of the six tested composite human antibody variants obtained from multi-cycle kinetics as determined using Biacore T200. D Divide by the KD of the chimeric parent antibody tested on each chip to calculate the KD compared to the chimeric parent antibody. D The average relative KD was determined by two independent experiments.
[0409]
[0410] Example 2: Removal of N-linked glycosylation sites
[0411] Sequence analysis revealed the presence of potential N-linked glycosylation motifs at position N56 of the original mouse hybridoma heavy chain and position S27 within the light chain (numbered based on the Kabat numbering system). These sites were mutated to remove N-linked glycosylation sites (i.e., N56Q and S27(f)A). The deglycosylated residues are highlighted in bold in Table 19.
[0412] Example 3: Specificity of isolated composite human antibody variants for CEACAM1
[0413] The binding selectivity of the selected antibody variants was evaluated by flow cytometry using HeLa cells transfected with vectors expressing CEACAM1, CEACAM5 and CEACAM6, respectively. The resulting cells were used for flow cytometry experiments and cultured in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum, penicillin (100U / ml) and dihydrostreptomycin (100μg / ml) at 37°C, 5.0% CO2. The cell line was stained with the antibodies shown, and then stained with a monoclonal antibody (such as human IgG4 or mouse IgG1) and a live dye (DAPI) conjugated with a fluorescent dye specific to the antibody isotype shown. Data were obtained with a Cytoflex flow cytometer (Invitrogen) and analyzed with FlowJo software (TreeStar, V7.6.5 for Windows).
[0414] The binding specificities of the selected CEACAM1 antibodies are shown in Table 9.
[0415] Table 9. Binding selectivity of selected antibody variants was assessed by flow cytometry using HeLa cells transfected with vectors expressing CEACAM1, CEACAM5 and CEACAM6, respectively. Shown are the relative fluorescence intensities of cells expressing the corresponding antigens bound by the indicated antibodies.
[0416] Variants CEACAM1 CEACAM5 CEACAM6 VH0 / VK0 84.2 0.42 2.72 VH1 N56Q / VK4 S27(f)A 87.1 0.0622 2.26 VH2 N56Q / VK1 S27(f)A 88.7 3.91 13.5 VH2 N56Q / VK2 S27(f)A 89.4 3.04 9.5 VH2 N56Q / VK3 S27(f)A 79.1 2.19 8.27 VH2 N56Q / VK4 S27(f)A 89.3 0 1.31 VH1 / VK4 81.1 4.47 1.19 hIgG4 (negative control) 0 0 0.0979
[0417] Example 4: Expansion of human hematopoietic cells induced by antibody treatment
[0418] To evaluate the antibody of choice for CD45 stimulation + To investigate the efficacy of human cell expansion, the HuNSG model was used (Fisher et al. Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity. Cancer Immunol Immunother. 2012 Oct; 61(10): 1721-33).
[0419] To this end, human whole blood was collected from healthy volunteer donors and peripheral blood mononuclear cells (PBMCs) were isolated. Ten million freshly isolated human PBMCs were adoptively transferred into NSG (NOD.Cg-Prkdc) cells via intraperitoneal injection. scid Iq tm1Wjl / SzJ) host mice. Fifteen days after PBMC injection, animals were administered a single dose of the indicated humanized antibodies (2 mg / kg via intraperitoneal injection). Five days later, PBMCs were stained with human CD45 antibody to identify hematopoietic cells and evaluated via fluorescence activated cell sorting (FACS). The results are summarized in Table 10. Lower values indicate higher intracellular dye dilution and human CD45 + Enhanced cell proliferation.
[0420] Table 10. Response of human CD45 to CEACAM1 by selected antibodies + The cells were treated in vivo to induce their proliferation. Lower values indicate higher intracellular dye dilution, which indicates that human hematopoietic CD45 + Cell expansion.
[0421] Antibody Fluorescence intensity hIgG4 control antibody 126,218 VH0 / Vκ0 100,419 VH2 / Vκ4 62,015 VH1 / Vκ4 38,087
[0422] Example 5: Affinity maturation of VH2 N56Q / Vκ4S27(f)A scFv
[0423] 1. Phage vector construction and binding test of parental VH2N56Q / Vκ4S27(f)AscFv
[0424] The template for affinity maturation is VH2 N56Q / Vκ4S27(f)A non-glycosylated humanized antibody. Overlapping PCR is used to convert the genes encoding starting antibody VH and Vκ into scFv form, wherein the heavy chain is connected to the light chain via 15 amino acids (G4S)3 joints (SEQ ID NO:47). Then restriction enzymes NcoI and NotI are used to clone the scFv sequence into phagemid vector pANT65 so that scFv is displayed as gene III fusion protein on the phage surface. This plasmid also allows expression of C-terminal Flag tags on the expressed scFv. The cloned scFv is transformed into Escherichia coli (TG1) and all constructs are confirmed by sequencing.
[0425] M13 helper phage (monovalent) and superphage (multivalent) displaying the parental VH2 N56Q / Vκ4S27(f)A scFv or an irrelevant scFv were prepared and tested for binding to CEACAM1 (Sino Biological). Phage derived from the parental VH2 N56Q / Vκ4S27(f)A sequence bound specifically to the antigen, whereas no binding was observed with the irrelevant phage. As expected, the binding titer of the parental scFv superphage was lower than that of the parental M13 helper phage due to the increased number of scFvs displayed on the phage surface.
[0426] 2. Library Design
[0427] The major determinant of antigen binding within an antibody is the CDR (Wu and Kabat, 1970). Targeted mutations to VH CDR3 and Vκ CDR3 have been shown to be one of the most effective means of improving affinity via phage display (e.g., Shier et al., 1996).
[0428] To construct the affinity maturation library, specific amino acids within the humanized antibody VH CDR3 and Vκ CDR3 were targeted for "hot spot" mutagenesis using semi-random codons. The sequence positions of possible contact residues were analyzed (http: / / www.bioinf.org.uk / abs / MeanContacts.html) and ranked in order within each block. This information was used together with the amino acid preference for any given position within the heavy and light chain CDR3 (http: / / www.abysis.org / ). Where possible, the highest ranked contact residues within each block were prioritized.
[0429] The VH CDR3 was identified as 11 amino acids in length (Kabat definition) and split into two libraries overlapping at G99: Block 1 (G95 to G99) and Block 2 (G99 to A101), each containing a subset of amino acids at all positions. Position T93 was included in Block 1 to allow for more diversity in the germline residues anchoring the CDR. The Vκ CDR3 (Q90 to W96) was covered in a single library, containing a set of amino acids at each position. Kabat numbering was used for all protein sequence coordinates.
[0430] 3. Library Construction
[0431] All oligonucleotides were designed and synthesized as previously described (IDT, Integrated DNA Technologies). Degenerate primers were mixed manually to reduce nucleotide bias during synthesis. An overview of library construction is shown in Figure 1 shown.
[0432] The non-expression plasmid containing the VH2 N56Q / Vκ4S27(f)A parental sequence and configured as scFv was designed to contain a stop codon to prevent the parental scFv from dominating the selection (as often observed in affinity maturation programs). Stop codons were placed in the VH2N56Q / VK4 S27(f)A scFv in pANT65 using Quikchange mutagenesis (Agilent) in each sequence region to be randomized so that only mutant antibody variants in which the stop codon has been replaced by an amino acid encoded by the library will be expressed. By using this approach, the non-mutated parental sequence will be truncated and therefore will not be displayed.
[0433] For two VH CDR3 libraries (block 1 and block 2), randomization was achieved by performing two PCRs using a stop codon template. Initially, a portion of VH and Vκ were amplified with a randomized 5' library primer and a 3' primer specific for Vκ light chain FW4. In a separate PCR, the remainder of VH was amplified with a 5' primer based on the heavy chain FW1 region plus a 3' primer complementary to a portion of the VH CDR randomization primer. The full-length VH CDR randomized scFv library was then constructed by annealing the two amplified fragments and re-amplifying the scFv using a primer with two restriction sites (Nco I or Not I) for subcloning of the fragment.
[0434] For the VκCDR3 library, randomization of VκCDR3 was performed by performing two PCRs. In the first PCR, a randomized 3' primer and a VH FW1-specific 5' primer containing an Nco I restriction site were used to amplify most of the scFv gene and introduce mutations into VκCDR3. The second PCR added the remainder of the scFv and appended a restriction site (Not I) for subcloning of the fragment.
[0435] The purified amplified DNA of all three libraries was digested with Nco I and Not I and connected to a similarly cut phagemid vector (pANT65). The connected DNA was precipitated, resuspended in nuclease-free water, and transformed into freshly prepared electrocompetent TG1 cells by electroporation. The next day, colonies were counted, plates were scraped and glycerol stocks were prepared. The library was electroporated multiple times to fully cover the theoretical library diversity. The library size of each of the three libraries observed is shown in Table 11. In all cases, 4.95 times or higher coverage was obtained. Single colonies from each of the three libraries were sequenced to confirm that the appropriate CDR blocks had mutated.
[0436] Table 11. Theoretical and observed phage library sizes for the three CDR libraries prepared.
[0437]
[0438]
[0439] 4. Library phage rescue
[0440] Bacteria from each library were inoculated into 150 ml 2TYCG (2%) cultures using an inoculum of at least 100x the observed library diversity. Cultures were grown to mid-log phase (OD 600nm ≈0.4), and the total number of cells was estimated (based on OD 600nm 1≈5x10 8Cells / ml). Superphage was added and incubated for 15min (static), then incubated at 250rpm for 45min, then centrifuged, resuspended in 2TYCK medium and grown overnight at 30°C. The next day, the culture supernatant was recovered by centrifugation, and then 3 / 10 volume of cooled 20% PEG / 2.5MNaCl precipitation was used to harvest the phage. After incubation on ice for 1 hour, the precipitated phage was recovered by centrifugation, and the precipitate was resuspended in 1x PBS pH 7.4. The supernatant was centrifuged again to remove any cell debris, and the supernatant was then reprecipitated as described above. The precipitated phage was resuspended in 1x PBS pH 7.4. In order to increase the chance of obtaining scFv with increased affinity, due to the relatively low affinity of the starting antibody, a multivalent superphage (M13K07ΔpIII helper phage) was used for library recovery at an infection multiplicity of 20. After the first round of selection, monovalent M13K07 helper phage (New England BioLab) was used at a multiplicity of infection of 10 due to the expected enrichment of antigen binders.
[0441] 5. Phage Selection for Improved Affinity
[0442] CEACAM1 was used throughout for positive selection. Soluble deselection was performed using closely related family members CEACAM3, CEACAM5 and CEACAM6 (Sino Biological) at a final concentration of 50 nM of each protein to reduce the possibility of selecting affinity-matured scFvs with cross-reactivity to CEACAM3, CEACAM5 and CEACAM6. This was performed twice during the campaign by deselection before the second and third rounds. The three libraries remained separated at all stages throughout the campaign.
[0443] For selection, each library was pre-blocked with 3% BSA / PBS, and then the phage was incubated with a decreasing concentration of biotinylated soluble CEACAM1 antigen for up to two hours. After incubation, streptavidin paramagnetic beads (pre-blocked as above) were added to each selection and rotated upside down for 10 minutes. The streptavidin-antigen-phage complex was washed with an increasing number of PBST washes in each round of continuous selection, followed by PBS washes, and captured with a magnet between each step. For the VH B2 library, in the second round, since the first round of output titers were low, a higher concentration of CEACAM1 was used to enrich the number of phage binders selected. Only for the light chain library, a fourth round of selection was performed to further enrich the positive binding phage, because the third round of output titers were relatively large. Phages were eluted from the beads by adding 50mM HCl, and then neutralized by adding 1M Tris-HCl pH 9.0 solution.
[0444] 6. Expression of soluble scFv (periprep)
[0445] Soluble scFv was initially expressed and tested as a crude periplasmic extract. A single colony from the selection output was picked into 1 ml 2TYCG (0.1%) medium and grown by shaking at 37°C for 5 hours. The culture was induced by adding IPTG to a final concentration of 1 mM and then grown overnight at 30°C with shaking. The next day, the culture was centrifuged and the supernatant was discarded. The bacterial pellet was resuspended in TES buffer pH 7.4 and incubated on ice for 30 minutes. The plate was then centrifuged and the supernatant containing the scFv was transferred to a fresh plate for determination.
[0446] 7. High-throughput competitive screening of peripreps
[0447] Peripreps from colonies selected at different rounds were screened in a single-site competition assay to determine their ability to compete with the parental RSB02 IgG for binding to CEACAM1. The parental RSB02 scFv and an irrelevant scFv were included on each assay plate for comparison.
[0448] Nunc Immuno MaxiSorp 96-well flat-bottom microtiter plates were coated with 0.0625 μg / ml of CEACAM1 overnight. The plates were then washed and blocked with 3% BSA / PBS at room temperature for 1 hour. Periplasmic extracts were diluted 1:1 with 0.246 μg / mL of VH2 N56Q / Vk4S27(f)A IgG (parent RSB02 IgG) in 6% BSA / PBS. The diluted periplasmic extracts were then added to the blocked plates (100 μL per well) and the samples were incubated on the plates for 1 hour at room temperature. The plates were then washed and the binding of VH2 N56Q / Vk4S27(f)A IgG was detected with anti-human HRP antibody (Sigma, Gillingham, UK) and TMB substrate (Invitrogen). The reaction was terminated with 1M HCl, the absorbance was read at 450nm on a Dynex Technologies MRX TC II plate reader, and the binding data were plotted.
[0449] Improved clones were identified based on activity in a competition ELISA relative to the parental RSB02 scFv assayed on the same plate. In total, over 7300 peripreps from all three libraries were analyzed. Positive hits were picked into a 'cherry' plate, retested in a competition ELISA to confirm the results and sequenced. Dominant single sequence clones were identified in both the VH B1 (approximately 41% of clones sequenced after round 3 were single dominant clones) and the VL library (approximately 20% of clones sequenced in rounds 3 and 4 were single dominant clones). The VL library appears to contain scFvs with greater inhibitory capacity, resulting in a higher cutoff point for positive hits (at least 50% inhibition). See Figure 2 .
[0450] In order to select the lead VH and VL for the combination production of IgG, positive hits (from primary and secondary screening) were sorted to determine the VH and VL with the highest average inhibition percentage compared to the parent. Five VH B1 clones, three VH B2 clones and 11 VL clones were selected. During sequence analysis, L4 was identified as a mixed VL clone consisting of two different sequences. These were cloned separately to produce clones L4#1 and L4#2, resulting in a total of twelve VL clones being advanced. After reformatting, light chain L4#2 was subsequently shown to have the same sequence as L17. He3, originally from the VH B1 library, contained a single mutation in B2 in addition to the changes in B1. A summary of twenty lead clones and their CDR sequences is shown in Table 12.
[0451]
[0452] Example 6: Construction and testing of affinity matured intact antibodies
[0453] 1. Reformatting the lead scFv into an antibody
[0454] Twenty variants identified by scFv screening were PCR amplified using primers that introduced flanking restriction enzyme sites for cloning into the IgG4 S241P pANTVhG4 vector and the kappa light chain pANTVK vector. Eight affinity-matured VH variants were subcloned into the IgG4 S241P pANTVhG4 vector using the MluI and HindIII restriction sites. Similarly, twelve affinity-matured Vκ sequences were subcloned into the kappa light chain pANTVK vector using the BssHII and BamHI restriction sites.
[0455] 2. Expression of lead 20 reformatted scFv as complete IgG
[0456] For expression, eight lead humanized affinity-matured IgG4 VH variants and parental humanized heavy chains (VH2 N56Q) were combined with parental humanized light chains (Vκ4S27 (f) A) and 12 lead humanized affinity-matured κ light chains to obtain a total of 117 combinations. These combinations were transiently transfected into HEK EBNA adherent cells (LGC standards) in 12-well plates using PEI transfection method. Seven days after transfection, supernatants were harvested, quantified by ELISA and filtered for Biacore single-cycle kinetic analysis.
[0457] Example 7: Single-cycle kinetic analysis of humanized and affinity-matured lead IgG binding to CEACAM1
[0458] In order to evaluate the binding of humanized affinity-matured IgG, single-cycle kinetic analysis was performed on the crude supernatant using Biacore T200 running Biacore T200 control software V2.0.1 and Biacore T200 evaluation software V3.0 (Uppsala, Sweden). The antibody was diluted to a final concentration of 1.0 μg / ml in HBS-P+ (GE Healthcare). At the beginning of each cycle, the antibody was loaded onto the Fc2, Fc3 and Fc4 of a protein A chip (GE Healthcare). IgG was captured at a flow rate of 10 μl / min to obtain an immobilization level (RL) of about 100RU (the level of Rmax of about 50-150RU obtained after the calculated binding analyte). The surface was then stabilized. Single-cycle kinetic data were obtained using CEACAM1 as an analyte at a flow rate of 35 μl / min to minimize any potential mass transfer effect. Multiple repetitions were performed with the parent (VH2 N56Q / Vκ4S27(f)A) antibody to examine the stability of the surface and analyte during the kinetic cycle. The signal from the reference channel Fc1 (no antibody) was subtracted from the signal of Fc2, Fc3 and Fc4 to correct for differences in nonspecific binding to the reference surface. A three-point two-fold dilution range of 25nM to 100nM CEACAM 1 was used without regeneration between concentrations. The signal from each antibody blank run (no CEACAM1) was subtracted to correct for differences in surface stability. The dissociation phase of three injections of increasing concentrations of CEACAM1 was monitored for 200 seconds each time and after the last injection of CEACAM1, a single dissociation phase was measured for 300 seconds. Two injections of 10mM glycine-HCL pH 1.5 were used to regenerate the protein A surface, followed by a 240-second stabilization period.
[0459] The 117 combinations were tested in two experiments.Table 13. Single cycle kinetic constants demonstrating binding of all affinity matured antibodies to CEACAM1.
[0460] Table 13. Single cycle kinetic analysis of humanized and affinity matured lead IgG binding to CEACAM1. Single cycle kinetic data obtained for 117 humanized and affinity matured variant test supernatants, ranked from best to worst. Fold = fold better than parent. K D Units are in nM. Variants selected for further analysis are in bold.
[0461]
[0462]
[0463] After analyzing the single cycle data, twelve variants were selected based on the improvement in affinity and the differences observed in the kinetic profiles (including significantly faster association and dissociation rates observed with He3 / L20, He17 / L1, and He17 / L16). The twelve variants included multiple heavy and light chains with different fold improvements to mitigate the risk of cross-reactivity with other CEACAM family members (bold in Table 13).
[0464] Example 8: Testing of lead antibodies
[0465] 1. Expression, purification and testing of lead antibodies
[0466] The 12 lead combinatorial variants as well as the parental IgG (variants in bold in Table 13) were transiently transfected into HEK EBNA adherent cells in three-necked flasks using the PEI method and incubated for 5-7 days post-transfection. Antibodies were purified from cell culture supernatants on a protein A agarose column (GE Healthcare), the buffer was exchanged to PBS pH 7.2, and the OD values were calculated using an extinction coefficient based on the predicted amino acid sequence. 280nm Quantification was performed. 2 μg of each reduced antibody was analyzed by SDS-PAGE, and a band corresponding to a typical antibody curve was observed.
[0467] 2. Cross-reactivity ELISA of 12 lead variants binding to CEACAM1 / -3 / -5 / -6
[0468] Binding experiments using the parental IgG have previously shown specific binding to CEACAM1 and no cross-reactivity to CEACAM3 / 5 and 6. The cross-reactivity of CEACAM3 / 5 and 6 of the 12 lead variants with the parental IgG was assessed using a binding ELISA assay. Binding to CEACAM1 was used as a positive control in the same assay. The mouse pan-CEACAM antibody D14HD11 (Abcam) was used as a positive control to confirm the integrity of CEACAM1- / -3 / -5 and -6.
[0469] Nunc Immuno MaxiSorp 96-well flat-bottom microtiter plates (ThermoFisher) were pre-coated with 0.5 μg / ml CEACAM1 in 1xPBS overnight at 4°C. The next day, the plates were blocked with 2% BSA / PBS for 1 hour at room temperature and then washed twice with PBS / 0.05% Tween20 pH 7.4. To identify appropriate antibody concentrations for evaluating cross-reactivity, binding curves for parental IgG and D14HD1 were generated. A three-fold dilution series was performed, starting from 5.0 μg / ml to 0.0069 μg / ml; they were added to the plates and incubated for 1 hour at room temperature. After 3 PBST washes, wells containing parental IgG were incubated with goat anti-human IgG kappa chain-HRP antibody (Merck Millipore). Wells containing D14HD11 were incubated with anti-mouse peroxidase IgG (Sigma Aldrich), binding was detected using TMB substrate (Invitrogen), and the reaction was stopped with 3M HCl. The absorbance was read at 450 nm on a Dynex Technologies MRX TC II plate reader and used to plot binding curves. Complete sigmoidal curves were obtained for both RSB02 parental antibody and D14HD11.
[0470] To test cross-reactivity, three concentrations were selected for testing, corresponding to the high (1.67 μg / ml), mid (0.062 μg / ml) and low (0.0069 μg / ml) points of the binding curve generated by parental IgG CEACAM1 binding. All 12 variants were tested for binding to CEACAM1 / -3 / -5 and -6 at 1.67 μg / ml, 0.062 μg / ml and 0.0069 μg / ml, all coated overnight at 4°C at 0.5 μg / ml in 1x PBS. The absorbance of parental IgG binding to CEACAM1 at 1.67 μg / ml was set as 100% binding. The percentage of CEACAM1 / -3 / -5 and -6 binding of all variants was then calculated relative to the absorbance of CEACAM1 binding of parental IgG at 1.67 μg / ml on the same plate. The plotted binding data obtained for the 12 variants are shown in Figure 3.
[0471] As expected, RSB02 parent IgG and all 12 tested variants bound to CEACAM1 at all tested concentrations (Figure 3). As a positive control, D14HD11 was tested and shown to bind to CEACAM1 / -3 / -5 and -6 ( Figure 3E ).
[0472] This high degree of selectivity can be observed despite the high homology of the N domains of the different CEACAMs: the N domains of CEACAM1 and CEACAM3 are 88% identical, the N domains of CEACAM1 and CEACAM5 are 89% identical, and the N domains of CEACAM1 and CEACAM6 are 90% identical, as shown in the percent identity matrix generated using Clustal 2.1. See Figure 13 of PCT Publication WO2020 / 118295.
[0473] 3. Cross-reactivity analysis of 12 leads by single-cycle kinetics
[0474] To further evaluate the cross-reactivity of the humanized, affinity-matured lead IgG, single-cycle Biacore kinetic analysis was performed using CEACAM3, 5, and 6 and CEACAM1 as a positive control.
[0475] The antibodies were diluted to a final concentration of 1.0 μg / ml in HBS-P+. At the beginning of each cycle, the antibodies were loaded onto Fc2, Fc3, and Fc4 of the protein A chip. After CEACAM binding, IgG was captured at a flow rate of 10 μl / min to obtain an Rmax of 50-150. Multiple repetitions were performed with the parent (VH2 N56Q / Vκ4S27(f)A) antibody to check the stability of the surface and analyte in the kinetic cycle. The signal from the reference channel Fc1 (no antibody) was subtracted from the signal of Fc2, Fc3, and Fc4 to correct for differences in nonspecific binding to the reference surface. A four-point two-fold dilution range of 25nM to 200nM CEACAM1 / -3 / -5 / -6 was used without regeneration between concentrations. The signal from each antibody blank run (no CEACAM) was subtracted to correct for differences in surface stability. The dissociation phase of each CEACAM injection of four increasing concentrations was monitored for 275 seconds each and after the last injection of each CEACAM, a single dissociation phase was measured for 250 seconds. Regeneration of the protein A surface was performed using two injections of 10 mM glycine-HCL pH 1.5, followed by a stabilization period.
[0476] The mouse pan-CEACAM antibody D14HD11 was used as a positive control to determine the functionality of CEACAM1 / -3 / -5 / -6. Use of the Protein A sensor chip resulted in suboptimal capture of D14HD11, so an anti-mouse capture kit (GE Healthcare) was used and additional runs were performed. D14HD11 was diluted to 5 μg / ml in HBS P+ and loaded onto the Fc2 of the anti-mouse sensor chip at a flow rate of 10 μl / min to obtain the desired immobilization level for each CEACAM. The signal from the reference channel Fc1 (no antibody) was subtracted from the signal of Fc2 to correct for differences in nonspecific binding to the reference surface. A three-point two-fold dilution range of 70nM to 280nM CEACAM1 / -3 / -5 / -6 was used without regeneration between concentrations. The signal from each antibody blank run (no CEACAM) was subtracted to correct for differences in surface stability. The dissociation phase of three injections of increasing concentrations of CEACAM was monitored for 275 seconds each and after the last injection of CEACAM, a single dissociation phase was measured for 1800 seconds (30 minutes). Regeneration of the anti-mouse sensor surface was performed using one injection of 10 mM glycine-HCL pH 1.7, followed by a stabilization period
[0477] While all tested variants bound to CEACAM1, no binding to CEACAM3 / 5 / 6 was observed by Biacore. This is consistent with the binding observed with the parental IgG. D14HD11 showed binding to all tested CEACAMs.
[0478] 4. Multi-cycle kinetics of 12 lead variants on CEACAM1
[0479] Multi-cycle kinetic analysis was performed on twelve lead antibodies using a Biacore T200 instrument running Biacore T200 evaluation software V3.0.1 (Uppsala, Sweden) to establish accurate affinity for CEACAM1. The purified antibodies were diluted to a concentration of 1 μg / ml in HBS-P+. At the beginning of each cycle, each antibody was captured on the protein A surface to obtain a RL of approximately 100 RU. After capture, the surface was stabilized. Kinetic data were obtained using a flow rate of 35 μl / min to minimize any potential mass transfer effects. For kinetic analysis, CEACAM1 was used. Multiple repetitions of the blank (CEACAM1) and repetitions of a single concentration of analyte were programmed into the kinetic run to check the stability of the surface and analyte in the kinetic cycle. For kinetic analysis, a two-fold dilution range from 200 to 3.125 nM CEACAM1 was selected. The association phase of CEACAM1 was monitored for 275 seconds, and the dissociation phase was measured for 250 seconds. At the end of each cycle, regeneration of the Protein A surface was performed using two injections of 10 mM Glycine-HCL pH 1.5.
[0480] The signal from the reference channel Fc1 was subtracted from the signals of Fc2, Fc3, and Fc4 to correct for differences in nonspecific binding to the reference surface, and a global Rmax parameter was used in a 1-to-1 binding model. D Relative K was calculated by dividing the K of humanized and affinity matured variants on the same chip. D The kinetic parameters measured for the interaction of CEACAM1 with the RSB02 affinity matured variants are shown in Table 14. All humanized, affinity matured variants showed improved affinity compared to the parental (VH2 N56Q / Vκ4S27(f)A).
[0481] Compared to the parental IgG, the He3 / L20, He17 / L1, He17 / L16 variants exhibited significantly faster association and dissociation rates.
[0482] Table 14. Multi-cycle kinetic data of RSB01 parental (VH2 N56Q / Vκ4S27(f)A) and twelve humanized affinity matured leads binding to CEACAM1 determined using Biacore T200. Relative K compared to parental (VH2 N56Q / Vκ4S27(f)A) D is by converting the parent's K D Calculated by dividing by the KD of the affinity matured variant assayed on the same chip. *Highlights variants showing a poor 1:1 fit, resulting in less accurate KD and relative KD determinations.
[0483]
[0484]
[0485] Example 9: Specificity of affinity matured CEACAM1 antibodies as determined by flow cytometry
[0486] The binding selectivity of the selected antibody variants was evaluated by flow cytometry using HeLa cells transfected with vectors expressing CEACAM1, CEACAM3, CEACAM5, CEACAM6 or CEACAM 8, respectively. The resulting cells were used for flow cytometry experiments and cultured in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum, penicillin (100U / ml) and dihydrostreptomycin (100μg / ml) at 37°C, 5.0% CO2. The cell lines were stained with the antibodies shown, followed by staining with monoclonal antibodies (such as human IgG4 or mouse IgG1) and live dyes (DAPI) conjugated with fluorescent dyes specific to the antibody isotypes shown. Data were obtained with a Cytoflex flow cytometer (Invitrogen) and analyzed with FlowJo software (TreeStar, V7.6.5 for Windows).
[0487] The binding specificity of the selected CEACAM1 antibodies is shown in Table 15.
[0488] Table 15. Binding selectivity of selected antibody variants was assessed by flow cytometry using HeLa cells transfected with vectors expressing no CEACAM (Neo), CEACAM1 (C1), CEACAM5 (C5), CEACAM6 (C6), or CEACAM 8 (C8), respectively. Shown are the relative amounts of cells expressing the corresponding antigen bound by the indicated antibodies. * indicates the parent antibody used for affinity maturation. Col-1 (CEACAM3 / 5), 9A6 (CEACAM6), T84.1 (CEACAM1, 3, 5), T84.66 (CEACAM5), and 80H3 (CEACAM 8) are control antibodies.
[0489] VH V L Neo C1 C3 C5 C6 C8 He3 20 +++ He4 16 +++ +++ +++ He9 3 +++ +++ +++ He9 6 +++ +++ + He9 17 +++ +++ ++ He9 L4#2 +++ +++ +++ He14 1 +++ VH2 N56Q* Vk4 S27(f)A +++ 17 1 +++ + + 17 16 +++ + VH2 N56Q 1 +++ VH2 N56Q 4#2 +++ + VH2 N56Q 18 +++ +++ Col-1 + +++ +++ 9A6 + +++ + T84.1 +++ +++ +++ +++ T84.66 + +++ + + 80H3 +++ + +++
[0490] Example 10: Specificity of the affinity matured CEACAM1 antibody He14 / L1 as determined by surface plasmon resonance (SPR)
[0491] The binding specificity of antibody He14 / L1 to hCEACAM1, hCEACAM3, hCEACAM5 and hCEACAM6 was shown by single-cycle surface plasmon resonance (SPR).
[0492] To evaluate the binding of He14 / L1 to hCEACAM1, hCEACAM3, hCEACAM5, and hCEACAM6, single-cycle kinetic analysis was performed. Kinetic experiments were performed at 25°C on a Biacore T200 running Biacore T200 control software V2.0.1 and evaluation software V3.0 (Cytiva, Uppsala, Sweden). HBS-P+ (Cytiva, Uppsala, Sweden) was used as running buffer and ligand and analyte diluent. At the beginning of each cycle, the antibodies were loaded onto a protein A sensor chip (Cytiva, Uppsala, Sweden). Considering the different analyte molecular weights (100RU for CEACAM1, 375RU for hCEACAM3, 71RU for hCEACAM5, and 150RU for hCEACAM6), IgG was captured to a predetermined immobilization level at a flow rate of 10 μl / min. The surface was then stabilized. A three-point two-fold dilution range of antigen from 70-280 nM in running buffer was used without regeneration between concentrations. The association phase of three injections of increasing concentrations of antigen was monitored for 80 seconds each and a single dissociation phase was measured for 150 seconds after the last injection of antigen. A similar approach was used for mouse D14HD11 (an anti-pan-hCEACAM control antibody). However, in this case, a CM5 chip immobilized with an anti-mouse capture reagent (Cytiva, Uppsala, Sweden) was used, association was monitored for 275 seconds, and dissociation was monitored for 1800 seconds. Data were double referenced and subtracted.
[0493] As shown in FIG. 4 , antibody He14 / L1 binds to hCEACAM1 with high specificity.
[0494] Example 11: Crystal structure of CEACAM antibody and CEACAM1
[0495] To precisely map the binding interface between CEACAM1 and the humanized, affinity matured and non-glycosylated antibody He14 / L1, the crystal structure of human CEACAM1 in complex with the He14 / L1 Fab fragment was determined at atomic resolution (Table 16). The structure of the co-crystal has been deposited in the RCSB Protein Data Bank using the PDB code 7N3W.
[0496] Table 16. Crystallographic information, data collection and refinement parameters for He14L1: human CEACAM1 structure (PDB ID 7N3W). The a values for the outermost shell are given in brackets.
[0497]
[0498]
[0499] Untagged CEACAM1 was expressed in E. coli, refolded and purified in a buffer containing arginine. He14 / L1 Fab was prepared by digesting the provided antibody with immobilized papain resin and then purified using a 1 ml HiTrap MabSelect SuRe column (GE Healthcare) followed by gel filtration chromatography. Purified CEACAM1 and Fab were mixed in a 1:1 molar ratio prior to crystallization screening. Initial crystallization hits for the CEACAM1:He14 / L1Fab complex were identified and subsequently optimized. Diffraction quality crystals were grown at room temperature in the presence of 20% PEG 8000 and 0.1 M HEPES pH 7.5. SDS-PAGE analysis and silver staining of washed crystals revealed all expected components of the complex.
[0500] The structure of the CEACAM1:VH14 / VL1 Fab complex was determined The complex was crystallized in the native monoclinic space group P21 and two copies of the complex were seen in the asymmetric unit. In the structure coordinate file, chains A and L correspond to the Fab light chain, chains B and H correspond to the Fab heavy chain, and chains C and D correspond to the CEACAM1 molecule. The structure of the complex (chains C, L and H) is shown in Figure 5A shown.
[0501] GFCC' surface bonding
[0502] He14 / L1Fab binds to the CEACAM1 symmetric partner present in the asymmetric unit of the crystal through the GFCC' interface in a 1:1 stoichiometric ratio ( Figure 5D ). In this interface, CEACAM1 GFCC' residues, especially F29, Q44, T56, Q89 and N97, contribute to tight binding with heavy and light chain residue CDRs (Table 17), and the CC' and FG loops of CEACAM1 show active participation in the formation of the complex. These GFCC' face residues are also important for the formation of human CEACAM1 homodimers and their interactions with various ligands (such as TIM-3, HopQ). Superposition of CEACAM1 in the Fab complex with the CEACAM1 protomer in the dimer yields a root mean square deviation of 0.453A over 81 aligned Cα positions. The GFCC' binding interface has a high shape complementarity score of 0.74, and this is the preferred face for binding.
[0503] ABED surface combination
[0504] He14 / L1Fab binds to CEACAM1 present in the crystal asymmetric unit in a 1:1 stoichiometry (Table 18). Upon complex formation, the Fab appears to perturb the structure of CEACAM1. Specifically, there are significant structural differences in the C' and C" of the β strands and the C' to C" loop that participate in self-association. In the complex, there are fewer intramolecular hydrogen bonding interactions in this perturbed region, resulting in a significant shortening of the C" strand and a shift in the orientation of C', as the residues that form the C" strand in the dimer become part of the extended loop ( Figure 5B ). Superposition of CEACAM1 in the Fab complex with the CEACAM1 protomer in the dimer yields an RMS deviation of 1.32 Å across 81 aligned Cα positions. As shown, the perturbed loops appear to interfere with dimerization and the relevant surfaces are altered by Fab binding.
[0505] The epitope on CEACAM1 is shown in the molecular surface representation of CEACAM1 ( Figure 5C ). In the He14 / L1 Fab light chain, CDR1 interacts primarily with CEACAM1 residues in the C' strand and the C' to C" loop, whereas CDR3 interacts primarily with residues in the D and E strands and the D to E loop. In the Fab heavy chain, CDR1 and CDR2 interact with strands A and B and the associated interconnecting loops. In addition, a weak electrostatic interaction may exist between the side chain of heavy chain Lys65 and CEACAM1 Glu5 (4.5 Å apart, not drawn). The interaction surfaces have a shape complementarity of 0.58. Light chain CDR2 and heavy chain CDR3 do not interact with CEACAM1.
[0506] The crystal structure of a human CEACAM1 homodimer (PDB 4QXW) highlights the importance of the GFCC' face in homodimer formation. In addition, the ABED face crystal structure (PDB 2GK2) supports the role of the ABED face as a secondary small interface in CEACAM1 oligomer formation. Both GFCC' and ABED face binding are present in the same lattice of the He14 / L1 CEACAM1 complex crystal structure, indicating that He14 / L1 exhibits a unique dual binding mode with human CEACAM1 through the GFCC' and ABED faces ( Figure 5E ).
[0507] Table 17. He14 / L1 Fab residues involved in binding to the GFCC' face of CEACAM1. $ The interaction site is located in the center of the CEACAM1 / CEACAM1 binding interface. This table describes the primary and secondary hydrogen bonding and hydrophobic interactions and the residues involved. * Primary hydrogen bonding interactions.
[0508]
[0509] Table 18. He14 / L1 Fab residues involved in binding to the ABED surface. The primary and secondary hydrogen (H) bonding interactions and residues involved are indicated. * Primary hydrogen bonding interactions.
[0510]
[0511]
[0512] Example 12: CEACAM1 Antibody Blocks CEACAM1:TIM-3 Interaction
[0513] The ability of the selected CEACAM1 antibodies to reduce the binding of CEACAM1 to TIM-3 was tested. CEACAM1 / TIM-3 competition ELISA studies were performed in triplicate to determine the ability of the selected antibodies (concentration range 0-250 nM) to inhibit the binding of human TIM-3 IgV domain untagged protein and human CEACAM1-GST protein. After incubation of 3 μg / ml hTIM-3 untagged protein overnight to coat the plate, the plate was washed with Tris-buffered saline buffer (TBS-CaCl2) containing 10 mM CaCl2. 2+ The wells were washed and blocked with 2% BSA in 4% BSA buffer. 4 μM hCEACAM1-GST tagged protein was used to block hTIM-3 binding to hCEACAM1-GST protein in the presence of antibody concentrations ranging from 0-250 nM. Human IgG4 antibody was used as a control (0-250 nM). Human CEACAM1-GST protein was detected using a goat polyclonal anti-GST-HSP antibody from Abcam (1:2000) and was measured by adding TMB solution (Life technologies). OD values were read at 450 nm on a plate reader. Data were plotted in Graphpad Prism and the best fit IC-50 value was determined. Figure 6 As shown, the indicated CEACAM antibodies blocked CEACAM1:TIM-3 heterophilic interactions.
[0514] Example 13: CEACAM1 Antibodies Reverse T Cell Function in Tumor-Dissociated Cells Derived from Patients Resistant to Checkpoint Inhibitor Therapy
[0515] To evaluate the ability of CEACAM1 antibodies to reverse T cell exhaustion in patients resistant to treatment with checkpoint inhibitors (such as PD-1 / PD-L1 and CTLA-4 inhibitors), peripheral blood mononuclear cells (PBMCs) were isolated from a melanoma patient (CY123.1) with secondary resistance to pembrolizumab (PD-1 inhibitor). PBMCs were resuspended and cultured under T cell stimulating conditions in 200 ml complete medium (RPMI 1640, Lonza) supplemented with 10% fetal calf serum (FCS), 1% glutamine, 100 IU / ml penicillin, 100 μg / ml streptomycin (Life Technologies), 25 mM HEPES (Sigma-Aldrich) in triplicate using 96-well U-bottom plates at 0.5 x 10 5 The concentration of cells / ml was incubated with 100 IU / ml recombinant IL-2 (NIH) and 1 mg / ml soluble CD3 (UCHT1, Abcam). After 96 hr of culture, CD3 was assessed by three + CD8 + Intracellular Ki67 expression in the T cell fraction was used to measure cell proliferation.
[0516] like Figure 7 As shown, CEACAM1 antibody reversed T cell exhaustion in PD-1-resistant tumors.
[0517] Example 14: CEACAM1 Antibody Induces B Cells and T Cells in CD45-Positive Cells from Metastatic Melanoma
[0518] The effect of the CEACAM1 antibody He14 / L1 on CD45-positive cells from metastatic melanoma was examined.
[0519] Equal amounts of sorted CD45-positive cells from three metastatic melanomas (naive treatment, n=1; treatment resistant, n=2) were treated in vitro with He14 / L1 (5 mg / ml) or human IgG4 isotype control (5 mg / ml) in culture medium for 42 hours at 37°C and subjected to single-cell sequencing. Briefly, cells were treated using the 10X Genomics ChromiumController and Chromium Single Cell 5'Library&Gel Bead kits according to the manufacturer's protocol. Samples were sequenced on an Illumina NovaSeq S2-100 instrument. Demultiplexing, barcoding, single-cell 5' unique molecular identifiers (UMIs), transcript alignment, and counting were performed using the Cell Ranger pipeline. Data were continuously imported into R for analysis by the Read10x() command function in Seurat. Cell counts and the number of UMIs / transcripts per cell (nUMI) in the merged data set were plotted and evaluated, and quality control metrics were applied. Data sets were merged and similar cells between groups were established using canonical correlation analysis, and cells were defined by applying principal component analysis scores and visualization of meta-clusters within 2D UMAP. Cluster identification was based on signature genes. This identified B cells within the meta-cluster (M2) in the isotype (ISO) and He14 / L1 samples and T cells within four meta-clusters (M0, M20, M23, M25).
[0520] As shown in Figure 8, treatment with antibody He14 / L1 resulted in expansion of B cells (from 164 cells to 347 cells) and T cells (from 394 cells to 913 cells) within 42 hours compared to control antibody, indicating that He14 / L1 caused extensive induction of B cells and T cells, and these responses are important for anti-tumor activity.
[0521] Example 15: CEACAM1 expression on cells from patients resistant to therapy
[0522] CEACAM1 expression on tumor-associated B cells, tumor-associated monocytes, and T cells isolated from treatment-resistant and naive patients was examined.
[0523] Peripheral blood mononuclear cells (PBMCs) from healthy donors (HD, n = 5), treatment-naive melanoma patients (PBMC-N, n = 5), and treatment-resistant melanoma patients (PBMC-R, n = 5), or mechanically dissociated metastatic tumors from treatment-naive melanoma (Tumor-N, n = 9) or treatment-resistant melanoma (Tumor-R, n = 16) were stained with Tb159-labeled anti-human CEACAM1 monoclonal antibody (parental antibody used to generate He14 / L1) or a panel of heavy metal-labeled antibodies for immunoassays ( Direct TM Immune Profiling Assay TM ). Stained cells were analyzed on a CyTOF2 mass cytometer. Sample acquisition, file processing using R, and mass cytometry data analysis using Cytobank were performed by standard methods to obtain comprehensive phenotypic analysis through multiplexed single cells. Cluster identification, characterization, and regression (Citrus) analysis was performed to establish associations between markers and clinical phenotypes. Cells consistent with B cell, monocyte, and CD8 T cell fractions were analyzed based on markers defined by the manufacturer (Fludigm) to determine the median level of human CEACAM1 expression detected by the Tb159-labeled monoclonal parental antibody in naive and treatment-resistant samples and associated with meta-clusters identified by Citrus analysis. Statistical analysis was performed with the Kruskal-Wallis test and Dunn's multiple comparison test. *, p, 0.05, **p < 0.01
[0524] As shown in Figure 9, there are more cells representing tumor-associated B cells, monocytes, and CD8 + CEACAM1 expression is increased in meta-clusters of T cells.
[0525] Table 19. Sequence summary.
[0526]
[0527]
[0528]
[0529]
[0530] While the above written description of the invention enables one of ordinary skill to make and use what is presently believed to be the best mode thereof, one of ordinary skill will understand and appreciate the existence of variations, combinations, and equivalents of the specific embodiments, methods, and examples herein.
Claims
1. An antibody or antigen-binding fragment thereof that binds to CEACAM1, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region; wherein each of the heavy chain variable region and the light chain variable region comprises CDR1, CDR2 and CDR3; and wherein: a) the sequence of CDR1H comprises the sequence DYYLY (SEQ ID NO: 1); b) the sequence of CDR2H comprises the sequence TISVGGGQTSYADSVKG (SEQ ID NO: 2); c) the sequence of CDR3H comprises the sequence GLYYGPSWVAY (SEQ ID NO: 3), ARTYGPAWFAY (SEQ ID NO: 4) or ALTYGPAWLAY (SEQ ID NO: 5); d) the sequence of CDR1L comprises the sequence KSSQSLLNSANQKNYLA (SEQ ID NO: 6); e) the sequence of CDR2L comprises the sequence FASTRES (SEQ ID NO: 7); and f) The sequence of CDR3L comprises the sequence QSHYPFYYT (SEQ ID NO: 8) or QSHFPYPLT (SEQ ID NO: 9).
2. The antibody or antigen-binding fragment thereof according to claim 1, wherein: a) the sequence of CDR3H comprises the sequence GLYYGPSWVAY (SEQ ID NO: 3); and b) The sequence of CDR3L comprises the sequence QSHYPFYYT (SEQ ID NO: 8).
3. An antibody or antigen-binding fragment thereof that binds to CEACAM1, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region; a) wherein the sequence of the heavy chain variable region comprises a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 15-17; and b) wherein the sequence of the light chain variable region comprises a sequence that is at least 90% identical to SEQ ID NO:21 or SEQ ID NO:
22.
4. The antibody or antigen-binding fragment thereof according to claim 3; a) wherein the sequence of the heavy chain variable region comprises a sequence that is at least 90% identical to the heavy chain variable region amino acid sequence of SEQ ID NO: 15; and b) wherein the sequence of the light chain variable region comprises a sequence that is at least 90% identical to the light chain variable region amino acid sequence of any one of SEQ ID NO:
21.
5. The antibody or antigen-binding fragment thereof according to claim 3, a) wherein the sequence of the heavy chain variable region comprises a sequence that is at least 95% identical to a sequence selected from the group consisting of SEQ ID NOs: 15-17; and b) wherein the sequence of the light chain variable region comprises a sequence that is at least 95% identical to SEQ ID NO:21 or SEQ ID NO:
22.
6. The antibody or antigen-binding fragment thereof according to claim 5, a) wherein the sequence of the heavy chain variable region comprises a sequence that is at least 95% identical to the heavy chain variable region amino acid sequence of SEQ ID NO: 15; and b) wherein the sequence of the light chain variable region comprises a sequence that is at least 95% identical to the light chain variable region amino acid sequence of any one of SEQ ID NO:
21.
7. The antibody or antigen-binding fragment thereof according to claim 3, a) wherein the sequence of the heavy chain variable region comprises a sequence selected from the group consisting of SEQ ID NOs: 15-17; and b) wherein the sequence of the light chain variable region comprises SEQ ID NO:21 or SEQ ID NO:
22.
8. The antibody or antigen-binding fragment thereof according to claim 7, a) wherein the sequence of the heavy chain variable region comprises SEQ ID NO: 15; and b) wherein the sequence of the light chain variable region comprises SEQ ID NO:
21.
9. The antibody or antigen-binding fragment thereof according to any one of the preceding claims, wherein the antibody or antigen-binding fragment is a chimeric antibody, a CDR-grafted antibody or a humanized antibody or antigen-binding fragment thereof.
10. The antibody or antigen-binding fragment thereof according to any one of the preceding claims, wherein the antibody or antigen-binding fragment is a multispecific or bispecific antibody or antigen-binding fragment thereof.
11. The antibody or antigen-binding fragment thereof according to claim 10, wherein the antibody or antigen-binding fragment is a bispecific antibody comprising a complementary region that binds to PD-1, PD-L1, CTLA-4, TIM-3, epidermal growth factor receptor (EGFR), CD25, CD19 or Fcγ receptor.
12. The antibody or antigen-binding fragment thereof according to any one of the preceding claims, wherein the antibody or antigen-binding fragment is a scFv, Fv, Fab', Fab, F(ab')2 or a diabody.
13. The antibody or antigen-binding fragment thereof according to any one of the preceding claims, wherein the antibody or antigen-binding fragment is of the isotype IgG4.
14. The antibody or antigen-binding fragment thereof according to any one of the preceding claims, wherein the antibody or antigen-binding fragment thereof contains a S241P substitution in the constant region of the heavy chain.
15. The antibody or antigen-binding fragment thereof according to any one of the preceding claims, wherein the antibody or antigen-binding fragment is aglycosylated.
16. The antibody or antigen-binding fragment thereof according to any one of the preceding claims, wherein the antibody or antigen-binding fragment lacks a C-terminal lysine in the heavy chain.
17. The antibody or antigen-binding fragment thereof according to any one of the preceding claims, wherein the antibody or antigen-binding fragment is conjugated to one or more of a cytotoxin, a fluorescent marker and an imaging agent.
18. An antibody or antigen-binding fragment thereof that binds to the same epitope on CEACAM1 as the antibody or antigen-binding fragment thereof according to any one of the preceding claims.
19. The antibody or antigen-binding fragment thereof according to any one of the preceding claims, wherein the antibody or antigen-binding fragment binds to the IgV-like N domain of CEACAM1.
20. The antibody or antigen-binding fragment thereof according to any one of the preceding claims, wherein the antibody or antigen-binding fragment does not bind to one or more of CEACAM3, CEACAM5, CEACAM6 and CEACAM8.
21. The antibody or antigen-binding fragment thereof according to any one of the preceding claims, wherein the antibody or antigen-binding fragment thereof: a) binds at least partially to the TIM-3 binding site on CEACAM1; and / or b) binds at least partially to the PD-1 binding site on CEACAM1.
22. The antibody or antigen-binding fragment thereof according to any one of the preceding claims, wherein the antibody or antigen-binding fragment binds at least partially to the CEACAM1 binding site on CEACAM1 during homodimerization.
23. An isolated nucleic acid encoding the antibody or antigen-binding fragment thereof according to any one of the preceding claims.
24. A vector comprising the nucleic acid according to claim 23.
25. An isolated cell comprising the vector according to claim 24.
26. A cell expressing the antibody or antigen-binding fragment thereof according to any one of claims 1 to 22.
27. A T cell having a chimeric antigen receptor comprising the CDRs of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 22.
28. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 22, and a pharmaceutically acceptable excipient.
29. A method of inhibiting the binding of CEACAM1 to a member of the CEACAM family, the method comprising contacting CEACAM1 with the antibody or antigen-binding fragment thereof according to any one of claims 1 to 22 or with the pharmaceutical composition according to claim 28.
30. The method of claim 29, wherein the member of the CEACAM family is selected from the group consisting of CEACAM1, CEACAM5 and CEACAM8.
31. The method of claim 29, wherein the member of the CEACAM family is CEACAM1.
32. A method for inhibiting the binding of CEACAM1 to a member of the TIM family, the method comprising contacting CEACAM1 with the antibody or antigen-binding fragment thereof according to any one of claims 1 to 22 or with the pharmaceutical composition according to claim 28.
33. The method of claim 32, wherein the member of the TIM family is TIM-3. 34 . A method for inhibiting the binding of CEACAM1 to PD-1, the method comprising contacting CEACAM1 with the antibody or antigen-binding fragment thereof according to any one of claims 1 to 22 or with the pharmaceutical composition according to claim 28. 35 . A method for inhibiting the binding of CEACAM1 to a bacterial adhesin, the method comprising contacting CEACAM1 with the antibody or antigen-binding fragment thereof according to any one of claims 1 to 22 or with the pharmaceutical composition according to claim 28 .
36. The method of claim 35, wherein the bacterial adhesin is Helicobacter pylori adhesin HopQ, Neisseria gonorrhoeae opacifying protein (Opa), Neisseria meningitidis Opa, Haemophilus influenzae outer membrane protein (OMP) P1, Haemophilus aegypti OMP P1 or Moraxella Opa-like protein (OlpA), Fusobacterium trimeric autotransporter adhesin CbpF, Salmonella adhesin or Streptococcus agalactiae adhesin. 37 . A method for inhibiting the binding of CEACAM1 to Candida albicans, the method comprising contacting CEACAM1 with the antibody or antigen-binding fragment thereof according to any one of claims 1 to 22 or with the pharmaceutical composition according to claim 28 .
38. A method of reducing colonization of mammalian epithelium by bacteria expressing bacterial adhesins, the method comprising contacting CEACAM1 with the antibody or antigen-binding fragment thereof according to any one of claims 1 to 22 or with the pharmaceutical composition according to claim 28.
39. The method of claim 38, wherein the bacterial adhesin is Helicobacter pylori adhesin HopQ, Neisseria gonorrhoeae opacifying protein (Opa), Neisseria meningitidis Opa, Haemophilus influenzae OMP P1, Haemophilus aegypti OMP P1 or Moraxella OlpA, Fusobacterium trimeric autotransporter adhesin CbpF, Salmonella adhesin or Streptococcus agalactiae adhesin.
40. A method of reducing colonization of mammalian epithelium by Candida albicans, the method comprising contacting CEACAM1 with the antibody or antigen-binding fragment thereof according to any one of claims 1 to 22 or with the pharmaceutical composition according to claim 28.
41. A method of reducing T cell tolerance, the method comprising contacting a cell population comprising T cells with the antibody or antigen-binding fragment thereof according to any one of claims 1 to 22 or with the pharmaceutical composition according to claim 28.
42. A method of enhancing T cell expansion, the method comprising contacting a cell population comprising T cells with the antibody or antigen-binding fragment thereof according to any one of claims 1 to 22 or with the pharmaceutical composition according to claim 28.
43. A method of reducing T cell tolerance in a subject in need thereof, the method comprising administering to the subject the antibody or antigen-binding fragment thereof according to any one of claims 1 to 22 or the pharmaceutical composition according to claim 28.
44. A method of enhancing T cell expansion in a subject in need thereof, the method comprising administering to the subject the antibody or antigen-binding fragment thereof according to any one of claims 1 to 22 or the pharmaceutical composition according to claim 28.
45. A method of enhancing B cell expansion, the method comprising contacting a cell population comprising T cells with the antibody or antigen-binding fragment thereof according to any one of claims 1 to 22 or with the pharmaceutical composition according to claim 28.
46. A method of enhancing B cell expansion in a subject in need thereof, the method comprising administering to the subject the antibody or antigen-binding fragment thereof according to any one of claims 1 to 22 or the pharmaceutical composition according to claim 28.
47. A method of enhancing monocyte expansion, the method comprising contacting a cell population comprising T cells with the antibody or antigen-binding fragment thereof according to any one of claims 1 to 22 or with the pharmaceutical composition according to claim 28.
48. A method of enhancing monocyte expansion in a subject in need thereof, the method comprising administering to the subject the antibody or antigen-binding fragment thereof according to any one of claims 1 to 22 or the pharmaceutical composition according to claim 28.
49. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject the antibody or antigen-binding fragment thereof according to any one of claims 1 to 22 or the pharmaceutical composition according to claim 28.
50. The method of claim 49, wherein the cancer is melanoma, pancreatic cancer, thyroid cancer, lung cancer, colorectal cancer, squamous cell carcinoma, prostate cancer, breast cancer, bladder cancer, or gastric cancer.
51. A method of reducing tumor growth in a subject in need thereof, the method comprising administering to the subject the antibody or antigen-binding fragment thereof according to any one of claims 1 to 22 or the pharmaceutical composition according to claim 28.
52. A method of reducing tumor metastasis in a subject in need thereof, the method comprising administering to the subject the antibody or antigen-binding fragment thereof according to any one of claims 1 to 22 or the pharmaceutical composition according to claim 28.
53. A method of reducing tumor-associated fibrosis in a subject in need thereof, the method comprising administering to the subject an antibody or antigen-binding fragment thereof according to any one of claims 1 to 22 or a pharmaceutical composition according to claim 28.
54. A method of reducing tumor stemness in a subject in need thereof, the method comprising administering to the subject the antibody or antigen-binding fragment thereof according to any one of claims 1 to 22 or the pharmaceutical composition according to claim 28.
55. A method of reducing epithelial colonization of a subject by bacteria expressing a bacterial adhesin in a subject in need thereof, the method comprising administering to the subject an antibody or antigen-binding fragment thereof according to any one of claims 1 to 22 or a pharmaceutical composition according to claim 28.
56. The method of claim 55, wherein the bacterial adhesin is Helicobacter pylori adhesin HopQ, Neisseria opacifying protein (Opa), Neisseria meningitidis Opa, Haemophilus influenzae OMP P1, Haemophilus aegypti OMPP1, Moraxella OlpA, Fusobacterium trimeric autotransporter adhesin CbpF, Salmonella adhesin or Streptococcus agalactiae adhesin.
57. A method of reducing epithelial colonization of a subject by Candida albicans in a subject in need thereof, the method comprising administering to the subject an antibody or antigen-binding fragment thereof according to any one of claims 1 to 22 or a pharmaceutical composition according to claim 28.
58. A method of reducing filarial invasion of the subject's lymphatic system in a subject in need thereof, the method comprising administering to the subject the antibody or antigen-binding fragment thereof according to any one of claims 1 to 22 or the pharmaceutical composition according to claim 28.
59. The method of claim 58, wherein the filarial worm is Wuchereria bancrofti.
60. A method of reducing invasion of a subject's lymphatic system by cancer cells in a subject in need thereof, the method comprising administering to the subject an antibody or antigen-binding fragment thereof according to any one of claims 1 to 22 or a pharmaceutical composition according to claim 28.
61. The method of any one of claims 43 to 54, further comprising administering a checkpoint inhibitor.
62. The method of claim 61, wherein the checkpoint inhibitor is a CTLA-4, PD-1, PD-L1, and PD-L2 inhibitor.
63. The method of any one of claims 43 to 54, further comprising administering one or more inhibitors of LAG3, TIGIT, LAP, Podoplanin, Protein C Receptor, ICOS, GITR, CD226 and / or CD160.
64. The method according to any one of claims 43 to 54, further comprising administering a TIM-3 inhibitor.
65. The method of any one of claims 61 to 64, wherein the additional inhibitor is administered simultaneously or sequentially with the antibody or antigen-binding fragment.
66. The method of any one of claims 61 to 64, wherein the additional inhibitor is administered alone or as a mixture with the antibody or antigen-binding fragment.
67. A method of treating a subject in need thereof, the method comprising administering to the subject an antibody or antigen-binding fragment thereof according to any one of claims 1 to 22 or a pharmaceutical composition according to claim 28, wherein the subject has acquired resistance to treatment with a checkpoint inhibitor therapy.
68. The method of claim 67, wherein the subject has acquired resistance to therapy with one or more of a PD-1 inhibitor, a PD-L1 inhibitor, or a CTLA-4 inhibitor.
